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The basics calcium  
homeostasis
Calcium (Ca2+) is one of the most versa-
tile ions in the human body. Its functions 
range from being a cofactor in enzymatic 
reactions, acting as cellular second mes-
senger in excitable cells to mineralizing 
bone skeleton (1). Most of Ca2+ (99%) is 
stored within the bone and only 1% is 
pooled in extracellular compartments. The 
extracellular Ca2+ concentration is tightly 
regulated by the intestine, bone, and kid-
ney through the action of the calciotropic 
factors, including 1,25-dihydroxyvitamin 
D3 (1,25-(OH)2D3) and parathyroid hor-
mone (PTH) (2) (Fig. 1). The concentration 
of ionized Ca2+ in plasma is approximately 
1.25 mM whereas Ca2+ concentration in 
the cytoplasm is maintained almost steady 
at 100 nM. Typically, daily dietary intake 
of Ca2+ is less than 1,000 mg majorly from 
dairy products (3). Intestinal Ca2+ uptake 
is approximately 30%, which is subjected 
to variation in certain circumstances such 
as skeletal growth, maternity, and chronic 
kidney diseases, depending mainly on cir-
culating 1,25-(OH)2D3 level (3,4).
Dietary Ca2+ is absorbed through in-
testinal epithelia into the blood circula-
tion by the transcellular route mainly in the 
duodenum and partially in colon; and by 
paracellular diffusion in all intestinal seg-
ments (1) (Fig. 2). The intestinal transcellu-
lar active Ca2+ absorption consists of three 
steps: Ca2+ entering the apical membrane 
through the transient receptor potential 
vanilloid type 6 (TRPV6) Ca2+ channel, 
Ca2+ translocation through the cytosol by 
the Ca2+-binding protein calbindin (CaBP-
Intestine Kidney Bone
Plasma Ca2+
Extracellular factors
Figure 1 : Ca2+ balance in the body is under the regulation of three Ca2+-regulating organs. Plasma Ca2+ concen-
tration is kept at physiological level via extracellular factors, intestinal absorption, renal reabsorption, and bone 
exchange.
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D9K), and Ca2+ extrusion into the intersti-
tial fluid by the basolateral plasma mem-
brane Ca2+-ATPase type 1b (PMCA1b) (1). 
1,25-(OH)2D3, the classic regulator of the 
active Ca2+ transport, stimulates the pro-
tein expression of all three steps (5). The 
paracellular diffusion of Ca2+ is passively 
driven by Ca2+ concentration in the luminal 
side independently of 1,25-(OH)2D3 (1). 
Ca2+ absorbed via the intestinal tract is 
majorly deposited in bone in the form of 
hydroxyapatite crystals [Ca5(PO4)3(OH)] 
embedded in an extracellular matrix (ECM) 
surrounded by a small population of cells 
(6). The matrix provides strength and sta-
bility while the cellular components re-
peatedly remodel bone to reform itself in 
response to stress (7). Bone remodeling 
processes rely on the coordinated ac-
tions of hematopoietic lineage-derived 
osteoclasts (OCs), mesenchyme-derived 
osteoblasts (OBs), and osteoblast-derived 
osteocytes (OCYs) (Fig. 3). The bone-re-
sorbing OCs degrade the mineralized ma-
trix by two means: creating acidic milieu 
to resorb the inorganic minerals including 
Ca2+, which partially returns to the blood 
circulation, and secreting proteases to de-
grade organic ECM (7,8). The bone-form-
ing OBs produce and subsequently miner-
alize an organic collagenous matrix with an 
inorganic Ca5(PO4)3(OH) (8). The mechano-
sensing OCYs sense and convert mechan-
ical to chemical signals and communicate 
with neighboring OCYs, OBs, and OCs 
through their long dendritic processes (9). 
To maintain bone integrity in adults, the 
coupling mechanism of bone remodeling 
is operated by crosstalk between OBs and 
OCs (6) (Fig. 3). OC development requires 
a stimulation of their surface receptor ac-
tivator of nuclear factor-KB (RANK) by 
RANK ligand (RANKL) secreted from OBs 
Figure 2 : Mechanisms of Ca2+ transport in the intestine and kidney. 1. The transcellular Ca2+ (re)absorption con-
sists of i) Ca2+ entering via apical TRPV5/TRPV6, ii) Ca2+ buffered and translocated to the basolateral membrane by 
the CaBP-D9K/CaBP-D28K, and iii) PMCA1b and NCX1 extruding Ca
2+ into the blood. 2. Paracellular Ca2+ transport 
is an electrochemical gradient-dependent process [adapted from (13)]. 
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(10). On the other hand, OBs secrete a de-
coy receptor osteoprotegerin (OPG) that 
specifically binds and neutralizes RANKL 
(8,10). Therefore, a raise in RANKL/OPG 
ratio determines domination of bone re-
sorption over bone formation and vice 
versa. Disturbances of RANKL/OPG ratio 
lead to skeletal abnormalities character-
ized by osteoporosis and osteopetrosis 
(11).
Ca2+ from bone and intestinal tract cir-
culates in blood and is eventually filtered 
in the kidney. More than 98% of Ca2+ from 
glomerular filtration is reabsorbed by renal 
tubules. In a healthy subject, urinary Ca2+ 
excretion the equals amount of the intes-
tinal Ca2+ uptake (1). Renal Ca2+ reabsorp-
tion occurs mainly as a paracellular passive 
process in proximal tubule (PT, ~65%) and 
thick ascending limb of the loop of Henle 
(TAL, ~20%) (Fig. 4). Meanwhile, the tightly 
regulated active Ca2+ reabsorption occur-
ring in late distal convoluted and connect-
ing tubules (DCT2/CNT) is responsible for 
~10% of the reabsorption. The active Ca2+ 
reabsorption is important as it determines 
the final Ca2+ excretion (1). This process, 
similarly to the active intestinal Ca2+ ab-
sorption, begins with the entry of Ca2+ via 
apically localized TRPV5. Once present in 
the cell, Ca2+ is buffered and translocated 
to the basolateral membrane by the CaBP-
D28K. Similarly to the intestine, renal PM-
CA1b and NCX1 energetically transport 
Ca2+ into the blood (Fig. 2).
Ca2+ entry via the transient receptor po-
tential vanilloid type 5 (TRPV5) Ca2+ chan-
Figure 3 : Coupling mechanism of bone remodeling operated by crosstalk between OBs (blue) and OCs (pink). 
OBs secrete receptor activator of nuclear factor-KB ligand (RANKL), an OC-activating factor; and osteoprotegerin 
(OPG), an anti-maturation factor of OCs. This machinery keeps bone formative and resorptive activities in balance.
Figure 4 : Segmental renal Ca2+ reabsorption. Paracel-
lular passive process in the proximal tubule (PT, ~65%) 
and thick ascending limb of the loop of Henle (TAL, 
~20%). Active Ca2+ reabsorption is present in late dis-
tal convoluted and connecting tubules (DCT2/CNT, 
~10%) and is responsible for fine-tuning of renal Ca2+ 
reabsorption.
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nel is the rate-limiting step and is intri-
cately regulated by various hormones and 
extracellular factors (1). TRPV5 knockout 
(TRPV5-/-) mice manifest renal Ca2+ loss, 
hyperabsorption, and osteopenia (3). Re-
cently, it has been revealed in mice that 
a mutation of a residue S682 in TRPV5 
causes autosomal dominant hypercalci-
uria (12). These data reveal the crucial role 
of TRPV5 in Ca2+ handling and the need 
to explore novel regulators of this channel.
Molecular structure of TRPV5
The transient receptor potential (TRP) 
channels are six transmembrane (TM)-
spanning proteins with intracellular amino 
(N)- and carboxy (C)-termini. TRPV5 is a 
730-amino acid protein with a pore region 
situated between the TM5 and TM6 (Fig. 5) 
(1). The aspartate-542 in the aqueous pore 
region is responsible for the Ca2+ perme-
ation of the channel (1). The first extracel-
lular loop between TM1 and TM2 possess-
es a N-glycosylation site; therefore, the 
size of TRPV5 can range from 85-100 kDa. 
The N-glycosylation is crucial for TRPV5 
retrieval from the plasma membrane. More 
details will be given in later section. As-
sembly of four TRPV5 subunits forms the 
functional tetramer (13). The six ankyrin 
repeats in the N-terminus likely play a 
role in the tetramerization process of the 
channel (13). Extracellular domains of ion 
channels are exposed to the pro-urinary 
milieu, which contains several organic and 
inorganic substances including hormones 
and enzymes that filtered from glomeruli or 
secreted by renal tubules (13,14). 
Regulation of TRPV5 channels 
by extracellular factors
Various extracellular factors (enzymes, 
hormones, and pH etc.) can control renal 
ion channels by two means:  interaction 
with plasma membrane/nuclear receptors 
to convey the signals to the channels and 
direct interaction with the channels. Con-
sequently, these can affect ion channels in 
Figure 5 : Molecular structure of TRPV5. TRPV5 channel consists of putative six TM domains and a pore-forming 
region between TM5 and TM6. The six serine residues (S) in the N- and C-termini, which are putative protein 
kinase C (PKC) phosphorylation sites, and a threonine residue (T) phosphorylated by protein kinase A (PKA) are 
designated [adapted from (13)].
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several aspects: i) gating the channels at 
the plasma membrane (signified by single 
channel open probability and conduc-
tance); ii) trafficking of ion channels from 
intracellular stores to the luminal mem-
brane and vice versa; iii) regulating tran-
scription and translation of the channel 
genes; and; iv) degrading the translated 
channel proteins (Fig. 6).
Membrane receptor-depen-
dent regulation
Regulation of TRPV5 activity: implica-
tions of G protein-coupled receptor 
signaling pathways
G protein-coupled receptors (GPCRs) 
differentially regulate TRPV5 activity. The 
typical GPCRs regulating TRPV5 activity 
are the PTH receptor type 1 (PTH1R) and 
the Ca2+-sensing receptor (CaSR). A previ-
ous study using the micropuncture tech-
nique demonstrated that PTH stimulated 
active Ca2+ reabsorption in the distal part 
of the nephron (15). Recently, de Groot et 
al. have described an in-depth molecu-
lar mechanism of PTH (16). PTH induced 
adenylyl cyclase (AC)/cyclic AMP (cAMP)-
dependent PKA phosphorylation of TRPV5 
on T709 residue on the C-terminus of the 
ion channel (Fig. 5) (16). T709 phosphory-
lation consequently impeded an inhibitory 
binding of calmodulin (CaM), resulting in 
an increased open probability (17). Sev-
eral studies have established that an AC 
activator (forskolin) and cell-permeable 
cAMP analogs mimic PTH action on ac-
tive Ca2+ reabsorption (18-21). Apart from 
cAMP, PTH also acts as phospholipase C 
(PLC)-activating hormone. PLC catalyzes 
the hydrolysis of phosphatidylinositol-4,5-
bisphosphate (PIP2) to produce inositol tri-
sphosphate (IP3) and diacylglycerol (DAG). 
IP3 releases Ca2+ from intracellular Ca2+ 
stores while DAG activates PKC, which 
has been found to boost TRPV5 activity 
within 10 minutes (22). Conventional iso-
forms of PKCs (α, βI, βII, and γ) were pro-
posed to be downstream of PTH1R (22). 
Interestingly, activation of CaSR enhanced 
Figure 6 : Regulation of ion channels. Ion channels including Ca2+ channels are proposed to subject to 4 modes of 
regulation. 1) transcription and translation of the channels, 2) trafficking of the channels between intracellular stores 
and plasma membrane, 3) channel gating at the plasma membrane, and 4) degradation of the channel proteins 
[adapted from (13)].
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TRPV5 activity via atypical forms of PKC 
(putatively ξ isoform) (23). Therefore, a 
quest for other PKA- and PKC-stimulating 
agents that can regulate TRPV5 is of inter-
est as it probably paves the way for dis-
covering novel treatments for individuals 
suffering from kidney diseases with Ca2+ 
loss.
Regulation of TRPV5 trafficking 
between plasma membrane and 
intracellular organelles 
Amount of Ca2+ influx in DCT/CNT 
depends among others on TRPV5 abun-
dance at the plasma membrane (13). In 
addition to its rapid effect on TRPV5 activi-
ty, PTH1R activation by PTH also prevents 
TRPV5 endocytosis, thereby increasing 
plasma membrane accumulation of the 
channel through PKC phosphorylation 
(22). Recently, Cha et al. evidenced that 
caveolin-1 is involved in TRPV5 endocy-
tosis (22). TRPV5 possesses six putative 
intracellular PKC phosphorylation sites 
(S144, S299, and S316 on the N-terminus 
and S654A, S664A, and S698A on the C-
terminus) (Fig. 5) (24). Mutations of S299/
S654 or blocking PKC activity could abol-
ish the effect of PTH (22). Gkika and co-
workers have previously demonstrated 
the importance of S299/S654 PKC phos-
phorylation sites (24). They demonstrated 
that activation of bradykinin receptor type 
2 (B2R) by serine protease tissue kalli-
krein (TK) increased plasma membrane 
abundance of TRPV5 (24). PKCξ has 
been proposed to mediate this TK effect 
(24). PKC-activated membrane accumula-
tion of TRPV5 could be also amplified by 
With-no-lysine [K] kinase-4 (WNK4) (25). 
Clinically, a missense mutation of WNK4 
causes the autosomal dominant disease 
pseudohypoaldosteronism type 2 (PHAII, 
Gordon’s syndrome) manifested by hyper-
tension, hyperkalemia, and hypercalciuria 
accompanied by DCT hyperplasia (26).
Regulation of TRPV5 transcription 
and translation
Besides affecting the gating and traf-
ficking of TRPV5, PTH has also been 
found to influence TRPV5 transcription 
and translation (27). Thyroparathyroidec-
tomized rats have low serum PTH levels 
and hypocalcaemia accompanied by de-
creased TRPV5 mRNA levels and protein 
abundance (27). Supplementation with 
PTH restored plasma Ca2+ concentrations 
and TRPV5 abundance in the kidney, con-
firming that PTH affects renal Ca2+ han-
dling through the regulation of TRPV5. 
Indirectly, PTH promoted the activity of 
25-hydroxyvitamin-D3-1α-hydroxylase 
(1α-OHase), a crucial enzyme in the bio-
synthesis of 1,25-(OH)2D3, and increased 
the 1,25-(OH)2D3-dependent absorption 
of Ca2+ in the small intestine (28). In con-
trast to the effect of 1,25-(OH)2D3, stimula-
tion of CaSR with its calcimimetic agonist 
(NPS R-467) decreased TRPV5 mRNA ex-
pression (27). Clinically, single-nucleotide 
polymorphisms (SNPs) in the CaSR are 
associated with kidney stone formation 
(29). Renkema and colleagues reported 
that CaSR also indirectly regulates renal 
Ca2+ handling by down-regulating aqua-
porin-2 (AQP2)-mediated water reabsorp-
tion and enhancing acid secretion by the 
H+-ATPase in principal and intercalated 
cells of collecting duct, respectively. Thus, 
CaSR activation increased Ca2+ solubility 
to prevent stone formation, especially in 
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the absence of TRPV5 (30).
Regulation of TRPV5 stability by 
degradation
In general, membrane protein expres-
sion can be controlled by ubiquitin-de-
pendent internalization and subsequent 
degradation by intracellular proteases (31). 
Mono-ubiquitin acts as a signal for protein 
sorting into the multivesicular body (MVB) 
for lysosomal degradation. On the other 
hand, polyubiquitinated proteins are tar-
geted to the proteasome for degradation 
(32). So far, however, there is no report 
pertaining to the role of proteolytic degra-
dation on TRPV5 expression. Interestingly, 
the TRPV5 homolog, TRPV4 has been 
found to be ubiquitinated upon angioten-
sin II (AngII) activation through GPCR an-
giotensin receptor type 1 (AT1 receptor) 
(33). More recently, TRPV1 in peripheral 
sensory neurons has been reported to be 
ubiquitinated and internalized via the p38 
MAPK signaling pathway (34). In DCT2/
CNT where TRPV5 is expressed, Wie-
muth and co-workers demonstrated that 
cell surface amiloride-sensitive epithelial 
Na+ channel (ENaC) ubiquitination leads to 
clathrin-mediated endocytosis and subse-
quent degradation (35).
Membrane receptor-indepen-
dent regulation
Organic and inorganic extracellular fac-
tors present in pro-urine and plasma influ-
ence TRPV5 either by direct interactions 
with the channel or by binding to their cor-
responding nuclear receptors. 
Regulation of TRPV5 activity: interaction 
with Ca2+ and H+  
Ca2+, Mg2+, and protons have been 
found to directly regulate TRPV5 gating 
activity and membrane trafficking. To pre-
vent intracellular Ca2+ overload, TRPV5 
possesses a property of Ca2+-dependent 
feedback inhibition i.e., Ca2+ entering the 
channel is able to inactivate channel ac-
tivity per se (36). Deletion of the last 30 
amino acids of the C-terminus of TRPV5 
decreased the sensitivity to Ca2+ inactiva-
tion. Another critical sequence for Ca2+-de-
pendent inactivation of TRPV5 was found 
upstream in the C-terminus (37). Analysis 
of truncations at amino acid 635, 639, 646, 
649 and 653 disclosed a critical sequence 
involved in Ca2+-dependent inactivation at 
positions 650–653. C653X had lower Ca2+ 
sensitivity comparable to G701X, while 
E649X lacked Ca2+-dependent inactiva-
tion (37). Another divalent cation affecting 
TRPV5 activity is Mg2+. Using point mu-
tants of the conserved negatively charged 
amino acids present in the putative pore, 
Nilius et al. have identified a single aspar-
tate residue that determines Ca2+ perme-
ation of TRPV5 and modulation by extra-
cellular Mg2+. Mutation of the aspartate 
residue D542A abolished Ca2+ permeation 
and Ca2+-dependent current decay as well 
as a block by extracellular Mg2+ (38).
It is well known that the acid-base sta-
tus influences Ca2+ homeostasis and a 
study using primary cultures of rabbit CNT 
cells pointed out that acidification of the 
apical medium inhibits the transcellular 
Ca2+ reabsorption (39). Using the whole-
cell patch clamp recording it was shown 
that extracellular acidification (pH 6.5) in-
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hibits TRPV5 single channel conductance 
and open probability (40). Single channel 
analysis revealed that mutation of gluta-
mate 522 to glutamine (E522Q) decreased 
the sensitivity of the channel to extracellu-
lar acidification (41). The two extracellular 
loops between the fifth and sixth trans-
membrane segments of TRPV5 presum-
ably form part of the outer opening of the 
pore and are likely important in binding 
and regulation by extracellular protons. 
These data denote that glutamate 522 of 
the TRPV5 is a pH sensor and proton bind-
ing to this residue leads to conformational 
changes of the channel (41). 
Regulation of TRPV5 trafficking
In addition to its influence on TRPV5 
gating activity, pH also regulates TRPV5 
endocytosis. Under alkaline pH, TRPV5 
was more translocated towards the plas-
ma membrane, resulting in an increase in 
Ca2+ transport. In contrast, acidification of 
extracellular solution enhanced TRPV5 en-
docytosis, thereby reducing Ca2+ transport 
(42). Similar to the effect of pH on TRPV5 
activity, aforementioned data showed that 
conformational changes within the channel 
pore control TRPV5 trafficking (41).
Similarly to alkalinization, klotho has 
been found to inhibit TRPV5 retrieval. 
Klotho is an anti-aging hormone since its 
deficiency caused premature aging phe-
notypes in multiple organs exemplified by 
decreased bone mineral density (BMD), 
soft tissue calcification and pulmonary 
emphysema, whereas overexpression of 
klotho elongated the life span (43). Chang 
and colleagues have demonstrated that 
pro-urinary klotho directly cleaves the 
extracellular N-glycan present on the first 
extracellular domain of TRPV5 to retain 
the channel at the plasma membrane (44). 
Subsequently, Cha and co-workers ex-
plained that klotho removes sialic acid to 
expose an underlying ligand disaccharide 
galactose-N-acetylglucosamine of TRPV5 
for surface membrane galectin-1, leading 
to plasma membrane accumulation (45). 
Recently; however, Leunissen et al. argued 
that klotho and sialidase affected TRPV5 
abundance with distinct mechanisms (46). 
Klotho cleaves the N-glycan, allowing 
galactose-N-acetylglucosamine binding 
to galectin-3, not galectin-1. On the other 
hand, the sialidase still inhibited lipid raft-
mediated TRPV5 retrieval in the absence 
of the N-glycan (46). These data imply that 
klotho inhibited TRPV5 internalization in-
dependently of its sialidase property and 
probably using glucuronidase activity.
The physiological importance of klotho 
has been elaborated in klotho-/- mice that 
manifested hypercalcaemia and hyper-
calciuria with abnormally high plasma 
1,25-(OH)2D3 level (47). Alexander and col-
leagues tested the effect of serum Ca2+ 
and 1,25-(OH)2D3 level normalization in 
klotho-/- mice with a low Ca2+, low phos-
phorus (Pi), and low 1,25-(OH)2D3 diet (48). 
Under these conditions, intestinal Ca2+ ab-
sorption returned to normal level, whereas 
hypercalciuria still persisted, illustrating 
that renal Ca2+ wasting is a primary dis-
turbance in klotho-/- mice leading to sec-
ondary hypervitaminosis D, intestinal Ca2+ 
hyperabsorption and bone loss. In kidney, 
TRPV5 was upregulated whereas CaBP-
D28K and NCX1 were decreased, hence 
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provoking primary renal Ca2+ loss. There is 
yet no explanation of how TRPV5 expres-
sion was enhanced, but it was reported 
that the channel was not present at the 
plasma membrane in the absence of klotho 
in HEK293 and mouse CNT cells (44,49). 
An observation that plasma membrane ex-
pression of TRPV5 stimulated CaBP-D28K 
and NCX1 expression might explain why 
the transporter expression levels were low 
in klotho-/- mice (27).
Regulation of TRPV5 transcription 
and translation: predominant roles of 
steroid hormones
Extracellular factors regulating TRPV5 
mRNA and protein expression include 
steroid hormones and acid-base status. 
The most classic regulator of Ca2+ trans-
porter gene expression demonstrated by 
various studies is 1,25-(OH)2D3 (2,5,50). 
Putative promoter region analysis of the 
TRPV5 gene disclosed potential vitamin 
D-response elements (2). Studies in cell 
models suggested that 1,25-(OH)2D3 en-
hances TRPV5 expression (51,52). In vivo, 
a single dose of 1,25-(OH)2D3 increased 
renal TRPV5 mRNA expression whereas 
1α-OHase ablation led to down-regulation 
of renal TRPV5 expression and hypo-
calcaemia, which were normalized with 
1,25-(OH)2D3 repletion (5). Furthermore, 
additional studies demonstrated differ-
ential upregulation of TRPV5 by vitamin 
D analogues which were developed in an 
effort to treat secondary hyperparathy-
roidism without the hypercalcaemic side 
effects of conventional 1,25-(OH)2D3 treat-
ment (53). In particular, the time course 
of TRPV5 augmentation was correlated 
with the 1,25-(OH)2D3 level (53). Thus, the 
ameliorated calcaemic effects appeared to 
result from differential stimulation of Ca2+ 
channel expression. Taken together, the 
transcriptional and translational regulation 
of TRPV5 by 1,25-(OH)2D3 was consistent-
ly established.
Gender difference has been implicated 
in renal Ca2+ handling (54). Urinary Ca2+ 
excretion was reportedly higher in male 
than in the female population, implying 
the suppressive role of male hormones or 
the stimulatory role of female hormones 
on Ca2+ reabsorption (55). Several clinical 
manifestations suggested positive effects 
of estrogen on the Ca2+ balance (56). Post-
menopausal women commonly suffer from 
renal Ca2+ loss, which can be alleviated by 
estrogen replacement therapy (57). In kid-
ney, estrogen increased TRPV5, CaBP-
D28K, NCX1, and PMCA1b mRNA expres-
sion (56). Interestingly, this stimulatory 
effect was still persistent in 1α-OHase-
deficient mice, indicating that the effect 
was probably independent of 1,25-(OH)2D3 
(56).
In contrast to the effects of estrogen, 
Hsu and co-workers recently demon-
strated that orchidectomy (ORX) reduced 
renal Ca2+ excretion (58). This phenotype 
was accompanied by increased TRPV5, 
CaBP-D28K, and NCX1 mRNA and protein 
expression. Moreover, ORX had no effect 
on intestinal Ca2+ absorption. It was pre-
sumably a direct effect of androgens on 
renal Ca2+ handling since the androgen re-
ceptor (AR) is co-expressed with TRPV5 in 
DCT2/CNT cells. Moreover, serum levels 
of 1,25-(OH)2D3, PTH, and estrogen were 
unaltered in ORX mice (58). To exclude 
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a possible role of testosterone on bone 
resorption, dihydrotestosterone (DHT), 
a non-aromatizable androgen, was em-
ployed and found to directly decrease Ca2+ 
transport in CNT cell cultures (58). These 
findings confirm the primary effect of tes-
tosterone on TRPV5 function. Effects of 
ORX on renal Ca2+ reabsorption and Ca2+ 
transporter expression were reversed by 
androgen (DHT) replacement. These re-
sults are in line with previous findings by 
Öz and colleagues who demonstrated that 
aromatase-deficient female mice exhibit 
urinary Ca2+ wasting and down-regulation 
of TRPV5, CaBP-D28K, PMCA1b, and NCX1 
mRNA levels (59).
In addition to sex hormones, glucocorti-
coids also control TRPV5 expression. Us-
ing the zebrafish as model system, Lin and 
co-workers demonstrated that cortisol sig-
nificantly enhanced TRPV5 and cyp27b1 
(1α-OHase) mRNA expression in zebrafish 
embryos (60). Associated with glucocorti-
coids, serum and glucocorticoid inducible 
kinase (SGK1) has been found to interact 
and amplify TRPV5 expression in Xenopus 
oocytes (61). Upon stimulation of gluco-
corticoids, nuclear glucocorticoid receptor 
induced SGK1 binding to TRPV5 putatively 
through PI3K signaling pathway (62), but 
detailed mechanisms are not known. Of 
note, the synthetic glucocorticoids dexa-
methasone and prednisolone increased 
mRNA expression of renal TRPV5 and in-
testinal TRPV6, respectively (63,64). These 
data might be useful as precaution of using 
glucocorticoids in patients prone to Ca2+ 
disturbances.
In addition to the calciotropic hormones, 
there were indications that Ca2+ itself could 
affect TRPV5 expression. However, it is 
difficult to study the effect of Ca2+ indepen-
dently from affecting plasma 1,25-(OH)2D3 
and PTH level. In order to investigate the 
relationship between TRPV5 and vitamin 
D, studies were performed in 1α-OHase-/- 
and VDR-/- mice under normal and high-
Ca2+ diets (5,50). Importantly, high dietary 
Ca2+ intake restored the expression lev-
els of renal TRPV5 in 1α-OHase-/- mice, 
accompanied by normalization of the 
plasma Ca2+ concentration. Furthermore, 
Dardenne and colleagues showed that a 
high Ca2+ diet mitigated osteomalacia in 
1α-OHase-/- mice, rescuing the bone phe-
notype (65). In contrast, the Ca2+-enriched 
rescue diet reduced renal TRPV5 and 
CaBP-D28K expression in wild-type mice, 
resulting in normal serum vitamin D and 
Ca2+ levels (5,50,66).
The systemic acid-base status also in-
fluenced TRPV5 expression. Chronic met-
abolic acidosis induced by NH4Cl loading 
or administration of the carbonic anhy-
drase inhibitor, acetazolamide enhanced 
hypercalciuria (39). This effect was ac-
companied by a decrease in renal TRPV5 
and CaBP-D28K mRNA and protein abun-
dance, in mouse DCT2/CNT (39). Accord-
ingly, duodenal TRPV6 expression was 
increased to compensate for urinary Ca2+ 
loss (67). In contrast, chronic metabolic al-
kalosis induced by NaHCO3 administration 
enhanced the expression of Ca2+ transport 
proteins, resulting in a reduction in urinary 
Ca2+ excretion (39). The exact mechanisms 
by which the acid-base status influences 
TRPV5 expression is not known, however, 
the acid-sensing receptor on the baso-
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lateral side is likely to be involved (68). 
A decrease in pH can trigger basolateral 
acid-sensing GPCRs, which further phos-
phorylate an intracellular pH sensor pro-
line-rich tyrosine kinase 2 (Pyk2) and even-
tually stimulate acid secretion by apical 
Na+-H+ exchanger type 3 (NHE3, SLC9A3) 
in PT (68). Recent findings of Pan and col-
leagues provided information pertaining to 
the role of intrinsic urinary acidity in regula-
tion of TRPV5 by NHE3 (69). NHE3-/- mice 
display a low level of TRPV5 mRNA and 
protein expression compared to wild types 
(69). On the other hand, high-Na+ diet up-
regulated both NHE3 and TRPV5 protein 
expression (70). Furthermore, Barone and 
co-workers demonstrated that Cl--/HCO3
- 
exchanger pendrin (SLC26A4), a member 
of solute carrier (SLC) superfamily, ex-
pressed in the HCO3
--secreting DCT/CNT 
cells is important for maintaining normal 
TRPV5 expression (71). Mice lacking pen-
drin exhibited acidic urine, accompanied 
by a decrease in TRPV5 mRNA and pro-
tein expression. These phenotypes could 
be normalized by HCO3
- (71). These find-
ings also provide a molecular link between 
pH, Na+ and Ca2+ balance.
Regulation of ion channel stability by 
degradation
Various proteases have been identified 
to degrade plasma membrane proteins in-
cluding ion channels. Even though direct 
cleavage of peptide bonds in TRPV5 has 
never been reported, the serine protease 
plasmin was shown to cleave the extra-
cellular membrane-attached osteocalcin, 
a protein released from osteoblasts and 
important for Ca2+ deposit in bone ECM 
(72). The cleaved osteocalcin fragments 
were detected in the urine as by-products 
(73). Another member of the serine prote-
ase family, TK was shown to inhibit TRPV5 
retrieval and also cleaved and down-regu-
lated the extracellular loop of acid-sensing 
ion channel type 1 (ASIC1) (74). Pretreat-
ment with the protease inhibitor aprotinin, 
inhibited the cleavage of ASIC1 by TK (74). 
Besides serine proteases, aspartic-acid 
protease β-secretase was also found to 
directly cleave voltage-gated Na+ channel 
(Navβ2), resulting in proteolysis and prob-
ably hippocampal neuron dysfunction (75). 
In kidney, juxtaglomerular cells can sense 
a low effective circulating volume (ECV) 
and release the protease renin that con-
verts angiotensinogen released from liver 
into angiotensin I (AngI) (76). Sequentially, 
angiotensin-converting enzyme (ACE) pro-
tease converses AngI to a potent vaso-
active peptide AngII (76). On the plasma 
membrane of glomerulosa cells of adre-
nal cortex, AngII binding to Gαq-coupled 
AT1 receptor activated the PLC/DAG/PKC 
signaling pathway leading to aldosterone 
secretion (76). Subsequently, aldosterone 
activated Na+ reabsorption through NCC 
in the DCT and ENaC in the DCT2/CNT, 
respectively (77). As a consequence, en-
hanced transepithelial Na+ reabsorption 
raised extracellular fluid volume and blood 
pressure. A high Na+ diet has been illus-
trated to induce ubiquitin-mediated NCC 
internalization (78). To this end, investiga-
tion of proteolytic regulation of TRPV5 is 
attractive because it could explain why the 
channel is up- or down-regulated under 
hormonal control and certain diseases. 
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Serine proteases and their 
roles in Ca2+ homeostasis
Proteases are enzymes that digest 
proteins by a process that is called pro-
teolysis, in which the components of the 
protein are broken down (79). Proteases 
were formerly categorized into endopep-
tidases and exopeptidases, which cleave 
internal peptide bonds or N- and C-termini 
of polypeptides (substrates), respectively 
(79). Nowadays, based on their catalytic 
mechanisms, proteases are classified into 
6 classes: aspartic, glutamic, cysteine, 
serine, threonine proteases and metallo-
proteinases (80). Furthermore, each class 
of proteases is grouped into families and 
subfamily (clans) depending on their tertia-
ry structures (80). Inside the cell, proteases 
play a key role in protein quality control 
(PQC), a cellular process that facilitates 
protein folding, protect unfolded poly-
peptides from aggregation, and degrade 
misfolded or unwanted polypeptides (81). 
The intracellular proteolytic processes 
are lysosome-dependent or proteasome-
dependent (31). Extracellularly, proteases 
execute positive and negative effects di-
rectly on target proteins, or indirectly upon 
binding to their membrane-anchored re-
ceptors. Serine proteases comprise of 10 
clans including chymotrypsin-like, which is 
made up of over 240 protease members 
functioning as regulators of fibrinolysis, 
immune response and ion transport (82). 
In kidney, membrane-bound serine pro-
teases are anchored to the plasma mem-
brane via either the C- (type I), or the N-ter-
minus (type II) (83). Girardi and colleagues 
demonstrated that dipeptidyl-peptidase 
IV (DPPIV or CD26) in PT enhances NHE3 
activity by translocating the exchanger 
to the apical microvillar membrane (84). 
The channel-activating protease type 1 
(CAP-1, prostasin), another member of 
membrane-anchored serine proteases 
also facilitated ENaC activity in CCD (85). 
Of note, CAP-1 might also play a role in 
ion transport in intestinal cells because 
CAP-3 (matriptase) reduces paracellular 
permeability by inhibiting the tight junc-
tion protein, claudin-2 expression (86,87). 
Meanwhile, soluble serine proteases pres-
ent in pro-urine endogenously synthesized 
by renal tubular cells (e.g., tissue kallikrein) 
or pathologically leaked from glomerular 
filtration (e.g., plasminogen), regulate Ca2+ 
and Na+ transport, respectively in DCT2/
CNT (24,88). Plasminogen, a chymotryp-
sin-like pro-enzyme important for fibri-
nolytic process, is converted into active 
serine protease plasmin by urokinase-type 
plasminogen activators (uPA) present in 
the pro-urine (89). Besides, the serine pro-
tease thrombin, secreted by osteoclasts, 
has been shown to directly cleave the 
ECM bone protein osteopontin. This pro-
tein is important for anchoring osteoclasts 
to the mineralized matrix (90). Thrombin-
deficient mice are lethal in embryonic and 
neonatal phases (91). Additionally, throm-
bin can also exert its biological effects via 
protease-activated receptors (PARs)-1, -3, 
and -4 (92). PAR-1 (thrombin receptor, TR) 
expressed in osteoblasts became activat-
ed upon proteolytic cleavage by thrombin 
(93,94). Thrombin-activated TR induced 
the proliferation rate of osteoblasts (95,96) 
whereas TR-/- mice manifested a reduc-
tion of mesenchymal cell proliferation into 
bone fracture areas (92). However, the role 
23
G
en
er
al
 in
tr
od
uc
tio
n
of the thrombin/TR system in Ca2+ homeo-
stasis has not been elucidated. 
Outline of the thesis
The aim of this thesis was to explore 
novel calciotropic factors involved in the 
regulation of TRPV5 and the whole body 
Ca2+ homeostasis. It focused on the roles 
of serine proteases and GPCRs on Ca2+ 
handling in (patho)physiology. In Chapter 
2, plasmin was purified from urine col-
lections of nephrotic patients and the ef-
fect of plasmin on TRPV5-mediated Ca2+ 
transport in kidney cells was investigated. 
To gain more knowledge on the respon-
sible molecular mechanisms, PKC phos-
phorylation sites in the N- and C- terminal 
domains were mutated and pharmaco-
logically inhibited with specific inhibitors. 
Patch-clamp experiments were performed 
to measure Ca2+ current alteration in non-
phosphorylated TRPV5 and constitutively 
active phosphorylated TRPV5 mutants 
in kidney cells. Finally, the nuclear mag-
netic resonance (NMR) technique was 
employed to gain insight into a possible 
involvement of calmodulin on PKC signal-
ing transduction. Chapter 3 aimed to iden-
tify the role of the urinary enzyme tissue 
transglutaminase (tTG) on TRPV5 activity. 
Urinary tTG was determined and the role 
of tTG on TRPV5-mediated Ca2+ transport 
was functionally investigated in primary 
CNT/CCD cells and in HEK293 cells us-
ing Ca2+ transport assays and patch clamp 
techniques, respectively. In Chapter 4, 
a series of in vivo experiments was per-
formed with GPCR TR-/- mice in order to 
gain knowledge on intestinal, renal, and 
bone Ca2+ handling including metabolic 
studies, biochemical analyses, and bone 
micro-computed tomography (μCT). In 
vitro experiments used to obtain mecha-
nistic data consisted of osteoblast cell 
culture in the presence of thrombin. Bone 
remodeling markers in serum, urine, and 
cultured media were analyzed by immu-
noassay techniques. Based on the out-
come of the previous chapters, Chapter 
5 aimed to unravel the calciotropic roles 
of GPCR β-adrenergic receptors (β-ARs) 
and inotropic drugs. Expression profiling 
of β-ARs in mouse kidney was performed. 
Molecular mechanisms of Ca2+ transport 
were studied using HEK cells and mouse 
DCT2/CNT primary cell culture. In Chapter 
6, the contents of the thesis are discussed 
and summarized.
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Abstract
Abnormal glomerular protein leakage elicits multiple tubulo-interstitial effects attributed 
to local effects of leaked proteins, such as tubulo-interstitial inflammation and eventually 
fibrosis. Recent data showed that tubular transport processes could be also affected by 
direct effects of urinary proteins on membrane transporters at the luminal side of the dis-
tal convoluted tubules (DCT). In nephrotic-range proteinuria, filtered plasminogen reach-
es the luminal side of DCT, where it is cleaved into active plasmin by urokinase. Here, we 
showed that purified plasmin from the urine of patients with nephrotic-range proteinuria 
inhibits Ca2+ uptake in HEK293 expressing TRPV5 via activation of protease-activated 
receptor-1 (PAR-1). PAR-1 was expressed in HEK293 cells and colocalized with TRPV5 
in mouse DCT. Pre-incubation with a plasmin inhibitor, PAR-1 antagonist, or PKC inhibi-
tor abolished the effect of plasmin on TRPV5. Ablation of the PKC phosphorylation site 
S144 rendered TRPV5 resistant to the action of plasmin. The plasmin-mediated reduction 
in Ca2+ uptake was accompanied by a decreased TRPV5 pore size and open probabil-
ity as shown by patch-clamp analysis. In addition, high-resolution NMR spectroscopy 
demonstrated the involvement of calmodulin (CaM) as specific interactions were shown 
between CaM and residues 133-154 of the N-terminus of TRPV5 for both wild-type and 
phosphorylated (S144pS) peptides. In conclusion, PAR-1 activation by plasmin induces 
a PKC-mediated phosphorylation of TRPV5, thereby altering the CaM-TRPV5 binding, 
resulting in decreased open probability which in turn decreases its activity. These results 
indicate that urinary plasmin could be involved in the downstream effects of proteinuria 
on the tubulo-interstitium by the negative modulation of TRPV5. 
Introduction
In kidney, the fine regulation of Ca2+ 
balance occurs through the activity of the 
epithelial Ca2+ channel TRPV5 (1). TRPV5 
is mostly expressed in the distal convo-
luted tubule (DCT) and connecting tubule 
(CNT) of the nephron, where it constitutes 
the apical entry mechanism for transcellu-
lar Ca2+ reabsorption. TRPV5 is a consti-
tutively active ion channel bearing unique 
electrophysiological characteristics in-
cluding calmodulin (CaM) and Ca2+-depen-
dent inactivation and high selectivity for 
Ca2+ (2, 3). The activity of TRPV5 is tightly 
controlled at multiple levels by an array 
of different factors, including parathyroid 
hormone (PTH) and the serine protease 
tissue kallikrein. Both PTH and tissue kalli-
krein initiate the phosphorylation of TRPV5 
through the cAMP/PKA and PLC/DAG/
PKC signaling cascades, respectively (4, 
5). 
Proteinuria is a hallmark of nephrotic 
syndrome (NS), in which large plasma pro-
teins pass through the disrupted glomeru-
lar basement membrane (GBM). Patholog-
ical leakage of glomerular proteins causes 
multiple tubulo-interstitial abnormalities 
such as interstitial inflammation and even-
tually fibrosis, but does not affect tubu-
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nephropathy. All patients were overtly pro-
teinuric i.e., median (IQR) urinary protein 
excretion was 6.5 (5.3-8.2) g/day. Collec-
tions were performed at University Medical 
Centre Groningen and all patients provided 
informed consent.
Plasmin purification and activity assay
Urine samples were dialyzed in Spectra/
Por® dialysis membrane (Spectrum Labo-
ratories, USA) for 12 h with dialysis buffer 
(10 mM Tris HCl pH 8.1 and 5 mM EDTA). 
Urine precipitates were purified with high 
affinity ion exchange chromatography with 
mono-Q column based on the theoreti-
cal pI of plasmin (7.08, http://expasy.org/
tools/pi_tool.html). Urine samples were in-
jected in the column with buffer A (10 mM 
Tris pH 8.1 and 5mM EDTA) and eluted with 
buffer B (10 mM Tris pH 8.1, 5 mM EDTA 
and 1 M NaCl). Chromatography fractions 
were concentrated with 50K Amicon® Ultra 
Centrifugal Filter Units (Millipore, USA) and 
the presence of plasmin was determined 
by immunoblotting. Plasmin activity was 
measured with SensoLyte® AFC plasmin 
activity assay kit (AnaSpec, USA) accord-
ing to a provided protocol.
Polymerase chain reaction analysis
To evaluate mRNA expression of F2R, 
PRSS8, and LRP2 (encoding PAR-1, pros-
tasin, and megalin, respectively), total RNA 
was extracted from human embryonic kid-
ney (HEK) 293 cells using TriZol Total RNA 
Isolation Reagent (Life Technologies BRL, 
the Netherlands) according to the manu-
facturer’s protocol. The obtained RNA was 
subjected to DNase treatment (Promega, 
USA) to prevent genomic DNA contamina-
tion. Thereafter, 2 µg of RNA was reverse 
lar morphology (6). However, recent data 
showed that tubular transport processes 
could be affected by direct effect of uri-
nary protein on membrane transporters at 
the luminal side of the DCT, such as ENaC 
(7). The observation of nephrocalcinosis in 
patients with nephrotic-range proteinuria 
(8, 9), associated with impaired transcellu-
lar Ca2+ reabsorption via TRPV5 in mouse 
model (10), suggests that proteinuria might 
be able to affect tubular Ca2+ handling.  
In patients with nephrotic syndrome, 
serum plasminogen levels are elevated 
(11). After leakage into the urine, plasmino-
gen is converted into active plasmin by tu-
bular urokinase-type plasminogen activa-
tor (uPA) and has recently been reported 
to regulate renal ion transport in NS by 
effects on ENaC (7, 12).  Whether urinary 
plasmin also can affect tubular Ca2+ han-
dling, and if so, by which mechanisms, has 
not been established so far.  The present 
study aims to investigate the effects and 
mechanism of urinary plasmin on TRPV5-
mediated Ca2+ reabsorption. 
Materials and Methods
Collection of urine samples
Twenty-four hour urine samples were 
collected from 5 nephrotic patients (all 
male, mean age 53±2.6 years, mean cre-
atinine clearance 24±9 ml/min) prior to 
their visits to the outpatient nephrology 
clinic. Their underlying diseases proven 
by biopsies were MPO-ANCA-associat-
ed glomerulonephritis, IgA nephropathy, 
membranous nephropathy, focal segmen-
tal glumerulosclerosis (FSGS) and diabetic 
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Table 1 : Homo Sapiens oligonucleotide sequences used in RT-PCR
Gene Forward primer Reverse primer Product length 
(bp)
   F2R     CTCTGCCTGCCGCGAAGACC      CCTGCGATGGCCAAAGCCCA            813
   PRSS8     GGCCAGACGGTGCTGGTGAC      GGGTGCTGACCTTGGCGTCC            582
   LRP2     GGCGGGTCGCTCGTGTCAAA      GTGACCGGGGCTGGACTTGC            981
   GAPDH     GTGAAGGTCGGAGTCAACGG      TCTTCTGGGTGGCAGTGATG            650
transcribed by Molony-Murine Leukemia 
Virus-Reverse Transcriptase (Invitrogen, 
the Netherlands). The cDNA was used 
to determine mRNA expression levels by 
PCR both of the target genes of interest 
and of the housekeeping gene GAPDH as 
an endogenous control. Primers targeting 
the genes of interest were designed using 
the computer program Primer3 (v.0.4.0) 
and are listed in Table 1.
DNA constructs and cell culture
TRPV5 pCINeo/IRES-GFP constructs 
were generated as described previously 
(13). Single and combined PKC mutants 
were generated by alanine substitution of 
the six putative phosphorylation sites of 
TRPV5 (S144A, S299A, S316A, S654A, 
S664A, S698A) using in vitro mutagenesis 
(QuikChange Site-Directed Mutagenesis 
kit, Stratagene, USA) (5). HEK293 cells 
were transfected at 70% of confluency us-
ing polyethylenimine (Polysciences, Inc., 
USA) or Lipofectamine 2000 (Invitrogen, 
the Netherlands). After 48 h, cells were 
used for 45Ca2+ uptake assays, patch-
clamp and/or biotinylation experiments. 
Prior to the assays, cells were incubated 
for 1 h in serum-free cell culture medium 
containing the particular compounds.
45Ca2+ uptake assay
HEK293 cells were transfected with 
TRPV5-HA pCINeo/IRES-GFP constructs. 
Ca2+ uptake was determined in uptake me-
dium (110 mM NaCl, 5 mM KCl, 1.2 mM 
MgCl2, 0.1 mM CaCl2, 10 mM Na-acetate, 
2 mM NaH2PO4, 20 mM HEPES–Tris, pH 
7.4, supplemented with 10 µM felodipine, 
10 µM methoxy-verapamil, and 1 µCi/ml 
45CaCl2) for 10 min at 37°C. Each well was 
washed extensively with stop buffer (110 
mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.5 
mM CaCl2, 1.5 mM LaCl3, 10 mM Na-ac-
etate, 20 mM HEPES–Tris, pH 7.4) at 4°C, 
incubated with 0.05% w/v SDS, and the ly-
sates were counted for radioactivity using 
liquid scintillation. 
Cell surface biotinylation and immu-
noblotting
HEK293 cells (9 X 104 cells/cm2) were 
plated and transfected with 15 µg TRPV5 
pCINeo/IRES-GFP or pCINeo/IRES-GFP 
F2R, coagulation factor II receptor; PRSS8, serine protease 8; LRP2, low density lipoprotein receptor-related pro-
tein 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase
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488-conjugated antibody (1:300) (Mo-
lecular Probes, USA) was used. TRPV5 
staining has been performed as previ-
ously described (14). All negative controls, 
including sections incubated with pre-
immune serum or conjugated antibodies 
solely, were devoid of any staining.
Electrophysiology and solutions
Patch-clamp experiments were per-
formed under the whole-cell configura-
tion using an EPC-9 patch-clamp amplifier 
controlled by the Pulse software (HEKA 
Elektronik, Germany). Borosilicate patch 
pipettes had a resistance between 3 and 
4 MΩ after being filled with the intracellular 
solutions. Series resistance (3-10 MΩ) was 
continuously monitored with the automatic 
capacitance compensation of Pulse soft-
ware. The extracellular solution consisted 
of (in mM) 150 NaCl, 6 CsCl, 10 glucose, 10 
HEPES, 44 mannitol, and 0.05 EDTA (DVF 
solution with EDTA, pH 7.4 NaOH).  The 
intracellular solution included (in mM) 20 
CsCl, 100 aspartate, 1 MgCl2, 10 BAPTA, 
1 Na2ATP, and 10 HEPES (pH 7.2 CsOH). 
For the recording of Ca2+ current, 10 mM 
CaCl2 was added to the extracellular solu-
tion. Cells were exposed for a maximum of 
1 min to a Krebs solution containing 1 mM 
Ca2+ before sealing the patch pipette to 
the cell. The analysis and display of patch-
clamp data were performed using Igor Pro 
software (WaveMetrics, USA).
NMR spectroscopy
Titration of 15N labeled CaM by non-
labeled peptides was done as previously 
described (15, 16). Briefly, 15N-labeled 
CaM was titrated by synthetic peptides 
with CaM:peptide molar ratios ranging 
in poly-L-lysine (Sigma)-coated 10 cm 
dishes. At 48 h after transfection, cells 
were incubated for 1 h with 10 nM plasmin 
and 50 nM α2-antiplasmin inhibitor. Cells 
were homogenized in 1 ml lysis buffer as 
described previously (4) using the NHS-
LC-LC-biotin (Pierce, the Netherlands). 
Finally, biotinylated proteins were precipi-
tated using NeutrAvidin® beads (Pierce). 
TRPV5 expression was analyzed by im-
munoblotting for the precipitates (plasma 
membrane fraction) and for the total cell 
lysates using the guinea-pig anti-rabbit 
TRPV5 antibody (1).
Ca2+ imaging using Fura-2/AM
HEK293 cells were seeded on fibro-
nectin-coated coverslips. After 24 h, cells 
were loaded with 3 μM fura-2-AM and 
0.01% (v/v) Pluronic F-129 in DMEM me-
dium at 37°C for 20 min. After loading, 
cells were washed twice with PBS and al-
lowed to equilibrate at 37°C for another 10 
min in 132 mM NaCl, 4.2 mM KCl, 1.0 mM 
MgCl2, 5.5 mM D-glucose, 10 mM EDTA, 
10 mM HEPES and titrated to pH 7.4 with 
Tris. Plasmin with final a concentration of 
10 nM was added directly to buffer solu-
tion. Changes in intracellular Ca2+ concen-
tration ([Ca2+]i) were monitored with fura-2 
excited at 340 and 380 nm using a mono-
chromator (Polychrome IV, Germany). All 
measurements were performed at room 
temperature. Details of this experiment 
were described previously (16).
Immunohistochemistry
Mouse kidney sections were incubated 
for 16 h at 4°C with rabbit polyclonal an-
tibody against PAR-1 (1:100). To visual-
ize PAR-1, goat anti-rabbit Alexa Fluor 
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from 1:0 to 1:3 in steps of 0.5. Prior to 
titrations, both CaM and peptides were 
dialyzed against the same buffer (1/100 of 
50 mM KCl, 10 mM CaCl2, 20 mM Tris [pH 
7.0]-HCl), freeze-dried and reconstituted in 
the same buffer. D2O and NaN3 (both from 
Sigma) were added to the NMR samples to 
the final concentrations of 5-7% (v/v) and 
0.01% (v/v), respectively. The concentra-
tion of CaM in the samples was 0.4 mM. 
Spectra were acquired at 308 K, 600 MHz 
Bruker Avance III spectrometer. 
Compounds
Plasmin, plasminogen, and α2 -antiplas-
min inhibitor were purchased from Sigma. 
PAR-1 antagonist (SCH79797) was from 
Axon Medchem, the Netherlands. A poly-
clonal PAR-1 antibody (rabbit IgG) was 
from Santa Cruz Biotechnology, USA. A 
polyclonal plasminogen antibody (goat 
IgG) was obtained from Abcam, UK. Chel-
erythrine was from Research Biochemicals 
International, Germany. 15NH4Cl was from 
Buchem BV, the Netherlands. Synthetic 
peptides corresponding to the residues 
133-154 of hTRPV5 (WT and with phos-
phorylated S144, S144pS) were purchased 
from GenicBio Limited (China).
Statistical analyses
If not specified otherwise, the data are 
expressed as mean±SEM. Multiple sets of 
data were compared by analysis of vari-
ance (ANOVA). The significant differences 
between the means of two groups were 
analyzed by unpaired t-test, while multiple 
comparisons between groups were per-
formed by Tukey’s post hoc analysis. The 
level of statistical significance is P<0.05. 
All data were analyzed by GraphPad Prism 
(version 4.0c for Mac OS X; GraphPad 
Software, USA).
Results
Plasmin in nephrotic urine inhibits 
TRPV5-mediated Ca2+ influx 
To investigate the effect of plasmin on 
TRPV5-mediated Ca2+ transport, HEK293 
cells were transfected with TRPV5 and 
treated with 10 nM plasmin for 1 h prior 
to radiotracer 45Ca2+ influx measurements. 
Plasmin inhibited TRPV5-mediated Ca2+ 
influx to an extent comparable to that seen 
with ruthenium red, thus indicating com-
pletely inhibited TRPV5 activity (Fig. 1A). 
Plasmin inhibits Ca2+ influx with an IC50 
of ~ 3 nM (Fig. 1B) after at least 30 min 
incubation (data not shown). The specific 
plasmin inhibitor α2-antiplasmin reversed 
this block (Fig. 1A). Purified plasmin from 
the urine of 5 nephrotic patients mimicked 
the inhibitory effect when compared with 
commercial plasmin. This urinary activity 
could be reversed by heat inactivation and 
α2-antiplasmin (Fig. 1C). The presence of 
plasmin in urine samples and their activi-
ties are depicted in Fig. 1D
Plasmin does not affect TRPV5 mem-
brane abundance
Because plasmin has been reported to 
cleave the membrane-bound Na+ channel 
ENaC (12), we investigated whether plas-
min could exert it effects via cleavage of 
TRPV5 by using cell surface biotinylation 
experiments. Fig. 2A shows no change in 
both plasma membrane and total expres-
sion of TRPV5 (protein input) after plas-
min treatment (immunoblot intensities are 
shown in Fig. 2B). The positive control tis-
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Figure 2 : Plasmin does not affect surface plasma mem-
brane abundance of TRPV5. A, TRPV5-transfected HEK293 
cells were treated with 10 nM plasmin. 100 nM tissue kalle-
krein (TK) was used as positive control. NHS-LC-LC-biotin 
was added to media for 30 min before cells were lysed, and 
the biotinylated fraction was pulled down with neutravidin-
agarose beads. TRPV5 was eluted and analyzed by immu-
noblot for plasma membrane expression. β-actin was used 
as an internal control. B, immunoblot densities calculated 
from A. C, control; P, plasmin-treated.
Figure 1 : Plasmin in nephrotic urine inhibits TRPV5-mediated Ca2+ influx in HEK293 cells. A, 1-h incubation of 10 
nM commercial plasmin was effective to inhibit Ca2+ influx and was reversed by 50 nM α2-antiplasmin (α2), specific 
plasmin inhibitor. 10 μM ruthenium red (RR) was administered to determine TRPV5-mediated Ca2+ influx. Cells 
were pretreated with 25 μM BAPTA-AM for 30 min. B, dose-response curve of Ca2+ uptake. C, plasmin purified 
from nephrotic urine inhibited Ca2+ influx and this effect was abolished by a heat inactivation (5 min at 80°C) and 
α2. D, Plasmin expression in urine samples of 5 nephrotic patients was shown on immunoblot (C=control urine 
sample, P=plasmin-added sample). Plasmin activities of the commercial plasmin (plasmin), nephrotic urine-purified 
(nephrotic) and urine from normally healthy subject (normal) are shown in the unit of relative fluorescence unit (RFU) 
under control (black), heat-inactivated (striped), and α2-antiplasmin (white), respectively. *P<0.05 versus respective 
mock or control.
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mouse kidney cortex is depicted by immu-
nohistochemistry (Fig. 3C). Fura-2-based 
Ca2+ imaging experiments showed that 
PAR-1 was functional because it stimu-
lated intracellular Ca2+ release (Fig. 3D). 
The PAR-1 inhibitor SCH79797 and PAR-1 
antibody prevented the TRPV5 inhibition 
by plasmin, indicating a specific action of 
plasmin through PAR-1 (Fig. 3E).
Plasmin-induced inhibition of TRPV5 
depends on PKC phosphorylation of 
serine-144 residue 
PAR-1 is a member of the G protein-
coupled receptor (GPCR) family, which 
normally exerts its effect through the PKA 
(21) or PLC/PKC pathways (22). We in-
vestigated whether these protein kinases 
are involved in plasmin-activated PAR-1 
signaling. TRPV5 possesses three poten-
tial phosphorylation sites for PKA:  one is 
sue kallikrein could enhance TRPV5 mem-
brane abundance and not affecting the 
channel total expression (5) (Fig. 2A). 
TRPV5 inhibition by plasmin is medi-
ated by protease-activated receptor-1 
As plasmin failed to cleave TRPV5 at the 
plasma membrane, we hypothesized that 
the reduced TRPV5 activity is mediated by 
a cell surface membrane receptor. Plas-
min has been previously shown to bind the 
protease-activated receptor-1 (PAR-1), 
prostasin, and megalin (17-20). Therefore, 
we examined mRNA expressions of F2R, 
PRSS8, and LRP2, which encode PAR-1, 
prostasin, and megalin, respectively. Our 
results showed that only PAR-1 is endog-
enously expressed in HEK293 cells (Fig. 
3A). PAR-1 protein expression is shown 
by immunoblot (Fig. 3B). Colocalization of 
PAR-1 and TRPV5 in late DCT and CNT of 
Figure 3 : PAR-1 is responsible for plasmin-induced reduction in TRPV5-mediated Ca2+ influx. A, F2R, PRSS8 and 
LRP2 mRNA expression were examined by RT-PCR. GAPDH was used as a control. (+) and (-) signify PCR prod-
ucts of reverse-transcribed and non-reverse-transcribed mRNA, respectively. B, Immunoblot shows endogenous 
PAR-1 expression in HEK293 cells in mock (M), TRPV5-transfected (C), and TRPV5-transfected and treated with 10 
nM plasmin (P). C, Immonohistochemistry depicts PAR-1 and TRPV5 colocalization. D, Fura-2 experiment tracer 
shows a PAR-1 induction of Ca2+i release in the presence of 10 mM EDTA. E, inhibitory action of plasmin (P) on 
TRPV5-mediated 45Ca2+ influx is reversed by 30-min pretreatment of 20 μM SCH79797 (S), a PAR-1 antagonist; and 
2 μg/mL PAR-1 antibody (Ab). *P<0.05 compared to control (C).
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on the N-terminus (Nter) and the other two 
are on the C-terminus (Cter) (4).   In addi-
tion, there are six sites for PKC, three sites 
on both the Nter and Cter(5). HEK293 cells 
were transfected with Nter-PKA, Cter-PKA, 
or six-PKC phosphorylation site-mutated 
TRPV5. All PKA- and PKC-TRPV5 mu-
tants were still able to transport Ca2+ to the 
same extent as wild-type TRPV5. Howev-
er, plasmin failed to inhibit Ca2+ uptake in 
the six-PKC-phosphorylation site mutant, 
suggesting that at least one of these sites 
is responsible for plasmin action (Fig. 4A). 
This finding prompted us to find the PKC 
phosphorylation site responsible for the 
inactivation of TRPV5. In combination with 
the Ca2+ uptake assay, serine (S) residue 
located in the ankyrin repeat domain 3 
(ANK3) of the Nter mutated to alanine (A), 
S144A (5), was found not responsive to 
plasmin action (Fig. 4C). The involvement 
of the PLC/PKC signaling pathway was 
further confirmed by establishing the re-
versal effect of PLC and PKC antagonists 
(U73122 and chelerythrine, respectively) 
on the inhibitory action of plasmin (Fig. 4B). 
Plasmin specifically decreases 
TRPV5-mediated Ca2+ current by 
reducing its pore size and open prob-
ability
The functional effect of plasmin on 
TRPV5-mediated Ca2+ current measured 
by patch clamp technique was studied in 
HEK293 cells expressing TRPV5, by incu-
bating cells for 1 h with 10 nM plasmin. Pri-
or to measuring Ca2+ currents, recordings 
of non-inactivating inward-rectifying Na+ 
currents were obtained in the presence 
of 50 μM EDTA. Neither the amplitude of 
the Na+ current nor current-to-voltage re-
lationship (I/V) was affected by plasmin 
(Fig. 5A and B). However, in the presence 
of 10 mM BAPTA intracellularly, a signifi-
cant decrease in the Ca2+ peak current 
from 1.02±0.07 to 0.73±0.06 nA/pF was 
observed in plasmin-treated group without 
affecting TRPV5 inactivation kinetics (Fig. 
Figure 4 : Inhibition of TRPV5 activity by plasmin 
requires the presence of S144 residue on amino-
terminus. A, effects of plasmin on Ca2+ uptake were 
measured in wild-type (WT) TRPV5, amino- and car-
boxy-terminal PKA-site mutants (N-PKA and C-PKA, 
respectively), and the six-site PKC TRPV5 mutant 
(PKC). B, Incubation of 10 μM U73122 (U), a PLC in-
hibitor and 10 μM chelerythrine (Ch), a cell-permeable 
PKC inhibitor for 30 min reversed the inhibitory effect 
of plasmin (P) to control (C) level. C, Effect of plasmin 
on Ca2+ uptake when TRPV5 contains single-point mu-
tations of six PKC phosphorylation sites. *P<0.05 ver-
sus a non-plasmin condition (-) or control (C).
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5C, D and E). This effect was not observed 
in the S144A mutant. Similar results were 
seen in the presence of 50 μM EGTA (data 
not shown).
To further substantiate the inhibitory ef-
fect of plasmin on the Ca2+-mediated cur-
rent, we performed sieving experiments 
after plasmin treatment to estimate chang-
es in TRPV5 effective pore diameter by 
measuring relative permeability to organic 
monovalent cations of increasing size. 
Divalent-free (DVF) intra- and extracellular 
solutions were used to avoid Mg2+ and Ca2+ 
block of monovalent currents. Starting 
with Na+ as the sole intra and extracellular 
Figure 5 : Plasmin-mediated inhibition of TRPV5 Ca2+ currents in HEK 293 cells. A, representative current traces 
(I/V) obtained from TRPV5 incubated with plasmin. Voltage ramps were applied in presence of EDTA (50 μM) until 
currents reached steady state (left, wild type and right, S144A mutant; solid line, control and dotted line, plasmin-
treated). B, averaged Na+ current density at -80 mV in the presence of EDTA for TRPV5 wild type and TRPV5-
S144A mutant. No differences in the Na+ currents were reported in those conditions. C, representative TRPV5 Ca2+ 
currents evoked by application of a hyperpolarizing voltage step to -100 mV in presence of 10 mM Ca2+ (left, wild 
type and right, S144A mutant). Plasmin promotes a significant reduction in the peak of Ca2+-currents without af-
fecting the inactivation kinetics. D, averaged density of the Ca2+-mediated peak currents shows that mutation of the 
S144 to A abolishes effect of plasmin on Ca2+ currents. E, Inactivation kinetics analysis from all the Ca2+ recordings 
in both wild type TRPV5 and S144A mutant in the presence and absence of plasmin. No change was reported at 
any of the conditions. F, relative permeabilities (Px/PNa) of the different organic cations plotted as a function of 
the cation diameter for TRPV5 in the absence and presence of plasmin (solid line and dotted line, respectively). 
Data points were fitted to a first order exponential decay equation and used to calculate pore diameter (G). *P<0.05 
versus a non-plasmin condition (-).
42
C
ha
pt
er
 2
 
cation, TRPV5 currents reversed close to 0 
mV. Subsequently, all Na+ in the extracel-
lular solution was replaced by mono-, di-, 
tri- or tetra-methyl substituents. Then per-
meability ratios of the substituents relative 
to Na+ (PX/PNa) from the bi-ionic reversal 
potential were determined. Fig. 5F shows 
the permeability ratios of the different 
cations versus their estimated diameters 
obtained for TRPV5 treated with plasmin. 
Data points were fitted using a modified 
excluded volume equation (PX/PNa)
1/2 = 
dP-dX/dP-dNa, where dP, dX, and dNa 
are diameters of the pore, specific cation 
X+ and Na+, respectively. Plasmin-treated 
cells showed a significant decrease in the 
estimated pore diameter (6.72±0.07 and 
6.18±0.04 Å for control and plasmin-treat-
ed cells, respectively, P<0.05) (Fig. 5G). 
In different cell types, PKC activation 
via PAR-2 affected open probability (NPo) 
of TRPV1 (19, 20). The cell-attached sin-
gle-channel recordings keep intracellular 
second messengers and kinases intact, 
thus suitable for investigating TRPV5 func-
tion in the present study. The recordings 
were made from HEK293 cells expressing 
TRPV5-WT (Fig. 6A) or TRPV5-S144A (Fig. 
6B). The averaged calculated slope con-
ductance was 68±4 pS for TRPV5-WT and 
72±4 pS for TRPV5-WT preincubated with 
Figure 6 : Plasmin inhibits single-channel activity of TRPV5-WT but not TRPV5-S144A. A and D, Cell-attached 
single-channel recordings were made from HEK293 cells expressing TRPV5-WT or TRPV5-S144A. Channel activ-
ity was elicited by step potentials varying from -100 to +80 mV for TRPV5-WT (A) and TRPV5-S144A (D). Downward 
currents indicate channel opening state. B and E, Amplitude histograms were constructed from regions of the 
single-channel recordings and were fitted by three Gaussian functions corresponding to closed, one open, or two 
open levels.  C and F, the averaged NPo upon plasmin incubation was assessed by averaging 10-s intervals for 1 
min using a holding potential of -80 mV. *, P< 0.05 versus untreated TRPV5-WT (n = 5-7).
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10 nM plasmin for 1h (Fig. 6B) Similarly, 
the averaged calculated slope conduc-
tance was 65±3 pS for TRPV5-S144A and 
66±2 pS for TRPV5-S144A preincubated 
with 10 nM plasmin for 1 h (Fig. 6D). In Fig. 
6C and F, the averaged NPo upon plas-
min incubation was assessed by averag-
ing 10-s intervals for 1 min using a holding 
potential of -80 mV. Plasmin significantly 
decreases NPo in TRPV5-WT-expressing 
cells, but does not influence NPo in cells 
expressing TRPV5-S144A.
Calmodulin selectively binds TRPV5 
and this binding is affected by phos-
phorylation of S144 in the N-terminus 
of TRPV5
The effect of plasmin on TRPV5 has 
been shown to be highly specific for Ca2+ 
and we decided, therefore, to test whether 
the ubiquitous Ca2+-sensor CaM was re-
quired for plasmin-mediated TRPV5 inhi-
bition. The Calmodulin Target Database 
(2002 Ikura Lab, Ontario Cancer Institute; 
http://calcium.uhnres.utoronto.ca) indicat-
ed that the specific region surrounding the 
highly conserved S144 amino acid holds 
the highest probability for potential CaM 
binding (RGASVSARA) (Fig. 7A). 15N-1H-
HSQC spectra of 15N-labeled CaM were 
measured by high-resolution nuclear mag-
netic resonance (NMR) spectroscopy un-
der various concentrations of the synthetic 
peptides corresponding to the residues 
Figure 7 : S144 residue located on the third ankyrin repeat domain-3 (ANK3) of the Nter-TRPV5 is conserved among 
mammalian species. The potential CaM-binding sequence (RGASVSARA) is depicted (A). 15N-1H-HSQC spectra of 
15N-calmodulin at various concentrations of the synthetic peptides: (B) WT, (C) S144pS mutant. Calmodulin:peptide 
molar ratios are represented as follows: black, 1:0; red, 1:1; blue, 1:2. Each peak corresponds to a unique proton 
attached to a 15N nucleus. Spectra were acquired at 308 K, 600 MHz Bruker Avance III spectrometer.
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133-154 of Nter. In the presence of Ca
2+, 
both WT and S144pS mutant peptides 
specifically bound CaM. As seen from the 
overlaid 15N-1H-HSQC spectra of CaM in 
Fig. 7B and C, CaM peaks shift in a simi-
lar fashion upon addition of the peptides. 
This indicates that both peptides interact 
with CaM in a generally similar way with 
some slight differences. Namely, in case of 
the WT peptide, the intensity of the peaks 
remains the same in the course of the titra-
tion, which implies fast exchange (on the 
NMR time-scale). However, in case of the 
S144pS mutant, the intensity of the shifted 
signals significantly decreases, e.g. I27, 
A57, D64, indicating that the CaM-peptide 
complex is now in intermediate exchange 
regime. Thus, phosphorylation of S144 
clearly affects CaM-TRPV5 binding and 
alters its dynamical properties.
Discussion
This study shows that plasmin present 
in the urine of NS patients inhibits TRPV5-
mediated Ca2+ transport. This inhibition is 
mediated by PAR-1 through PKC phos-
phorylation of the Ca2+ channel at the 
S144 residue. Our conclusion is based on 
the following findings: i )  plasmin, both the 
commercially-available form and that con-
centrated from the urine of NS patients, 
inhibits TRPV5-mediated Ca2+ transport 
without affecting TRPV5 surface mem-
brane expression. Inhibition of Ca2+ trans-
port could be prevented by the specific 
plasmin inhibitor α2-antiplasmin and heat 
inactivation; ii) plasmin activity requires an 
intact PAR-1/PLC/PKC signaling pathway, 
which phosphorylates TRPV5 at S144; iii) 
plasmin decreases TRPV5-mediated Ca2+ 
currents mainly by reducing the open 
probability of TRPV5 without affecting 
monovalent currents; iv) residues 133-154 
of TRPV5 selectively bind CaM and this 
binding is affected by phosphorylation of 
S144.
Plasmin is well-known for its action in 
fibrinolytic processes. Our data suggest 
that plasmin may be involved in modulat-
ing Ca2+ reabsorption in the kidney under 
pathophysiological conditions, namely 
glomerular protein leakage. Plasmin has 
been recently identified as a crucial fac-
Figure 8 : Molecular model of plasmin action on TRPV5 in nephrotic syndrome. The basal level of TRPV5-depen-
dent Ca2+ influx is constitutively established by the endogenous CaM binding (A). Plasmin (PL) from nephrotic urine 
catalyzes PAR-1, promoting S144 phosphorylation by PKC. This results in decreased open probability (NPo) and 
pore size of TRPV5 and modification of CaM binding to the CaM-binding sequence (B). 
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tor for Ca2+ homeostasis and normal bone 
maintenance (25). Plasminogen-deficient 
mice manifest decreased trabecular and 
cortical bone density due to enhanced 
osteoclast activity and retarded osteo-
blast activity. In kidney, plasmin is known 
to play a major role in the degradation 
and turnover of the extracellular matrix 
and especially the glomerular mesangial 
matrix (26). In addition, plasmin has long 
been hypothesized to be involved in renal 
stone formation since plasmin and uPA 
activities are decreased in stone-forming 
patients (27). In that study, van Aswegen 
and colleagues reported that urate inhib-
ited urokinase/plasmin activities at pH 3.9 
(in the presence of acetate), but is minimal 
under alkaline condition (in the absence of 
acetate). Therefore, it can be implied that 
plasmin is still stable in our patient’s urine 
with pH 7.5-7.7. Our laboratory previously 
showed that extracellular alkalinization re-
sulted in a pool of TRPV5-containing ves-
icles recruitment to the cell surface (28). 
Our findings suggest that, once present at 
the cell surface, TRPV5 activity is inhibited 
by plasmin in nephritic urine via its recep-
tor PAR-1. In vivo studies on Ca2+ balance, 
however, would be required to fully sub-
stantiate this assumption. Of note, in line 
with our data pharmacological reduction 
of proteinuria leads to a corresponding 
reduction in calciuria in clinical study (29).
PAR-1 has been reported to couple to 
various heterotrimeric G proteins and con-
veys its signal through several kinases in-
cluding Src family tyrosine kinases, JNK, 
Rho kinases, MAPK, PKA and PKC (21, 
23). Protein kinases have been found to 
differentially regulate ion channel gating 
and trafficking. Upon stimulation, PAR-
1 enhances PLC-β-dependent hydroly-
sis of PIP2, which results in DAG and IP3 
production. DAG further stimulates PKC-
dependent phosphorylation of TRPV5. 
Here we show that S299 and S654 double 
mutant is still responsive to plasmin effect 
. On the other hand, the S144 mutant is 
also stimulated by TK (data not shown). 
Therefore, plasmin and TK induce PKC 
phosphorylation of TRPV5 at independent 
sites. TPA has been previously shown to 
downregulate α, β, and ε (5). Accordingly, 
the present study revealed that 24-h TPA 
treatment prevented the effects of both TK 
and plasmin (data not shown). The specific 
subtype of PKC involved in this process 
has not yet been characterized. However, 
PKC-α and PKC-ε  have been reported to 
mediate PAR-1 signaling (30), we would 
like to suggest that the Ca2+-independent 
PKC-ε isoform is more likely to be involved 
in this pathway because plasmin-mediat-
ed PAR-1 activation is sufficient to inhibit 
TRPV5 in presence of intracellular Ca2+ 
chelator BAPTA. The atypical PKC iso-
forms were unlikely involved because the 
effect of plasmin is DAG-dependent.
TRPV5 is the most Ca2+-selective mem-
ber of the TRP superfamily involved in Ca2+ 
reabsorption in renal epithelia as shown by 
knockout mice studies (31). TRPV5 activity 
is dependent on calciotropic hormones to 
ensure proper Ca2+ reabsorption (32), but 
other molecules are also involved in the 
TRPV5 regulation. Activation of PKC by 
tissue kallikrein via the bradykinin (BK) re-
ceptor phosphorylates TRPV5 at S299 and 
S654, resulting in an inhibition of channel 
internalization (5). This process retains the 
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channel at the plasma membrane, thus in-
creasing Ca2+ reabsorption. A similar effect 
of plasmin on TRPV5 surface expression 
was, however, not observed. 
Electrophysiological analysis of 
HEK293 cells expressing TRPV5 showed 
that plasmin specifically decreased Ca2+ 
permeability, but had no effect on Na+ 
permeability. This can be explained by ex-
amining the selectivity filter of Ca2+ chan-
nels, which have the terminal carboxyl side 
chains of their aspartates and glutamates 
in the permeation pathway, directly inter-
acting with passing Ca2+ ions (33, 34). This 
structural organization is thought to be 
flexible, and, therefore, its configuration 
can change as a consequence of rear-
rangements of the tertiary and quaternary 
structure of the channel.  Here, we have 
shown that phosphorylation of the S144 
amino acid in the Nter of TRPV5 is required 
to observe the inhibitory effect of plasmin. 
We can, therefore, infer an alteration of 
pore structure, probably through changes 
in ion-ion interactions in the pore. This no-
tion is supported by the observation that 
the effective pore diameter of TRPV5 (6.18 
Å) after plasmin treatment is smaller than 
the hydrated size of Ca2+ ion (6.2 Å) (35). 
At present it is unclear whether this reduc-
tion contributed to the diminished TRPV5 
activity. Further analysis suggests that our 
reduction in Ca2+ transport is likely a con-
sequence of a decrease in NPo induced 
by plasmin. This observation further sug-
gests a role of plasmin in regulating Ca2+ 
reabsorption in the context of NS, as the 
glomerular protein leakage allows this en-
zyme to enter into the pro-urine to reach 
the DCT. Because of the specific effect of 
plasmin on TRPV5 Ca2+ current and NPo, 
we hypothesized that another player could 
be involved in the plasmin activated path-
way. CaM has been recently shown to en-
hance Ca2+-dependent TRPV5 inactivation 
by binding to the distal region of the Cter 
domain (16).  The phosphorylation of T709 
by PTH (via the PKA pathway) impedes 
CaM binding to the Cter and subsequently 
increases the open probability of TRPV5 
(16). CaM can be activated by either Ca2+ 
influx via TRPV5 (16) as well as the release 
of Ca2+  from intracellular stores (36). Dur-
ing the resting state, intracellular free Ca2+ 
([Ca2+]i) is relatively low and CaM remains 
inactive. Once [Ca2+]i rises, Ca
2+ binds to 
CaM via Ca2+-binding EF-hand structures 
(2), which in turn stretches CaM as each 
pair of EF hands exposes a hydrophobic 
patch available to bind target amino acid 
sequences (37).  One of the consequences 
is the inhibition of Ca2+ channel activities 
(38). In addition to binding of CaM to the 
Cter domain, several studies have shown 
that CaM is able to bind the Nter domain 
of TRPV5 in a Ca2+-dependent manner (16, 
39, 40), although no functional experiments 
have been performed to assess the effects 
of Nter binding on channel activity. In fact, 
CaM has recently been reported to bind in 
vitro to the Nter (residues 133-154 and 310-
330) (15). The present study revealed that 
plasmin-induced S144 phosphorylation 
modifies CaM binding affinity of the sur-
rounding region of S144, in addition to a 
decrease of TRPV5 NPo and changing the 
channel pore diameter (Fig. 8).
In conclusion, the present study demon-
strates that plasmin inhibits TRPV5 activity 
through the activation of the PAR-1 recep-
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tor via a PLC/PKC-dependent pathway. 
PKC activation results in phosphorylation 
of the S144 residue and consequently 
inhibits TRPV5 activity by decreasing its 
NPo and pore diameter. Urinary plasmin, 
by inhibiting TRPV5 activity, could poten-
tially be involved in disturbances in renal 
Ca2+ handling found in nephrotic patients 
and may play a role in the tubulo-toxic ef-
fects of proteinuric urine.
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Abstract
Tissue transglutaminase (tTG) is a multifunctional Ca2+-dependent enzyme, catalyz-
ing protein crosslinking. The transient receptor potential vanilloid (TRPV) family of cation 
channels was recently shown to contribute to the regulation of TG activities in keratino-
cytes and hence skin barrier formation. In kidney, where active transcellular Ca2+ trans-
port via TRPV5 predominates, the potential effect of tTG remains unknown. A multitude 
of factors regulate TRPV5, many secreted into the pro-urine and acting from the extracel-
lular side. We detected tTG in mouse urine and in the apical medium of polarized cul-
tures of rabbit connecting tubule and cortical collecting duct (CNT/CCD) cells. Extracel-
lular application of tTG significantly reduced TRPV5 activity in human embryonic kidney 
cells transiently expressing the channel. Similarly, a strong inhibition of transepithelial 
Ca2+ transport was observed after apical application of purified tTG to polarized rabbit 
CNT/CCD cells. Furthermore, tTG promoted the aggregation of the plasma membrane-
associated fraction of TRPV5. Using patch clamp analysis, we observed a reduction in 
the pore diameter after tTG treatment, suggesting distinct structural changes in TRPV5 
upon crosslinking by tTG. As N-linked glycosylation of TRPV5 is a key step in regulating 
channel function, we determined the effect of tTG in the N-glycosylation-deficient TRPV5 
mutant. In the absence of N-linked glycosylation, TRPV5 was insensitive to tTG. Taken 
together, these observations imply that tTG is a novel extracellular enzyme inhibiting the 
activity of TRPV5. The inhibition of TRPV5 occurs in an N-glycosylation-dependent man-
ner, signifying a common final pathway by which distinct extracellular factors regulate 
channel activity.
Introduction
Maintenance of the systemic Ca2+ con-
centration is essential for many physiologi-
cal processes, ranging from enzyme acti-
vation to bone mineralization. As such, the 
kidney plays a key role in stabilizing plas-
ma Ca2+ by changing the urinary excretion 
of Ca2+ in response to excess or depletion 
of this divalent cation (1-3). In kidney, Ca2+ 
is reabsorbed primarily via a passive para-
cellular pathway along the proximal tubule 
and the thick ascending loop of Henle (3). 
Approximately 10% of the Ca2+ load re-
enters the bloodstream via an active trans-
cellular transport process in the distal part 
of the nephron (3, 4). The transient recep-
tor potential vanilloid type 5 (TRPV5) cation 
channel facilitates the apical uptake of Ca2+ 
in these segments (5). In rabbit, TRPV5 is 
expressed predominantly in the collecting 
tubule (CNT), while in other species, such 
as mouse and rat, substantial expression 
of the channel is also observed in the distal 
convoluted tubule (DCT) (4, 6). Ablation of 
TRPV5 in mice (TRPV5-/-) impairs transcel-
lular Ca2+ reabsorption, resulting in robust 
hypercalciuria and compensatory vitamin 
D-dependent hyperabsorption (7).
TRPV5 has unique electrophysiological 
characteristics, including the constitutive 
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inward rectifying activity at low intracel-
lular Ca2+ concentrations and physiologi-
cal membrane potentials, Ca2+-dependent 
inactivation and selectivity for Ca2+ (8). 
Monomers of TRPV5 associate into func-
tional tetramers by facing each other with 
their pore-forming regions (9). Furthermore, 
a single conserved N-glycosylation site at 
asparagine-358 (N358), harbored in the 
first extracellular loop is another important 
structural feature of TRPV5. Native TRPV5 
has been shown to undergo N-glycosyl-
ation, resulting in high mannose and com-
plex-glycosylated proteins (9). The activity 
of TRPV5 is controlled at multiple levels by 
an array of different factors, including cal-
ciotropic hormones (e.g. 1,25-(OH)2D3) and 
extracellular factors (e.g. the glycosidase 
klotho) (10-12). Klotho, as an extracellular 
glycosidase (10, 13) hydrolyzes oligosac-
charide chains from the complex N-glycan 
of TRPV5. This extracellular modification 
results in delayed retrieval of the Ca2+ 
channel from the apical plasma membrane 
and subsequently increases Ca2+ transport 
(10, 13). The stimulatory effect of klotho is 
entirely dependent on the N-glycosylation 
of TRPV5, suggesting that the N-glyco-
sylation status of TRPV5 is crucial for this 
type of extracellular regulation (10, 13). 
Tissue transglutaminase (tTG, also 
known as TGase2; EC 2.3.2.1.3) is a mul-
tifunctional protein catalyzing the Ca2+-de-
pendent covalent crosslinking of specific 
lysine (Lys) and glutamine (Gln) residues 
of substrate proteins (14, 15). Interestingly, 
several Ca2+-binding proteins are known 
substrates of tTG. Calbindin-D28K, an in-
tracellular protein involved in Ca2+-binding 
playing a key role in transcellular Ca2+ 
transport, has been shown to be a sub-
strate of tTG (16, 17). Furthermore, several 
members of the family of S100A EF-hand 
proteins are also substrates of tTG (18, 
19). This includes S100A10, which is in-
volved in the forward trafficking of TRPV5 
to the plasma membrane (19, 20).
A recent study by Cheng et al. elegantly 
showed that TRPV3, another member of 
the TRPV family, contributes in part to epi-
dermal barrier function by affecting the ac-
tivity of transglutaminase (21). This is likely 
to occur via increased TRPV3-dependent 
Ca2+ influx and subsequent Ca2+-depen-
dent activation of the enzyme. In addition 
to these observations, TGase1 expression 
has also been shown to be regulated by 
TRPV6 during Ca2+-induced differentiation 
of keratinocytes (22). Transporters in the 
renal epithelium can be directly affected 
by extracellular factors found in the urine, 
secreted by the cells themselves or filtered 
by the glomerulus from the blood, consti-
tuting a unique environment. tTG is found 
in the intracellular compartment, but the 
enzyme is also secreted, indicating that in 
these epithelia, the enzyme could act from 
the urinary side. In terms of TRPV5-depen-
dent transport, such a mechanism could 
suggest an alternative mode of regulation, 
in comparison to what is observed in e.g. 
the skin barrier formation. Our experiments 
describe the identification of tTG as a novel 
molecular inhibitor of TRPV5. We find that 
the kidney secretes tTG into the pro-urine 
where it covalently crosslinks TRPV5 from 
the extracellular compartment and thereby 
changes the pore size of the channel in an 
N-glycosylation-dependent manner.
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Material and Methods
DNA constructs
The pCINeo/IRES-GFP plasmid en-
coding HA-TRPV5 was generated as de-
scribed previously (20). HA-TRPV5-N358Q 
was obtained by in vitro mutagenesis of 
HA-TRPV5-pCINeo/IRES-GFP cDNA ac-
cording to the manufacturer’s instructions 
(Stratagene, La Jolla, CA, USA) (10). All 
constructs were verified by DNA sequence 
analysis.
Cell lines and transfections
Human embryonic kidney (HEK293) 
cells were cultured in Dulbecco’s modified 
essential medium (DMEM) supplemented 
with 10% v/v fetal calf serum and 2 mM 
L-glutamine. For cell surface biotinylation 
experiments, cells were transiently trans-
fected in Petri dishes, using polyethylene-
imine (PEI). 
Collection and concentration of pre-
conditioned culture medium
CNT/CCD cells were isolated from New 
Zealand White rabbits as described pre-
viously (23), and grown to confluence on 
0.33 cm2 permeable filter supports (Corn-
ing-Costar, Cambridge, MA, USA). Apical 
and basolateral media were collected after 
seeding the cells on permeable supports. 
All collected media were concentrated 3 
times (Millipore), and salts and proteins 
<30 kDa were removed by using cen-
triprep ultracel-YM-30 columns (Millipore 
corporation, Bedford, MA, USA) as de-
scribed (10).
Immunoblotting, and protein concen-
tration determination
TRPV5 and tTG protein expression was 
determined by SDS-PAGE followed by im-
munoblotting, using anti-HA (Cell Signal-
ing, Danvers, USA), anti-tTG (Lab vision/
Immunologic, Duiven, the Netherlands) 
and peroxidase-labeled rabbit anti-mouse 
IgG (Sigma-Aldrich, St. Louis, MO, USA) 
antibodies. Protein concentration was 
measured by using the bicinchoninic acid 
protein assay kit (Thermo Scientific, Rock-
ford, IL, USA), according to the manufac-
turer’s manual.
Cell surface biotinylation
HEK293 cells were transfected with HA-
TRPV5 or HA-TRPV5-N358Q in pCINeo/
IRES-GFP. One day after transfection, 
cells were re-seeded on poly-L-lysine-
coated (0.1 mg/ml) culture dishes and 
incubated with guinea pig tTG (1 µg/ml, 
Sigma-Aldrich, St. Louis, MO, USA)  for  6 
hours at 37°C. Subsequently, cells were 
biotinylated, and TRPV5 was precipitated 
from the cell lysates with neutravidin beads 
(Pierce, Etten-leur, the Netherlands) as de-
scribed previously (10). Briefly, cells were 
collected from the plates and disrupted in 
1 ml lysis buffer (1% v/v Triton-X100, 150 
mM NaCl, 5 mM EDTA, 50 mM Tris (pH 7.5 
adjusted with HCl), PMSF 1 mM, leupeptin 
5 µg/ml, aprotinin 5 µg/ml, pepstatin-A 1 
µg/ml), immediately after biotinylation. 
Cells were subsequently washed with ice-
cold PBS, and homogenized in 1 ml lysis 
buffer, followed by precipitation using neu-
travidin beads. TRPV5 protein expression 
at the cell surface and in total cell lysates 
was measured as described above.
45Ca2+ uptake assay
HEK293 cells transfected with TRPV5 
pCINeo/IRES-GFP constructs were cul-
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tured in 24 wells plates and incubated with 
uptake buffer containing 110 mM NaCl, 5 
mM KCl, 1.2 mM MgCl2, 0.1 mM CaCl2, 10 
mM Na-acetate, 2 mM NaH2PO4, 20 mM 
HEPES–Tris, pH 7.4 supplemented with 10 
µM felodipine, 10 µM methoxy-verapamil, 
and 1 µCi/ml 45CaCl2 for 10 min at 37°C. 
After extensive washing with stop buffer 
(110 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 
0.5 mM CaCl2, 1.5 mM LaCl3, 10 mM Na-
acetate, 20 mM HEPES–Tris, pH 7.4) at 
4°C, cells were disrupted with 0.05% w/v 
SDS and radioactivity was counted using 
liquid scintillation.
Electrophysiology
Whole-cell currents were measured 
with an EPC-10 (HEKA electronic, Lam-
brecht, Germany) amplifier using Patch 
master V2.20 software. The borosilicate 
glass electrode resistance was between 
2.5 and 4 MΩ. The ramp protocol for mea-
suring the current-voltage (I/V) relationship 
of Na+ consisted of linear voltage ramps 
from -100 to +100 mV within 450 millisec-
onds repeated every 5 seconds. The step 
protocol for measuring the Ca2+ current 
consisted of a 10 seconds long voltage 
step applied from +70 to -100 mV. Cur-
rent traces were sampled at 0.5 ms for 
the ramp and 2 ms for the step protocol. 
Current densities were calculated from 
the current at -80 mV during the ramp 
protocol. The standard extracellular solu-
tion contained 150 mM NaCl, 6 mM CsCl, 
10 mM HEPES, 50 µM EDTA and 10 mM 
glucose, (pH 7.4 adjusted with NaOH) for 
divalent free Na+, and 10 mM CaCl2 was 
supplemented for the Ca2+ measurement. 
The internal (pipette) solution contained 
20 mM CsCl, 100 mM Cs-aspartate, 1 mM 
MgCl2, 10 mM BAPTA, 4 mM NaCl, 2 mM 
ATP and 10 mM HEPES (pH 7.2 adjusted 
with CsOH). Data was analyzed using Igor-
pro software (WaveMetrics, Oswego, OR, 
USA). 
Pore measurements
The standard pipette solution con-
tained Tris-HCl buffered 150 mM NaCl, 
10 mM EDTA and 10 mM HEPES (pH 7.2 
adjusted with Tris-HCl) whereas the extra-
cellular solution contained 150 mM NaCl 
and 10 mM HEPES (pH 7.4 adjusted with 
Tris-HCl). The relative permeabilities (PX
+/
PNa
+) of mono-, di-, tri- and tetra-methyl-
ammonium derivatives and of N-methyl-
D-glucamine chloride (NMDG+) were mea-
sured using solutions in which Na+ was 
substituted by the respective cations. Re-
versal potentials were calculated from the 
bi-ionic reversal potentials furthermore, all 
potentials were corrected for possible liq-
uid junction potentials calculated accord-
ing to Barry et al (24). In these permeation 
experiments, the standard pipette solution 
was used as intracellular solution. For the 
ammonium derivatives, the following com-
pound diameters were used (in nm): 0.36, 
0.46, 0.52, 0.58 and 0.68 for monomethyl 
ammonium (MA+) dimethylammonium 
(DMA+), trimethylammonium (TriMA+), tet-
ramethylammonium (TetMA+) and for 
NMDG+ (all compounds obtained from 
Sigma), respectively. For curve-fitting, the 
points from the graph plotting permeability 
ratios of the different organic cations (X) 
versus the estimated diameters, the ex-
cluded volume considering friction of the 
permeating ion Eq. PX
+/PNa
+ = k(1−a/d)2/a 
was used (24), where a is the organic cat-
ion diameter, k the constant factor and d is 
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the minimal pore diameter. 
Statistical analysis
In all experiments, the data were ex-
pressed as mean ± S.E.M. Statistical 
significance (p<0.05) was determined by 
analysis of variance (ANOVA) and a Bon-
ferroni post-hoc test.
Results
tTG is secreted into the pro-urine and 
into the apical medium of CNT/CCD 
cells 
24-hour urine samples from wild-type 
mice were desalted, concentrated and the 
total amounts were subsequently analyzed 
for tTG expression by SDS-PAGE followed 
by tTG Western blotting. A band with a 
molecular size slightly above 75 kDa was 
observed in urine samples (Fig. 1A), cor-
responding to the known 75-78 kDa size 
of tTG. Since tTG was detected in the 
24-hour urine of mice, we next analyzed 
the expression levels of tTG in the CNT/
CCD region. To this end, polarized primary 
cultures of rabbit CNT/CCD were used. 
Western blot analysis, wherein β-actin 
was used as loading control, revealed 
that polarized CNT/CCD cells abundantly 
express tTG (Fig. 1B, upper panel). In the 
apical conditioned media of primary CNT/
CCD cells a significant amount of tTG 
could be detected (Fig. 1C upper panel). In 
addition, tTG was also abundantly present 
in the basolateral compartment (Fig. 1C, 
lower panel). 
tTG inhibits the activity of TRPV5
First, we investigated the dose response 
relationship between tTG and TRPV5 by 
radioactive Ca2+ uptake measurements. 
TRPV5 expressing HEK293 cells were ir-
responsive to low concentration tTG (10-4-
Figure 1 : tTG is secreted into mouse urine and into 
the apical media of rabbit primary CNT/CCD cells. A, 
Mice (n=3) were housed in metabolic cages and 24-
hour urine samples were collected. Samples were 
concentrated and subsequently analyzed for tTG ex-
pression by SDS-PAGE followed by anti tTG Western 
blotting. B, Isolated rabbit primary CNT/CCD cells 
were allowed to polarize on filter supports. Polarized 
monolayers (n=3) were probed for tTG expression by 
SDS-PAGE and subsequent immunoblot with anti-tTG 
(upper panel), and anti-β-actin antibodies (lower pan-
els) respectively. C, Apical and basolateral media from 
polarized CNT/CCD cells were collected and concen-
trated, and subsequently analyzed for tTG secretion by 
immunoblotting. 
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Figure 2 : tTG inhibits TRPV5-mediated currents and transcellular Ca2+ 
transport in primary CNT/CCD cells. A, Dose response relationship be-
tween tTG and TRPV5. HEK293 cells expressing TRPV5 were treated with 
different concentrations of tTG 10-4-3x101 µg/ml and subjected to 45Ca2+ 
uptake. B, tTG inhibited 45Ca2+ uptake via TRPV5 is counteracted by the 
tTG inhibitors cystamine and cadaverine. HEK293 cells transfected with 
TRPV5 pCINeo/IRESGFP or pCINeo/IRES-GFP (mock) constructs were 
treated with active or inactive tTG (1 μg/ml for 6 h), in the presence or 
absence of cadaverine (150 μM) and cystamine (50 mM). After treatment, 
the effect of tTG was assayed in radiotracer experiments following the 
protocol described in ‘‘Materials and methods’’. C, tTG inhibits the activ-
ity of TRPV5. Na+ I/V relations were measured from TRPV5-transfected 
HEK293 cells. The cells were subjected to 6-hour tTG treatment (1 µg/ml) 
in the presence and absence of cadaverine (150 µM) before the current 
measurements. Data are shown as mean ± S.E.M. * indicates significant difference from the cells expressing TRPV5 
(n=15; p <0.05). D, Representative Na+ I/V relations of TRPV5 treated with tTG in the absence or presence of cadav-
erine. Inset: Na+ currents from panel C were normalized to INa max for better comparison. E, Representative Ca2+ 
currents of untreated and tTG-treated TRPV5. F, Polarized rabbit primary CNT/CCD cells were treated for 6 hours 
with 1 µg/ml apically administered tTG and transport was measured as described previously (23). Data are shown as 
mean ± S.E.M. * indicates significant difference from the control situation (n=15; p<0.05). G, Cell surface biotinylation 
of HEK293 cells transiently transfected with pCINeo-HA-TRPV5/IRES-GFP and treated for 6 hours with 1 µg/ml tTG. 
After treatment, cells were subjected to cell surface biotinylation, followed by neutravidin pull-down. The upper and 
the lower panels represent the biotinylated cell surface fractions and the total cell lysates, respectively. Lysates were 
separated on SDS-PAGE and blots were probed with an anti-HA antibody.
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10-2 µg/ml), but a strong reduction in the 
Ca2+ influx was observed in the presence 
of 0.1-30 µg/ml tTG, with an EC50 of 5 µg/
ml (Fig. 2A). Next, we analyzed whether 
the inhibitory effect of tTG on TRPV5-
mediated Ca2+ uptake could be reversed 
by coincubation of tTG in the presence of 
the tTG inhibitors cadaverine or cystamine. 
To this end, HEK293 cells transiently ex-
pressing TRPV5 were treated with tTG (1 
μg/ml) for 6 h in the absence or presence 
of cadaverine or cystamine. As depicted 
in Fig. 2B, both cadaverine and cystamine 
can reverse the inhibitory effect of tTG on 
TRPV5. Heat-inactivated tTG (95°C  heat 
denaturation for 10 min) was not able to 
inhibit TRPV5-mediated Ca2+ uptake. In 
addition, we investigated whether tTG 
can affect the activity of TRPV5. HEK293 
cells transiently expressing the channel 
were treated with tTG (1 µg/ml), for 6 hours 
and subjected to patch clamp analysis 
(Fig. 2C). Heterologous overexpression 
of TRPV5 yielded a large, approximately 
1,500 pA/pF Na+ current density (Fig. 2C). 
Incubation with tTG for 6 hours resulted 
in a significant, 50% reduction of the cur-
rent density (Fig. 2C). Additionally, the tTG 
inhibitor cadaverine (150 µM) prevented 
the tTG-mediated inhibition of TRPV5 (Fig. 
2C and 2D). Normalizing the Na+ currents 
(INa+/INa+max) showed that only the tTG-
treated TRPV5 changed its conducting 
properties (Fig. 2D inset). Furthermore, 
compared with control we could also ob-
serve a significantly reduced TRPV5 Ca2+ 
current upon tTG administration (Fig. 2E) 
The inhibitory effect of tTG was further 
investigated by transcellular Ca2+ trans-
port assays in polarized rabbit primary 
CNT/CCD cell monolayers. The forskolin-
stimulated transcellular Ca2+ transport was 
significantly reduced by tTG and this in-
hibitory effect of the enzyme could be pre-
vented by the tTG blocker cadaverine (Fig. 
2F). Although endogenous tTG could be 
detected in the primary cultures, incubat-
ing the cells with cadaverine did not result 
in a detectable change in transcellular Ca2+ 
transport (Fig. 2F).
To address whether tTG reduces the 
number of channels at the plasma mem-
brane, the action of tTG on TRPV5 was 
assessed by cell surface biotinylation 
studies. TRPV5, with molecular masses 
between approximately 70 and 85 kDa, 
representing the core and complex glyco-
sylated monomers of the channel, respec-
tively, were detected in the plasma mem-
brane fraction (Fig. 2G). Compared to the 
control (-tTG), a decrease in the amount of 
TRPV5 monomers was observed after tTG 
treatment (Fig. 2G). More importantly, af-
ter incubation with tTG, TRPV5 oligomers 
with a molecular mass of ~ 250 kDa were 
observed (Fig. 2G). 
tTG reduces the pore diameter of 
TRPV5
To estimate whether tTG-induced ag-
gregation of TRPV5 can affect the pore of 
the channel, the pore diameter was deter-
mined both in the absence and the pres-
ence of the enzyme. First, the Na+ and Ca2+ 
currents were recorded in the absence and 
presence of tTG, revealing a significant re-
duction in both the Na+ and the Ca2+ cur-
rents upon tTG administration (Fig. 3A and 
B). Next, the permeability ratios of currents 
carried by organic monovalent cations of 
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Figure 3 : tTG decreases the pore diameter of TRPV5. A, TRPV5 Na+ current density in the absence and presence 
of tTG (for details see legends for Fig. 2). B, TRPV5 Ca2+ current density in the absence and presence of tTG. The 
cells were subjected to 6-hour tTG treatment (1 µg/ml). Data are shown as mean ± S.E.M. * indicates significant 
difference from the cells expressing TRPV5 (n=15; p< 0.05). C to H Representative current voltage relationships 
of the different ions in the absence and presence of tTG. Panel C shows the IV for Na+, panels D, E, F, G and H 
are the IV plots for MA+, DMA+, TriMA+, TetMA+ and NMDG+, respectively (n= 7). The currents carried by organic 
monovalent cations were measured using solutions in which Na+ was substituted by the respective cations. Arrows 
with continuous and dashed lines indicate the reversal potential in the untreated and the tTG treated samples, re-
spectively. The insets in panels C to H display the I/V relations in an expanded scale to show the reversal potentials. 
I, Calculated relative permeability ratios of untreated and tTG-treated TRPV5. (PX+/PNa+), were calculated from the 
recorded biionic reversal potentials for all five cations (MA+, DMA+, TriMA+, TetMA+ and NMDG+) for both untreated 
and tTG-treated TRPV5 and subsequently plotted against the estimated diameter of each cation. For curve-fitting, 
the points from the graph plotting permeability ratios of the different organic cations (X) versus the estimated diam-
eters, the excluded volume considering friction of the permeating ion Eq. PX+/PNa+ = k(1−a/d)2/a was used where a 
is the organic cation diameter, k a constant factor and d is the minimal pore diameter. Black dots with continuous 
line and black squares with dashed lines indicate untreated and tTG-treated TRPV5, respectively. J, The pore 
diameter of TRPV5 is reduced by tTG. * indicates significant difference from control (n=7; p< 0.05). K, Tentative 
working model to demonstrate the effect of tTG on the pore size of TRPV5. The upper panels demonstrate the 
control situation and the lower panels depict the case upon tTG treatment. In the absence of tTG, Na+ and Ca2+ can 
be transported through the pore. Na+ flows continuously whereas, Ca2+ moves gradually from one Ca2+ -binding 
pocket to another in the pore of TRPV5. After tTG treatment the continuous Na+ transport is less inhibited whereas 
the gradual transport of Ca2+ is more severely blocked, as the pockets may not be accessible for Ca2+ ions.
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increasing size relative to Na+ current were 
measured. When Na+ was used as the sole 
charge carrier, the current reverted close 
to 0 mV with a clearly inward-rectifying 
shape (Fig. 3C grey curve). Next, all Na+ 
ions from the extracellular solution were 
substituted by monomethyl ammonium 
or its di-, tri- and tetramethyl derivatives 
(MA+, DMA+, TriMA+, TetMA+) and finally 
by the larger organic cation N-methyl-D-
glucamine (NMDG+). To a lesser extent, 
these cations, were also able to perme-
ate TRPV5, and the recorded currents 
were directly proportional to the size of 
each cation (Fig. 3D to H grey curves). In-
cubation with tTG resulted in significantly 
smaller currents in the case of all cations 
except NMDG+, which showed virtually no 
change compared to control (Fig. 3D to 
H black curves). Furthermore, a negative 
shift in the reversal potential of MA+, DMA+, 
TriMA+ was observed (Fig. 3D to F insets). 
The permeability ratios, relative to Na+ 
(PX
+/PNa
+), were calculated from the re-
corded bi-ionic reversal potentials for all 
five cations (MA+, DMA+, TriMA+, TetMA+ 
and NMDG+) for untreated and tTG-treat-
ed HEK293 cells expressing TRPV5, and 
subsequently plotted against the estimat-
ed diameter of each cation. Compared to 
control tTG clearly reduced the PX
+/PNa
+ ra-
tios of TRPV5 in the cases of MA+, DMA+, 
TriMA+ (Fig. 3I dashed line). Next, using 
the permeability ratios, the pore diameters 
were calculated. In the control situation 
the pore diameter for TRPV5 was calculat-
ed to be 6.44±0.01 Å (Fig. 3J). Treatment 
with tTG resulted in a slight but significant 
decrease in the pore size as the diameter 
was calculated to be 5.79±0.02 Å (Fig. 3J). 
N-glycosylation of TRPV5 is important 
for tTG-mediated inhibition
The N-glycan of TRPV5 is crucial for its 
regulation by extracellular factors, such 
as klotho. We next tested if this was also 
the case for the inhibitory effect of tTG. To 
this end, HEK293 cells expressing the N-
glycosylation-deficient mutant form of the 
channel (HA-TRPV5-N358Q) were treated 
with tTG and subjected to patch clamp 
and cell surface biotinylation analyses. 
Patch clamp recordings showed similar 
Na+ currents for the untreated wild type 
and the mutant form of TRPV5 (Fig. 4A). 
However, tTG incubation reduced the ac-
tivity of the wild type channel, but not of 
TRPV5-N358Q (Fig. 4A and B). This was 
further substantiated by normalizing the 
Na+ currents (Fig. 4C) as changes in the 
curve shape could be observed only for the 
tTG treated wild type TRPV5 current. Cell 
surface labeling of HEK293 cells express-
ing either the wild type or TRPV5-N358Q 
showed abundant expression of both wild 
type and the mutant TRPV5 at the plasma 
membrane (Fig. 4D, upper panel). Treat-
ment with tTG caused the aggregation of 
TRPV5 at the plasma membrane and con-
comitantly decreased the amount of wild 
type TRPV5 monomers (Fig. 4D, upper 
panel and 4E). However, this aggregation 
could not be observed in case of the mu-
tant channel (Fig. 4D, upper panel and 4E). 
Additionally, incubation with tTG did not 
alter the total expression of the wild type 
or the mutant form of TRPV5 (Fig. 4D). 
Semi-quantitative analysis of the signal in-
tensities further substantiated the previous 
findings as the percentage of aggregation 
was found to be significantly altered only 
in the case of the tTG treated wild type 
TRPV5 (Fig. 4E). 
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Finally, we investigated the binding ca-
pacity of tTG to wild type and the N-gly-
cosylation deficient TRPV5 channels. The 
immunoprecipitated wild type and mutant 
TRPV5 were incubated with or without tTG 
at 4ºC in the absence of Ca2+ to reduce the 
enzymatic activity of tTG. These immu-
noprecipitation experiments revealed that 
tTG binds to both wild type and the mutant 
form of TRPV5 with equal affinity (Fig. 4F). 
Discussion
Active transcellular Ca2+ transport in 
the kidney takes place exclusively in the 
DCT2/CNT segments of the nephron, 
where the epithelial Ca2+ channel TRPV5 
controls the Ca2+ entry. In this study, we 
identified tTG as a novel inhibitor of TRPV5 
activity, acting from the extracellular side 
in a N-glycosylation-dependent manner. 
This conclusion is based on the following 
observations: i ) tTG is found in the urine in 
mice, in line with the expression and se-
cretion of the enzyme in polarized primary 
CNT/CCD cells; ii ) tTG decreases the ac-
tivity of TRPV5 in transiently transfected 
HEK293 cells and inhibits transcellular 
Ca2+ transport in polarized primary CNT/
CCD cells; iii ) crosslinking of TRPV5 by 
tTG results in a decrease in the pore size 
of the channel; iv) the inhibitory effect of 
tTG depends on the N-glycosylation state 
of TRPV5 as the N-glycosylation-deficient 
mutant is not susceptible to tTG-catalyzed 
modifications.
Increased expression and activity of tTG 
have been previously observed in renal 
disorders such as diabetic nephropathy 
or chronic kidney disease (25-30). In these 
diseases, tTG activity has been associated 
with tissue fibrosis and scar formation, 
taking place in the extracellular matrix (25, 
31). However, whether tTG is secreted into 
the urine during these conditions, has not 
been tested. We established the presence 
of tTG in the urine of mice, which together 
with the fact that primary cultures of po-
larized rabbit CNT/CCD cells also secrete 
a fraction of endogenously expressed tTG 
into the apical medium suggests that tTG 
is present in the pro-urine. Though tTG is 
secreted into the apical medium of pri-
mary CNT/CCD cultures, transcellular Ca2+ 
transport was not affected by cadaverine 
in these cells. An insufficient concentra-
tion of endogenous tTG may explain such 
a discrepancy. In line with this, one may en-
visage that in renal disorders the amount of 
tTG in the urine is sufficient for an effective 
inhibition of TRPV5. The possibility that 
the endogenous tTG in these extracellular 
compartments is present in a catalytically 
inactive, so-called closed state is also fea-
sible (32). The presence of tTG has been 
reported previously in the DCT region and 
in other nephron segments as well (25, 27, 
31). Tubular secretion is, therefore, likely 
to contribute to the amount of tTG found 
in the urine. These observations imply that 
tTG could function as a novel urinary fac-
tor, involved in regulating Ca2+ reabsorp-
tion in the distal part of the nephron. 
Patch clamp recordings of TRPV5 and 
transcellular transport assays in primary 
CNT/CCD cells showed a significant in-
hibitory effect of tTG on Ca2+ transport. 
Earlier studies have reported that tTG has 
the ability to modify the activity of the large 
conductance Ca2+-activated K+ (Maxi-K) 
63
Ti
ss
ue
 tr
an
sg
lu
ta
m
in
as
e 
in
hi
bi
ts
 th
e 
TR
P
V
5-
 d
ep
en
de
nt
 
ca
lc
iu
m
 tr
an
sp
or
t i
n 
an
 N
-g
ly
co
sy
la
tio
n-
de
pe
nd
en
t m
an
ne
r
Figure 4 : N-glycosylation-deficient mutant TRPV5 is insensitive to tTG-mediated inhibition. A, Na+ currents were 
measured from wild type TRPV5 and N-glycosylation-deficient TRPV5-N358Q mutant channels. The cells were 
subjected to 6-hour tTG treatment (1 µg/ml) before the current measurement. Data are shown as mean ± S.E.M. 
* indicates significant difference from the cells expressing either wild type or N-glycosylation-deficient mutant 
TRPV5 (n =11; p < 0.05). B, Representative Na+ I/V relations of wild type TRPV5 and TRPV5-N358Q in the absence 
or presence of purified transglutaminase. C, Na+ currents from panel B were normalized to INa+ max for better 
comparison and plotted as current voltage relationship. D, Cell surface biotinylation of HEK293 cells transiently ex-
pressing HA-TRPV5 or HA-TRPV5-N358Q, after for 6 hours of tTG treatment (1 µg/ml). The upper and lower panels 
represent the biotinylated cell surface fractions and the total cell lysates, respectively. E, Semi-quantitative analysis 
of panel D. The left graph shows the % of tTG-induced multimer formation of TRPV5, right bar graph illustrates 
the tTG-induced changes in the monomeric form of TRPV5. F, Wild type TRPV5 and TRPV5-N358Q bind tTG with 
equal efficiency. HA-tagged wild type TRPV5 or TRPV5-N358Q was immunoprecipitated with HA-antibody from 
transiently transfected HEK293 cells. The precipitated fractions were incubated overnight at 4°C with 1 µg/ml puri-
fied tTG in EDTA-containing Ca2+ free buffer to prevent any enzymatic activity of tTG and proteolysis. The beads 
with TRPV5 and tTG were successively washed and subjected to SDS-PAGE followed by anti-tTG or anti-TRPV5 
immunoblot, respectively.
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channel (33). Using the non-hydrolysable 
GTP analogue GTPγS, this study showed 
that the GTPγS-stimulated channel activ-
ity is decreased to basal levels when cells 
are treated with an antibody against tTG 
(33). Such a G-protein-like effect of tTG 
on TRPV5 is unlikely, as cadaverine, the 
inhibitor of the crosslinking activity of the 
enzyme, abolished the effect of tTG. Next 
to the functional assays, cell surface bio-
tinylation studies revealed the formation 
of SDS-resistant, probably covalently 
crosslinked TRPV5 aggregates in the 
plasma membrane upon tTG incubation. 
tTG is known to be externalized into the 
extracellular space where it crosslinks and 
therefore stabilizes the heteromeric as-
semblies of several matrix and basolateral 
membrane proteins (34-38). In case of the 
tTG substrate small heat shock proteins 
(αB-crystallin, Hsp27, Hsp20 and HspB2), 
crosslinking between different small heat 
shock proteins has been demonstrated to 
be more efficient when they interact with 
each other in the same macromolecular 
assembly (39). These observations sug-
gested that tTG-substrate proteins in close 
proximity to each other are more prone to 
crosslinking than those existing in different 
complexes. TRPV5 exists in a homotet-
rameric form, as four monomers need to 
associate into operational tetramers prior 
to plasma membrane insertion (9). Fur-
thermore, it also harbors several glutamine 
and lysine residues facing the extracellular 
environment. Since the extracellular envi-
ronment as well as the pro-urine contains 
sufficient amount of Ca2+ for the activation 
of tTG, the tTG-mediated aggregation of 
TRPV5 monomers could take place from 
the extracellular side. 
tTG did not change the protein stabil-
ity, membrane expression or trafficking/
recycling properties of TRPV5. Instead, 
we found that extracellular addition of tTG 
decreases the pore size of TRPV5. TRPV5 
harbors several glutamines and two ly-
sines in the first extracellular loop, which 
are the potential substrate sites for tTG. 
Crosslinking these sites could introduce 
extra rigidity or tension into the structure 
of the membrane-inserted TRPV5 in such 
a way that it could cause either a slight 
deformation in the dynamic structure of 
the pore and a subsequent reduction in 
ion permeability. Previously, acidification 
of both the intra- and extracellular envi-
ronment has been shown to decrease the 
pore diameter of TRPV5 by intracellular pH 
(40). tTG reduced the pore size with 10%, 
which is similar to the decrease observed 
upon acidification (40), suggesting that 
such a degree of reduction could already 
account for the decreased channel activ-
ity. We propose a tentative model how this 
change in the pore size could inhibit the 
activity of TRPV5. Crosslinking of TRPV5 
may cause extra rigidity in the channel, 
which in turn results in a smaller pore size. 
This decrease could inhibit the influx of 
Ca2+ more efficiently than that of Na+, as 
the flow of Na+ is continuous in the pore, 
whereas Ca2+ migrates in the pore through 
Ca2+-binding pocket, which could be less 
accessible to Ca2+ due to the rigidity of the 
channel (Fig. 3K). Our observations sug-
gest that not only pH changes, but also 
tTG could inhibit the activity of TRPV5 by 
reducing its pore size. 
N-glycosylation of TRPV5 is crucial for 
the extracellular regulation of the channel 
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by klotho (10, 13). Surprisingly, tTG had no 
inhibitory effect on TRPV5-N358Q, sug-
gesting that the presence of the sugar tree 
is critical for tTG action. Negatively charged 
glycosaminoglycans such as heparin are 
known to bind tTG (41-43). We specu-
lated that the sialic acid containing and, 
therefore, negatively charged N-glycan of 
TRPV5 may bind tTG, providing better ac-
cessibility to the substrate sites located in 
the vicinity of the N-glycan. However, co-
immunoprecipitation experiments showed 
that tTG equally binds to both the wild 
type and to the N-glycosylation-deficient 
TRPV5 mutant. Because of the equal bind-
ing efficiency, the substrate site exposure 
is more likely to depend on the N-glycosyl-
ation status of TRPV5. Klotho (as well as 
other glycosidases) can hydrolyze sugar 
residues from the N-glycan of TRPV5 and 
thereby increase the activity of the channel 
(10, 13, 44). Modification of the N-glycan 
by klotho might safeguard TRPV5 from the 
tTG-mediated inhibition. However, further 
experiments should clarify the presence of 
such cross-talk between klotho and tTG 
The fact that these different enzymes re-
quire intact N-glycosylation of TRPV5 for 
their actions could imply a central role for 
the N-glycan in the extracellular regulation 
of the channel. 
Taken together, our observations sug-
gest that the apically secreted tTG func-
tions as an inhibitor of TRPV5 and thereby 
contributes to the regulation of body Ca2+ 
homeostasis. Currently, it remains unclear 
whether an increased urinary tTG concen-
tration is observed in conditions related 
to defective Ca2+ handling. One could en-
vision several pathological conditions in 
which tTG reaches higher urinary concen-
trations, due to increased tissue damage 
or secretion of the enzyme. As such, rats 
with experimentally induced diabetes and 
diabetic nephropathy have increased renal 
tTG expression and activity resulting in ab-
normal extracellular crosslinking. 
Here, we delineate a potential molecu-
lar mechanism by which tTG can inhibit 
TRPV5 channel activity by changing the 
pore diameter. This reduction is function-
ally coupled to crosslinking of the channel.
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Abstract
Thrombin and its receptor (TR) are, respectively, expressed in osteoclasts and osteo-
blasts. However, their physiological roles on bone metabolism have not been fully eluci-
dated. Here we investigated the bone microarchitecture by micro-computed tomography 
(μCT) and demonstrated increased trabecular and cortical bone mass in femurs of TR KO 
mice compared to WT littermates. Trabecular thickness and connectivity were signifi-
cantly enhanced. The physiological role of TR on both inorganic and organic phases of 
bone is illustrated by a significant increase in BMD and a decrease in urinary deoxypyr-
idinoline crosslinks (DPD) concentration in TR KO mice. Moreover, TR KO cortical bone 
expanded and had a higher polar moment of inertia (J), implying stronger bone. Bone 
histomorphometry illustrated unaltered osteoblast and osteoclast number and surface in 
femoral metaphyses, indicating that thrombin/TR regulates osteoblasts and osteoclasts 
at functional levels. Serum analysis showed a decrease in RANKL and an increase in os-
teoprotegerin (OPG) levels and reflected a reduced RANKL/OPG ratio in TR KO group. In 
vitro experiments using MC3T3 pre-osteoblasts demonstrated a TR-dependent stimula-
tory effect of thrombin on RANKL/OPG ratio. This effect was blocked by TR antagonist 
and p42/p44-ERK inhibitor. In addition, thrombin also intensified p42/p44-ERK expres-
sion and phosphorylation. In conclusion, the thrombin/TR system maintains normal bone 
remodeling by activating RANKL and limiting OPG synthesis by osteoblasts through the 
p42/44-ERK signaling pathway. Consequently, TR deficiency inhibits osteoclastogen-
esis, resulting in a high bone mass phenotype.
Introduction
Osteoblasts together with osteoclasts 
are responsible for bone remodeling. The 
bone-forming osteoblasts produce an or-
ganic collagenous matrix and mineralize it 
with an inorganic calcium-phosphate hy-
droxyapatite [Ca5(PO4)3(OH)] (1). The bone-
resorbing osteoclasts degrade the mineral-
ized matrix by two means—creating acidic 
milieu to resorb the inorganic mineralized 
phase and secreting proteases to degrade 
organic collagen I-based extracellular ma-
trix (ECM), (1, 2). Bone remodeling is regu-
lated by coupling mechanism of osteoblast 
and osteoclast activities (3). On one hand, 
osteoclast development requires a stimu-
lation of its surface receptor activator of 
nuclear factor-κB (RANK) by RANK ligand 
(RANKL) secreted from osteoblasts (4). On 
the other hand, osteoblasts secrete a de-
coy receptor osteoprotegerin (OPG) that 
specifically binds and neutralizes RANKL 
(1, 4). Therefore, a decrease in RANKL/
OPG ratio determines domination of 
bone resorption over bone formation and 
vice versa. Disturbances of RANKL/OPG 
causes skeletal abnormalities represented 
by reduced (osteoporosis) and increased 
(osteopetrosis) bone mass (5).
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The serine protease thrombin (coagu-
lation factor II, EC 3.4.21.5), with known 
function to convert fibrinogen to fibrin in 
the final step of coagulation cascade, is 
also synthesized and secreted by osteo-
clasts (6, 7). Heterozygous thrombin-defi-
cient mice are lethal in embryonic phase, 
while surviving neonates died after a few 
days due to severe hemorrhage (8). Among 
other proteases, thrombin has been shown 
to play a role in bone remodeling including 
direct cleavage of the bone protein osteo-
pontin, which is important for anchoring 
osteoclasts to the mineralized matrix (9). 
Recently, thrombin has been found to in-
hibit osteoclast differentiation and down-
regulate RANK expression in isolated 
pre-osteoclast cultures (10). In addition, 
thrombin can also exert its biological effect 
via protease-activated receptors (PARs)-1, 
-3, and -4 (11). PAR-1 (thrombin receptor, 
TR) is expressed in osteoblasts, but not in 
osteoclasts (12). PAR-3 is not expressed 
in murine osteoblasts, whereas PAR-4 has 
been reported only in osteoblast-like cal-
varial cells (6). Therefore, TR is responsible 
for almost, if not all, thrombin signaling in 
mouse osteoblast cells (13). TR is a trans-
membrane G protein-coupled receptor 
(GPCR) of which the extracellular domain 
can be activated upon proteolytic cleav-
age by thrombin (6). In vitro experiments 
showed that activation of TR increased 
proliferation rate of osteoblasts and stimu-
lated the activity of alkaline phosphatase 
(ALP), an osteoblast differentiation marker 
(14). TR has been reported to convey its 
intracellular signal via PLC-β, p42/44-ERK, 
and PKC pathways (15, 16). By using in 
vitro calvarial and long bone cultures, 
thrombin induced bone resorption, while 
TR knockout mice (TR KO) manifested de-
creased migration and proliferation of mes-
enchymal cells into the bone fracture area 
of bone-drilled model (11, 17, 18). These 
data suggest a potentially physiological 
importance of TR. However, the role of 
thrombin/TR system in bone homeostasis 
has not been investigated. The purpose of 
this present study was, therefore, to inves-
tigate the function of thrombin/TR in bone 
metabolism using an in vivo TR KO mouse 
model and in vitro osteoblast cell cultures.
Materials and Methods
Animal experiments and collection of 
samples 
TR KO mice and WT littermates (75% 
C57BI/6 x 25% 129/Sv background, 10-12 
weeks old) purchased, respectively, from 
The Jackson Laboratory (Bar Harbor, ME, 
USA) and Charles River (Maastricht, The 
Netherlands) were genotyped. All experi-
ments were approved by the Institutional 
Animal Care and Use Committee of the 
University of Amsterdam. Four male mice 
of WT and the other four male TR KO mice 
were placed in metabolic cages. Twenty 
four-hour food and water consumption; 
and fecal and urine excretions were col-
lected for weight, volume, electrolyte, and 
DPD determinations. The mice were anes-
thetized under 2% (v/v) isoflurane. Blood 
was collected for electrolyte, RANKL, and 
OPG determinations before termination. 
Bones were removed, rinsed in iced-cold 
PBS and kept in 75% (v/v) ethanol at 4°C 
for further μCT analyses. Kidney and du-
odenal tissues were removed, rinsed in 
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iced-cold PBS and kept in -80°C and/or 
PLP for further RNA and protein extrac-
tion, and cryosection, respectively as de-
scribed previously (19). 
Serum, urine, and fecal analyses
Serum and urine Ca2+ concentrations 
were determined by a colorimetric assay 
as described previously (20). Fecal sam-
ples were desiccated at 50°C overnight 
and stored at -80°C until analysis. Each 
24-h fecal sample was dissolved in 20 ml 
nitric acid (1.5 M) at room temperature for 
12 hours. The solution was adjusted to a 
total volume of 20 ml with deionized water, 
and Ca2+ was determined with the same 
methods for serum and urine Ca2+ analy-
ses. A flame spectrophotometer FCM6343 
(Eppendorf) was used to measure serum 
and urine Na+ concentrations and urine 
K+ concentrations. Urine osmolality was 
obtained using a Halbmikro-Osmometer 
K-7400 (Knauer).
μCT measurements
Femurs from male WT and TR KO mice 
(n=4) were scanned at a resolution of 9 
μm, using a SkyScan 1172 system (Sky-
Scan). According to guidelines recently 
published (21), the following settings were 
used: X-Ray power and tube current were 
40 kV and 0.25 mA, respectively. Beam 
hardening (20%) was reduced using a 1 
mm aluminium filter, ring-artifacts were 
reduced (set at 5), exposure time was 5.9 
seconds and an average of three pictures 
was taken at each angle (0.9º) to gener-
ate final images. Using different software 
packages from SkyScan (NRecon, CtAn 
and Dataviewer), bone microarchitectural 
parameters were assessed in trabecular 
and cortical bone of all mice. The trabecu-
lar bone parameters: trabecular tissue vol-
ume, bone volume, volume fraction (BV/
TV), thickness, number and patterning 
factor (connectivity of trabeculae) were 
determined in the distal metaphysis of the 
femur (scan area of 1.3 mm from distal 
growth plate towards femoral centre). In 
the mid-diaphysis (scan area of 0.43 mm 
in the femoral centre), cortical volume, 
thickness, J (proxy for bone strength) and 
perimeter were analyzed. For image pro-
cessing, trabecular bone was manually 
selected and cortical bone was automati-
cally selected. In addition, trabecular and 
cortical BMD was measured on basis of 
calibration scanning, using two phantoms 
with known density (0.25 mg/cm2 and 0.75 
mg/cm2; Skyscan) under identical condi-
tions as for the femurs (method note from 
SkyScan provided on http://www.skyscan.
be). All terms used in μCT experiments 
comply with the standard nomenclature, 
symbols, and units previously described 
(21). 
Bone histomorphometry 
After excision, femurs were routinely 
embedded in methylmetacrylate as de-
scribed before (22). Sections of 6 µm were 
subjected to tartrate-resistant acid phos-
phatase (TRAP) staining. Sections were 
deacrylated, hydrated and rinsed in 0.2 M 
sodium acetate/50 mM tartaric acid for 5 
min. Naphtol AS-MX (0.5 mg/ml) and 1.1 
mg/ml Fast red TR salt (both from Sigma) 
were added and incubated for 120 min-
utes at 37°C. Counterstaining was per-
formed with hematoxylin for 5 sec and 
after air-drying; the sections were embed-
ded in Permount (Thermo Fischer Scien-
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tific). For osteoblast and osteocyte mea-
surements, sections were stained with a 
Goldner staining as described before (23). 
Images were taken from the TRAP and 
Goldner stainings with a Nikon Eclipse 
E400 system (Nikon). Measurements were 
performed, using the software package 
Bioquant (Version 7.20; Bioquant image 
analysis corporation). 
Preparation of cultured pre-osteo-
blastic cells
MC3T3 pre-osteoblastic cells were 
purchased from ATCC and grown in 
α-minimal essential medium (α-MEM) 
(Gibco) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (Gibco), 50 
μg/mL penicillin/streptomycin (Gibco), 
50 μg/mL vitamin C (Sigma), and 10 mM 
β-glycerophosphate (Sigma) in 5% (v/v) 
CO2 at 37°C. The medium was refreshed 
twice a week. The cells were seeded at 2.5 
x 104 cells/cm2 into 6-well plates and left in 
the incubator for 24 h prior to exposure to 
different treatments for 16 h.
qPCR expression analyses
To evaluate mRNA expression of 
RANKL and OPG, total RNA was extracted 
from thrombin-treated (16 h) MC3T3 cells 
using TriZol Total RNA Isolation Reagent 
(Life Technologies BRL) according to the 
manufacturer’s protocol. The obtained 
RNA was subjected to DNase treatment 
(Promega) to prevent genomic DNA con-
tamination. Thereafter, 2 µg of RNA was 
reverse transcribed by Molony-Murine 
Leukemia Virus-Reverse Transcriptase (In-
vitrogen). The cDNA was used to determine 
mRNA expression levels by SYBR green 
PCR both of the target genes of interest 
and of the housekeeping gene Gapdh as 
an endogenous control. Primers targeting 
the genes of interest were designed using 
the computer program Primer3 (v.0.4.0) 
and are listed in Table 1.
Western blot analysis
MC3T3 cell lysates were added to 
sample buffer and incubated for 30 min 
at 37°C. Homogenates of mouse duo-
denal and kidney tissues; and cells were 
prepared and analyzed as previously de-
scribed (24, 25). Protein concentrations 
were determined by BCA protein assay kit 
(Bio-Rad) and volumes of samples were 
normalized accordingly. Subsequently, 
30-μg samples were loaded and separated 
on 8% SDS-PAGE gels for p42/44-ERK. 
Protein fractions were transferred to poly-
vinylidene difluoride-nitrocellulose mem-
branes (Immobilon-P, Millipore). Proteins 
on the membranes were detected using 
a rabbit monoclonal anti-phospho-p42/44 
Table 1 : Mus Musculus oligonucleotide sequences used in RT-PCR 
Tnfsf11, receptor activator of nuclear factor-κB ligand; Tnfrsf11b, osteoprotegerin; Gapdh, glyceraldehyde-
3-phosphate dehydrogenase.
Gene                 Forward primer              Reverse primer
Tnfsf11 CATGTGCCACTGAGAACCTTGAA CAGGTCCCAGCGCAATGTAAC
Tnfrsf11b CAATGGCTGGCTTGGTTTCATAG CTGAACCAGACATGACAGCTGGA
Gapdh TAACATCAAATGGGGTGAGG GGTTCACACCCATCACAAAC
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ERK and anti-p42/44 ERK antibodies (Cell 
Signaling Technology). Mouse polyclonal 
anti-β-actin Ab was from Santa Cruz.  
Analytical procedures 
 RANKL was measured with the DouSet 
ELISA development kit (R&D Systems, 
Inc.). OPG was measured with OPG ELISA 
kit (Abnova). DPD crosslinks were mea-
sured with the MicroVue total DPD EIA kit 
(Quidel Corporation). All protocols were 
in accordance with the manufacture’s in-
structions. 96-well plates were read at the 
specified wavelengths, on a Benchmark 
PlusTM microplate spectrophotometer (Bio-
Rad). 
45Ca2+ transport measurement in the 
intestinal Caco-2 cell line
For radioactive 45Ca2+ transport experi-
ments, Caco-2 cells were seeded onto 
0.33 cm2 polycarbonate Transwell® inserts 
(Corning Costar) for 21 days in DMEM (Bio 
Whittaker) supplemented with 10% (v/v) 
FCS (PAA), 2 mM L-glutamine, and 10 μl/
ml non-essential amino acids at 37°C in a 
humidity controlled incubator with 5% (v/v) 
CO2 before use. The day prior to the exper-
iments, transepithelial electrical resistance 
(TEER) was measured using an epithelial 
volt-ohmmeter (EVOM, World Precision In-
struments). On the experimental day, cul-
ture medium was removed and replaced 
with physiological salt solution (PSS: 140 
mM NaCl, 2 mM KCl, 1 mM K2HPO4, 1 mM 
MgCl2, 1 mM CaCl2, 5 mM D-glucose, 5 
mM L-alanine, 5 µM indomethacin, 10 mM 
HEPES/Tris, pH 7.4.). The apical compart-
ment contained 100 µl and basolateral 
compartment contained 600 μl. After 30 
minutes of incubation, PSS was replaced 
with the same volumes of the pre-warmed 
identical solution with and without 10-nM 
thrombin (T4648, Sigma); apical medium 
contains 3 µCi/ml 45Ca2+. Ten microliters of 
basolateral medium was collected at time 
points 10, 30, and 60 minutes and ana-
lyzed for radioactivity in a Perkin Elmer liq-
uid scintillation counter. Unidirectional flux 
from the apical side to the basolateral side 
(JA→B) was calculated with Equations 1 and 
2 as previously described (26).  
Where RA→B was the rate of tracer ap-
pearance in the basolateral side (cpm/
min); SA was the specific activity in the 
apical side (cpm/nmol); A was the surface 
area of the Transwell; CA was a mean of 
radioactivity of 45Ca2+ in the apical side 
(cpm); and CT was the total Ca
2+ in the api-
cal side (nmol).
Compounds
Thrombin, U0126, and U73122 were 
purchased from Sigma. Thrombin recep-
tor antagonist (SCH79797) was from Axon 
Medchem. Chelerythrine was from Re-
search Biochemicals International.
Statistical analysis
If not specified otherwise, the data are 
expressed as mean±SEM. Multiple sets 
of data were compared by ANOVA. The 
significant differences between the means 
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of two groups were analyzed by paired 
Student’s t-test, while multiple compari-
sons between groups were performed by 
Tukey’s post hoc multi analysis. The level 
of statistical significance is P<0.05. All 
data were analyzed by GraphPad Prism 
(version 4.0c for Mac OS X; GraphPad 
Software).
Results
TR-deficient mice have increased 
bone mass
Gross observation revealed that TR KO 
mice have an increased body weight com-
pared to WT littermates (Fig. 1A). TR KO 
mice consumed similar amounts of food 
and water and excreted the same extent 
of feces compared to WT mice (Fig. 1B, 
C, and D).  Subsequently, we analyzed 
the bone tissue of TR KO mice. First, we 
compared the bone microarchitectural 
structure of the femoral metaphysis and 
diaphysis between WT and TR KO mice. 
Data in Table 2 showed that, in WT and 
TR KO groups respectively, trabecular 
bone volume (BV), femoral head volume 
(Fh.V), and trabecular number (Tb.N) were 
significantly increased (0.47±0.01 vs 0.81 
±0.06 mm3, 4.15±0.09 vs 5.06±0.18 mm3, 
and 3.13±0.04 vs 3.98±0.19 mm-1, respec-
tively, P<0.05) whereas trabecular separa-
tion (Tb.Sp) was decreased (145±0.3 vs 
129±4.2 μm, P<0.05) (Table 2). Diaphy-
seal endocortical volume (Ec.V) was also 
increased (0.46±0.02 vs 0.54±0.01 mm3). 
The increased trabecular and cortical bone 
mass in the mice lacking TR can only par-
tially be explained by a small, albeit signifi-
cant, increase in femur length (15.79±0.08 
vs 16.26±0.03 mm, P<0.05).
TR deficiency increased trabecular 
bone thickness and connectivit
Detailed structural analysis of the fe-
murs revealed that trabecular bone volume 
fraction in the distal metaphyseal bone 
compartment of TR KO mice was elevated 
(15.14±0.15 vs 20.94±0.01 %, P<0.05, 
Fig. 3A and B), which is explained by in-
creased trabecular thickness (48.37±0.12 
vs 52.53±0.41 μm, P<0.05) and trabecular 
number (3.13±0.04 vs 3.98±0.19 mm-1, 
P<0.05) (Fig. 3C and Table 2, respective-
ly). This led to reduced trabecular separa-
tion (145±0.3 vs 129±4.2 μm, P<0.01) and 
more trabecular connectivity (indicated by 
a decrease in trabecular patterning factor, 
23.27±0.75 vs 15.65±0.76 mm-1, P<0.01) 
as shown in Table 2 and Fig. 3D, respec-
tively. The structure model index estimat-
ing whether a bone structure is plate-like 
(value of 0) or rod-like (value of 3) re-
Figure 1: General phenotype of wild-type (WT) and 
TR-deficient (KO) mice. Body weight of WT and TR KO 
mice are depicted (A). 24-h food and water consump-
tion; and fecal excretion in KO were comparable to the 
WT mice (B, C, and D, respectively). n= 4 per group, 
*P<0.05 compared to WT littermates.
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vealed that TR deficiency leads to a more 
plate-like microarchitecture (1.99±0.04 vs 
1.70±0.03, P<0.01, Fig. 3E).
Histomorphometrical parameters of 
WT and TR KO mice
In order to investigate bone turnover, 
histological analyses of femoral metaphy-
seal bone sections from WT and TR KO 
mice were performed with Goldner’s tri-
chrome (Fig. 4A and B) and TRAP (Fig. 
4C and D) staining for osteoblasts and 
osteoclasts, respectively. Osteoblast 
number and surface were not significantly 
different between WT and TR KO groups 
(0.61±0.05 vs 0.91±0.25 no./mm and 
1.78±0.17 vs 2.96±0.85 %, P>0.05, Fig. 4E 
and F, respectively). Similarly, Figures 4G 
and H also showed no changes in osteo-
clast number and surface when corrected 
Table 2 : Bone microarchitectural data and femur length from wild-type (WT) and thrombin 
receptor-deficient (TR KO) mice. 
 
Femurs from wild-type (WT) and thrombin receptor-deficient (TR KO) mice (n=4) were ana-
lyzed in detail by μCT. Parameters indicated are femoral head volume (Fh.V), bone volume, 
metaphyseal bone volume (BV), trabecular separation (Tb.Sp), trabecular number (Tb.N), 
diaphyseal endocortical volume (Ec.V) and femoral length. Data are presented as mean ± 
SEM. aP<0.05 versus wild-type, bP<0.01 versus wild-type.
Parameter        WT     TR KO
                                                                Metaphysis
BV (mm3) 0.47 ± 0.01 0.81 ± 0.06a
Fh.V (mm3) 4.15 ± 0.09 5.06 ± 0.18b
Tb.N (mm-1) 3.13 ± 0.04 3.98 ± 0.19b
Tb.Sp (μm)  145 ± 0.3  129 ± 4.2a
Diaphysis
Ec.V (mm3) 0.46 ± 0.02 0.54 ± 0.01b
Whole femur
Femur length (mm) 15.79 ± 0.08 16.26 ± 0.03a
for bone surface (1.69±0.11 vs 1.49±0.21 
no./mm and 15.94±1.40 vs 15.12±2.77 %, 
P>0.05).
TR deficiency decreased urinary bone 
resorption marker protein, but did not 
affect serum and urinary Ca2+ con-
tents
Because bone proteases are involved 
in ECM degradation (27) and bone mass 
was increased, urinary DPD crosslinks 
(degradation products of collagen I); and 
serum and urinary Ca2+ were measured. 
Urinary DPD concentration in TR KO mice 
was reduced compared to WT (141±27 vs 
79±3 nM in WT and TR KO, respectively, 
P<0.05, Fig. 5), indicating that TR is re-
quired for proper bone resorption. Elec-
trolyte analyses revealed that urinary Ca2+ 
excretion was unchanged, but polyuria 
(0.8±0.2 vs 2.1±0.3 ml, P<0.05) and alka-
line urine (pH 6.7±0.1 vs 7.1±0.1, P<0.05) 
were observed (Table 3). Serum Ca2+ con-
centration was not affected (2.23±0.03 vs 
2.16±0.15, P>0.05). Additionally, urinary 
Na+ excretion was enhanced whereas se-
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Figure 2 : Cortical bone microarchitecture and bone mineral density of wild-type (WT) and TR-deficient (KO) 
mice. A, the cross-sectional geometry of mouse femoral metaphyses were determined with μCT. Endocortical and 
cortical volumes were measured at metaphyseal areas (B and C). Cortical thickness, cortical perimeter (mid-chaft 
circumference), and polar moment of inertia (J) were obtained from diaphyseal analyses (D, E, and F). Femoral BMD 
is depicted (G). N= 4 per group, *P<0.05 in comparison to WT.
Figure 3: Trabecular bone structural analysis of wild-type (WT) and TR-deficient (KO) mice femurs by μCT. Rep-
resentative 3D-construction specimens show trabecular bone structure of WT (upper) and TR KO (lower) mice (A). 
Arrows indicate majorities of rod-like and plate-like trabecular bones in WT and TR KO mice, respectively. Basic set 
of variables includes bone volume fraction (BV/TV), trabecular thickness, trabecular patterning factor (1/trabecular 
connectivity) and structure model index (plate-like, value of 0 and rod-like, value of 3) are depicted (B-E). TV, tissue 
volume; BV, bone volume. N=4 per group, *P<0.05 in comparison to WT. 
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Data are presented as mean ± SEM.  *P<0.05 versus WT. Wild-type (WT) and thrombin receptor deficient (TR KO) 
mice (n=4).
Parameter WT TR KO
Serum 
Ca2+ (mM)      2.23±0.03      2.16±0.15
Na+ (mM) 136.1±0.7  136.8±1.6
K+ (mM)     7.1±0.1      7.4±0.3
Urine
Ca2+ excretion (μmol/24 h)     5.5±1.2       9.5±1.1*
Na+ excretion (μmol/24 h)      99±21     199±44*
K+ excretion (μmol/24 h)      94±48    416±91
Osmolarity (mOsm)    2430±478    1653±222
Volume (mL/24 h)      0.8±0.2       2.1±0.3*
pH      6.7±0.1       7.1±0.1*
rum Na+ and K+ values appeared normal 
(see Table 3).
TR deficiency decreased serum 
RANKL/OPG ratio 
Based on the fact that TR is expressed 
in osteoblasts and the finding of an ab-
normal increase in bone formation, we hy-
pothesized that TR deficiency might alter 
osteoblast function to secrete RANKL and 
OPG. Fig. 6A shows that serum RANKL 
level was significantly decreased from 
1,419±576 pg/ml to 355±34 pg/ml in WT 
and TR KO mice, respectively, P<0.05, 
while OPG level was increased (992±29 
pg/ml vs 1189±57 pg/ml in WT and TR 
KO mice, respectively, P<0.05) (Fig. 6B). 
As a consequence, RANKL/OPG ratio 
was significantly reduced (1.00±0.35 vs 
0.22±0.03, P<0.05, Fig. 6C).Figure 4: Bone histomorphometry in wild-type (WT) 
and TR-deficient (KO) mice. Goldner (A-B) and TRAP 
(C-D) staining was performed on femoral bone sec-
tions from WT (A and C) and TR KO (B and D) mice 
and images were taken of the metaphyses. From these 
stainings, osteoblast number (E) and surface (F) as well 
as osteoclast number (G) and osteoclast surface (H) 
per bone surface area were quantified (n=4 per group).
Table 3 : Blood and urine parameters of wild-type (WT) and thrombin receptor-deficient (TR KO) mice 
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Thrombin upregulated RANKL/OPG 
ratio in osteoblast-culture medium 
via TR-dependent and p42/44-ERK-
mediated pathway
In order to elucidate the mechanism of 
thrombin action, TR-expressing MC3T3 
pre-osteoblastic cells (13) were cultured 
with thrombin-containing medium (0.1-
10 nM) for 16 h. RANKL/OPG ratio in the 
cultured medium was significantly upregu-
lated after incubation with 10-nM thrombin 
(1.00±0.06 vs 1.47±0.13 in control and 10-
nM thrombin-treated respectively, P<0.05, 
Fig. 7A). RANKL and OPG mRNA expres-
sion was analyzed in the cells treated with 
a maximal dose of thrombin (10 nM). Inter-
estingly, only RANKL mRNA was increased 
whereas OPG mRNA and RANKL/OPG 
mRNA ratio were unchanged by thrombin 
incubation (Fig. 7B-D). We further inves-
tigated if thrombin action was dependent 
on TR and if so, which signaling pathway 
was responsible for this stimulatory effect. 
Figure 7E shows that pre-incubation (30 
min prior to thrombin) with TR antagonist, 
20 μM SCH79797, prevents an upregu-
lation of RANKL/OPG ratio by thrombin 
(1.00±0.14, 1.47±0.27, and 0.84±0.11 in 
control, 10-nM thrombin-treated, and 10-
nM thrombin-treated+SCH79797, respec-
tively). Moreover, the inhibitors for p42/44-
Figure 5: Deoxypyridinoline (DPD) crosslink concen-
tration in urine samples of wild-type (WT) and TR-defi-
cient (KO) mice. n=4 per group. *P<0.05 in comparison 
to WT.
Figure 6: Serum RANKL and OPG levels in wild-type (WT) and TR-deficient (KO) mice (A and B, respectively).  C, 
Relative RANKL/OPG ratio was calculated from A and B. n=4 per group, *P<0.05 in comparison to WT. 
ERK (25 μM U0126) and PLC-β (10 μM 
U73122) blocked the effect of thrombin, 
whereas PKC inhibitors (10 μM Chelery-
thrine) failed to reverse the effect of throm-
bin (1.87±0.31, P<0.05 compared to con-
trol, Fig. 7E). Furthermore, immunoblotting 
analysis showed that both phosphorylated 
and total p42/44-ERK expression is stimu-
lated by thrombin (100±23 vs 170±21 and 
100±14 vs 177±2, respectively, P<0.05, 
Fig. 7F). 
Increased BMD in TR-deficient mice 
was not due to intestinal Ca2+ hyper-
absorption
To investigate the origin of the incre-
ment of BMD in TR KO mice, fecal Ca2+ 
content was measured in both mouse 
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Figure 7: Stimulation of RANKL/OPG synthesis ratio by thrombin in osteoblasts depends on TR and p42/44-ERK 
signaling pathway. RANKL/OPG ratio was obtained from media of MC3T3 cells treated with thrombin with indi-
cated concentrations for 16 h (A). Cells treated with 10 nM thrombin were analyzed for RANKL and OPG mRNA 
expression (B-D). E, RANKL/OPG ratios were calculated upon treatments of MC3T3 cells with thrombin with dif-
ferent inhibitors. -, non-thrombin-treated. F, Immunoblotting analysis of phosphorylated and total p42/44-ERK 
expression (upper and middle left panels, respectively). β-actin was used as internal control (lower left panel). 
Relative p42/44-ERK expression was calculated from the blot densities (right panel). n= 6 per group, *P<0.05 in 
comparison to non-thrombin-treated condition.
strains, but no significant difference was 
observed between the groups (105±25 vs 
145±56 μmol/g/d, Fig. 8A). Furthermore, 
10-nM thrombin had no effect on transepi-
thelial Ca2+ transport in Caco-2 cells that 
endogenously express TR, TRPV6, and 
CaBP-D9K (28, 29) (Fig. 8B). Moreover, 
2-h incubation with 10-nM thrombin did 
not affect PD and TEER, suggesting that 
thrombin had also no effect on the para-
cellular transport (Fig. 8C).
Discussion
Serine proteases and their receptors 
have been characterized as important play-
ers in bone metabolism as exemplified by 
tissue- and urokinase-type plasminogen 
activators and plasminogen/plasmin (30-
32). The present study provides evidence 
that the thrombin/TR system is required for 
a normal bone resorption process mainly 
by stimulating RANKL secretion from os-
teoblasts, thereby indirectly triggering os-
teoclastogenesis. Furthermore, the system 
seems to be crucial for proper degradation 
of both inorganic and organic bone com-
partments. These conclusions are drawn 
from the following observations in TR KO 
mice and osteoblast cells. First, TR KO 
mice manifested increments in both corti-
cal and trabecular bone mass, increased 
BMD, and changes in bone microarchi-
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Figure 8: Roles of thrombin and TR on intestinal Ca2+ transport. Fecal Ca2+ excretion represents a whole non-
absorbed Ca2+ in gastrointestinal tract (A). Time-response in vitro transepithelial Ca2+ transport in Caco-2 cells en-
dogenously expressing TR, TRPV6, and CaBP-D9K upon treatment of 10 nM thrombin (B). Epithelial electrical pa-
rameters of Caco-2 cells were determined after 2-h incubation with and without 10 nM thrombin (C), n=4 per group. 
Transepithelial potential difference (PD) and transepithelial electrical resistance (TEER) were directly measured.
tecture. Second, urine analyses showed 
a reduction of DPD crosslink concentra-
tion, an organic-phase bone resorption 
marker. Third, TR deficiency decreased 
serum RANKL/OPG ratio. Fourth, in vitro 
experiments revealed that thrombin up-
regulated the RANKL/OPG protein ratio in 
osteoblast-culturing medium via TR and 
p42/44-ERK-mediated pathway. Finally, 
thrombin had no direct effect on intestinal 
Ca2+ transport.
The physical appearance of the TR KO 
mice was normal, but their body weights 
were higher compared to WT in spite of 
normal food and water intakes. These 
observations can be explained by the in-
creases in bone size and mass as well 
as possibly adipocyte hypertrophy since 
thrombin was reported to control the size 
of adipocytes (10). Indeed, femur length 
was increased in TR KO mice, as were var-
ious parameters of cortical and trabecular 
bone mass. In addition, a transformation 
of rod-like into plate-like microarchitecture 
indicated that TR-deficient mice gained 
bone (33). As a consequence of the micro-
structural changes in cortical and trabecu-
lar bones, a higher J ensued. This finding 
confirms the osteoporotic phenotype since 
the combined measurement of BMD and J 
has been used as important indicators for 
bone strength and stiffness (34). It is un-
likely that the observed increase in bone 
mass and strength in TR KO mice was due 
to enhanced bone-forming activity of os-
teoblasts, since bone histomorphometry 
showed that osteoblast number and sur-
face (Ob.N/BS and Ob.S/BS, respectively) 
were not altered. These findings are in line 
with the study by Song and colleagues 
who reported that Ob.S/BS was not dif-
ferent between WT and TR KO mice (35). 
Therefore, the observed increase in bone 
mass likely resulted from a decrease in the 
cytokine-producing activity of osteoblasts 
as signified by decreases in serum RANKL/
OPG ratio and urinary DPD concentration 
in the present study.
RANKL and OPG can be considered 
as central players harmonizing bone for-
mation and resorption (36). RANKL-de-
ficient mice completely lack osteoclasts 
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and have severe osteopetrosis whereas 
OPG deficiency essentially causes the 
opposite traits i.e., osteoporosis with se-
vere cortical and trabecular bone thinning 
and porosity (37, 38). Various factors can 
positively or negatively affect RANKL and 
OPG synthesis. For example, 1,25(OH)2D3, 
PTH, interleukin-11 (IL-11), and prosta-
glandin E2 (PGE2) stimulate RANKL syn-
thesis whereas estrogen and transforming 
growth factor-β (TGF-β) are inhibitors of 
RANKL production (5, 37, 39). RANKL and 
proteases are bone regulators that work 
in close interrelationship. For instance, a 
cysteine protease cathepsin K localized 
in lysosome in the ruffled border of osteo-
clasts has been identified as major osteo-
clastic protease and plays a principal role 
in degrading the ECM (27). RANKL, upon 
its binding to RANK, has been reported to 
stimulate cathepsin K mRNA and protein 
expression (40). Besides, ADAM (a disin-
tegrin and metalloproteinase domain), a 
member of metalloproteinases, also indi-
rectly facilitates RANKL-induced osteo-
clastogenesis by shedding a RANKL en-
hancer TNF-α (27). Importantly, MMP and 
ADAM family members have been shown 
to cleave RANKL in vitro, increasing the 
RANKL concentration in the culture me-
dium (23, 41). In the present study; how-
ever, the possibility that thrombin cleaves 
RANKL was excluded by the observation 
that an increase in RANKL/OPG ratio af-
ter thrombin treatment was blocked by TR 
antagonist. Altogether, the thrombin/TR 
signaling cascade is essential for RANKL-
dependent osteoclastogenesis.
Osteoclasts cells derived from HSC 
that reside in the endosteal region i.e., 
the active bone modeling and remodeling 
interface region between bone and bone 
marrow (42). Recently, Mansour and col-
leagues demonstrated that the proper 
osteoclast function is imperative for HSC 
Figure 9: Cartoon postulating the molecular mechanism of thrombin/TR action on bone metabolism. In wild-type 
(WT) mice, TR is expressed on osteoblasts, of which precursors secrete receptor activator of nuclear factor-κB 
ligand (RANKL), an osteoclast-activating factor (green line); and by osteoblasts themselves osteoprotegerin (OPG), 
an anti-maturation factor of osteoclasts (red line). In WT mice, RANKL/OPG secretion ratio was in balance. In TR-
deficient mice, the lack of TR causes a reduction in RANKL and an upregulation of OPG secretion from osteoblasts 
and impairs osteoclastogenesis and bone resorptive capacity. This eventually results in an increase in bone mass.
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niches and osteoblast differentiation (42). 
Interestingly, thrombin/TR was found to 
be involved with osteoblast differentiation, 
which is comprised of three overlapping 
phases: collagenous phase (synthesis of 
collagen type 1, a major component of 
ECM), non-collagenous phase (osteo-
pontin and ALP expression), and miner-
alizing phase (osteocalcin expression) 
(14, 43). In vitro experiment showed that 
thrombin inhibited ALP activity in primary 
osteoblast-like cells through TR, indicat-
ing the negative effect of thrombin on the 
non-collagenous phase (14). Accordingly, 
the results in the present study suggested 
that lower concentration of urinary DPD 
crosslinks and increased BMD might be 
due to the enhanced collagenous and min-
eralizing phases in in the absence of TR. 
In other words, it could be extrapolated 
that thrombin/TR negatively influences all 
steps of bone formation by osteoblasts. 
On the other hand, RANKL and OPG syn-
thesis was independent of osteoblast dif-
ferentiation stages, but rather relied on the 
presence of TR/p42/44-ERK signaling sys-
tem (43). 
The serine proteases can exert their 
physiological effects via various signaling 
pathways including p42/44-ERK, p38-
MAPK, PKC, and Rac1 (15, 16, 32, 44, 
45). Upon stimulation by thrombin; how-
ever, TR conveys its signal via either PKC 
through Gq11/Gi2 or p42/44-ERK through 
G12/G13 (16, 46-49). Based on our finding 
that thrombin stimulated RANKL expres-
sion through p42/44 ERK signaling, it was 
thus presumed in the present study that 
TR mediated its effect via G12/G13. An ac-
tivation of p42/44-ERK signaling by other 
serine proteases demonstrated differential 
effects on osteoblast activity. Urokinase, 
through urokinase receptor/p42/44-ERK, 
inhibited bone-forming osteoblast activity 
whereas plasmin induced OPG expression 
and preserved normal BMD (31, 32). Of 
note, thrombin has been reported to stim-
ulate IL-6 synthesis in osteoblasts through 
p42/44-ERK pathway (15). IL-6 was a po-
tent stimulator of RANKL production and 
surface membrane expression (29, 50). 
Therefore, in the present study, thrombin/
TR might also indirectly raise RANKL/OPG 
ratio in osteoblasts through IL-6. 
Many proteases including thrombin 
are synthesized as inactive precursors. 
Prothrombin mainly produced in paren-
chymal cells of the liver is converted to 
active thrombin by coagulation factor Xa 
(FXa) (51). Recently, Karlström and col-
leagues reported that prothrombin was 
also expressed in osteoclasts as well as in 
the metaphyseal trabecular bone and to a 
lesser extent, in cortical bone (7). The high-
est expression of prothrombin in the sub-
epiphysis, the bone-growing area, might 
explain our observation of longer femurs in 
TR KO mice in such a way that TR served 
as bone growth suppressor (7). This re-
search group also demonstrated interplay 
between RANKL and FXa in osteoclasts 
that, in a co-culture of the monocyte/mac-
rophage cells, RANKL induced the precur-
sor differentiation into mature osteoclast 
phenotypes and the prothrombinase ac-
tivity of FXa (52). This finding suggested 
a positive feedback of thrombin synthesis 
from osteoclasts, which in turn exerted 
its stimulatory effect on osteoblasts as 
observed in the present study. In addi-
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tion to the effect on osteoclast maturation 
presented here, thrombin has been found 
to recruit non-adherent osteoclast precur-
sors and inhibit osteoclast differentiation, 
but these effects were TR-independent 
(10, 35). Moreover, thrombin could not di-
rectly inhibit osteoclast differentiation un-
less bone marrow cells were primed with 
PTH and 1,25(OH)2D3 (10). Therefore, we 
postulate here that thrombin activates 
osteoclastogenesis by majorly inducing 
RANKL synthesis and inhibiting OPG pro-
duction from osteoblasts in TR-dependent 
manner.
Apart from bone, thrombin and TR are 
also expressed in the intestine (28, 53). 
Therefore, an excessive BMD in TR-de-
ficient bone might be taken up from Ca2+ 
hyperabsorption in the gastrointestinal 
tract. However, intestinal Ca2+ absorption 
signified by fecal Ca2+ excretion appeared 
normal in TR KO mice. Moreover, in vitro 
data indicates that thrombin had no ef-
fect on Ca2+ transport as well as electrical 
parameters across Caco-2 cells, suggest-
ing that both transcellular and paracellular 
Ca2+ absorption were unaffected. These 
data are in line with a previous finding that 
an activation of PAR-2, but not PAR-1 (TR) 
changed intestinal paracellular permeabil-
ity and ion transport (54). Further study is 
needed to define the source of Ca2+ de-
posited in TR-deficient bone.
In conclusion, the thrombin/TR system 
regulates bone remodeling by stimulat-
ing RANKL synthesis in osteoblasts via a 
p42/44-ERK signaling pathway. Conse-
quently, RANKL/RANK binding induces 
osteoclast maturation and concomitant 
bone resorption. In TR KO mice, the lack 
of TR causes a decrease in RANKL and 
partially increases OPG secretion from 
osteoblasts, thereby retarding proper os-
teoclastogenesis, which results in a high 
bone mass phenotype (see Fig. 9). We 
suggest that TR is a kind of ‘gate keeper’ 
for RANKL production during osteoblast 
differentiation.
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Abstract
Epinephrine (Epi) and norepinephrine (NE) are present in the pro-urine. β-adrenergic 
receptor (β-AR) blockers administered to counteract sympathetic overstimulation in pa-
tients with congestive heart failure (CHF) have a negative inotropic effect, resulting in 
reduced cardiac contractility. Positive inotropes, β1-AR agonists, are used to improve 
cardiac functions. Active Ca2+ reabsorption in the late distal convoluted and connecting 
tubules (DCT2/CNT) is initiated by Ca2+ influx through the transient receptor potential 
vanilloid type 5 (TRPV5) Ca2+ channel. Although it was reported that β-ARs are pres-
ent in the DCT2/CNT region, their role in active Ca2+ reabsorption remains elusive. Here 
we revealed that β1-AR, but not β2-AR is localized with TRPV5 in DCT2/CNT. Sub-
sequently, treatment of TRPV5-expressing mouse DCT2/CNT primary cell cultures with 
the β1-AR agonist dobutamine showed enhanced apical-to-basolateral transepithelial 
Ca2+ transport. In human embryonic kidney (HEK293) cells, dobutamine was shown to 
stimulate cAMP production, signifying functional β1-AR-expression. Fura-2 experiments 
demonstrated increased activity of TRPV5 in response to dobutamine, which could be 
prevented by the PKA inhibitor H89. Moreover, non-phosphorylable T709A-TRPV5 and 
phosphorylation-mimicking T709D-TRPV5 mutants were unresponsive to dobutamine. 
Surface biotinylation showed that dobutamine did not affect plasma membrane abun-
dance of TRPV5. In conclusion, activation of β1-AR stimulates active Ca2+ reabsorption 
in DCT2/CNT, increase in TRPV5 activity via PKA phosphorylation of residue T709 pos-
sibly plays an important role. These data explicate a calciotropic role in addition to the 
inotropic property of β1-AR. 
Introduction
Ca2+ plays a pivotal role in bone skel-
etal development and acts as a second 
messenger in excitatory cells; thus main-
tenance of Ca2+ homeostasis is vital for the 
body (1). Ca2+ balance is tightly regulated 
by three primary organs: the gastrointesti-
nal tract, bone, and the kidney (1). Ca2+ ab-
sorbed from the intestine is majorly stored 
in bone (99%) whilst the rest is either con-
jugated with other charged molecules or 
freely circulating in blood (2). The latter 
portion of Ca2+ is filtered in the glomerulus 
of the kidney and is reabsorbed to the cir-
culation by the proximal tubule (PT, 65%), 
thick ascending limb of Henle’s loop (TAL, 
20%), and DCT2/CNT (14%) (3). Mecha-
nisms of Ca2+ reabsorption in these three 
segments are of different origin: passive 
Ca2+ reabsorption through the paracellular 
space in the PT and TAL, dependent on 
the electrochemical gradient, whereas ac-
tive transcellular Ca2+ reabsorption in the 
DCT2/CNT is energetically driven by ATP 
hydrolysis (1). Ca2+ transport in the TAL 
and DCT2/CNT is subject to regulation by 
several factors including G protein-cou-
pled receptors (GPCRs) (1). Agonists of 
two members of GPCRs i.e., Ca2+-sensing 
receptor (CaSR) and parathyroid hormone 
receptor type 1 (PTH1R) inhibit and stimu-
late Ca2+ reabsorption in TAL and in DCT2/
CNT, respectively (4-6). 
92
C
ha
pt
er
 5
 
Active Ca2+ reabsorption in the DCT2/
CNT is a crucial fine-tuning event deter-
mining final urinary Ca2+ excretion and 
consists of three consecutive steps: api-
cal entry through the TRPV5 Ca2+ channel, 
intracellular buffering and translocation to 
basolateral membrane by calbindin-D28K 
(CaBP-D28K), and extrusion into the blood 
by Na+-Ca2+ exchange (NCX1) and plasma 
membrane Ca2+ ATPase-type 1b (PM-
CA1b) (1). TRPV5-mediated Ca2+ influx is 
the rate-limiting step for the active renal 
Ca2+ reabsorption as shown by hypercal-
ciuria and osteopenia in TRPV5-deficient 
mice (3). Among six members of the vanil-
loid TRP family, TRPV5 is the most Ca2+-
selective channel possessing a constitutive 
inward rectifying property at low intracellu-
lar Ca2+ concentrations and physiological 
membrane potentials (7-9). Therefore, the 
amount of Ca2+ influx through the channel 
depends on channel activity and plasma 
membrane abundance (3). TRPV5 activ-
ity and plasma membrane abundance are 
regulated by various factors, including GP-
CRs. For example, activation of bradykinin 
receptor type 2 (B2R) and PTH1R initiate 
phosphorylation of TRPV5 through PLC/
DAG/PKC and AC/cAMP/PKA signaling 
cascades, respectively (6, 10). 
Epinephrine and norepinephrine (Epi 
and NE) have diverse hormonal and neu-
rotransmitter functions in the body. Epi and 
NE were shown to be present in pro-urine 
filtered from blood, but were also found 
to be synthesized by renal glomeruli/tu-
bules and released from renal sympathetic 
nerves (11). Epi and NE can act through 
several members of GPCR adrenergic re-
ceptors: α1-AR, α2-AR, and three β-ARs. 
In kidney, α1-AR is expressed in arterioles 
whereas α2-AR is predominantly located 
in proximal tubules (12). α1-AR and α2-
AR are responsible for stimulation of renal 
vasoconstriction and Na+ reabsorption, re-
spectively (12). β-ARs can be divided into 
three subtypes: β1-AR, β2-AR, and β3-
AR (13, 14). β1 and 2-ARs are reportedly 
expressed in rat and mouse DCT, while 
β3-AR is not detectable in the kidney (15-
18). The roles of β1- and β2-ARs are well 
known respectively for myocardial contrac-
tion and vasodilation, while β3-AR is im-
portant for lipolysis (16, 19). β-AR blockers 
(β-blockers) are frequently administered to 
counteract sympathetic overstimulation in 
patients with congestive heart failure (CHF), 
resulting in reduced cardiac contractility 
(20). Positive inotropes, β1-AR agonists, 
are used to improve cardiac functions (20). 
Upon stimulation by Epi and NE, β-ARs 
activate Gα by the exchange of GDP for 
GTP, which can further enhance the activ-
ity of adenylyl cyclase (AC) and phospholi-
pase C (PLC), mediators of cAMP/protein 
kinase A (cAMP/PKA)- and diacyl glycerol/
protein kinase C (DAG/PKC)-dependent 
phosphorylation, respectively (18).
Even though Epi and NE are secreted 
in the pro-urine, to our knowledge, no ef-
fects of these hormones through signaling 
via β-ARs on renal active Ca2+ transport 
have been reported. We hypothesized that 
β-ARs regulate active Ca2+ reabsorption in 
DCT2/CNT. Thus, the present study aims 
to investigate i) colocalization of β1- and 
β2-AR with TRPV5 in DCT2/CNT; ii) ef-
fect of β-AR activation by a β-AR agonist 
on active Ca2+ reabsorption; iii) molecular 
mechanism of TRPV5 activation by β-AR.
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Materials and Methods
Immunohistochemistry
Mouse kidney sections were incubated 
for 16 h at 4°C with rabbit polyclonal an-
tibody against β1-AR (1:100) or β2-AR 
(1:300) (NB100-92439 and NBP1-68227, 
Novus Biologicals). To visualize the recep-
tors, an enhancer step was performed us-
ing a biotinylated goat anti rabbit antibody. 
Biotin was then coupled to streptavidin-
HRP and visualized with Thyramid. (TSA 
Fluorescein System, NEL701A001KT, 
Perkin Elmer). TRPV5 staining was previ-
ously described (4). Negative controls i.e., 
conjugated antibodies solely were devoid 
of any staining.
Isolation of DCT2/CNT using COPAS 
sorting and primary cell culture
Transgenic mice expressing eGFP un-
der the TRPV5 promoter were generated 
as described (21). Mice were maintained 
on a SSNIFF rodent complete diet (SS-
NIFF) with free access to water. The ani-
mal ethics board of Radboud University 
Nijmegen approved all the experimental 
procedures. The process of renal tubular 
sorting by COPAS (Union Biometrica) has 
been described (22). Approximately 4,000-
10,000 tubules from one mouse were pel-
leted (0.8 g, 5 minutes, 4°C) prior to culture 
or mRNA isolation as described below. For 
primary culture 2,000 fluorescent tubules, 
a mixture of tubules from two mice, were 
resuspended into warmed cell culture me-
dium (DMEM/Ham’s F12, Life Technolo-
gies BRL) with supplements as described 
(22) and seeded onto 0.33 cm2 polycar-
bonate Transwell® inserts (Corning Costar) 
previously coated with rat-tail collagen (16 
µl per insert of 0.75 mg/ml collagen in 95 
% v/v ethanol with 0.25% v/v acetic acid). 
Volumes used in the apical and basolateral 
compartments were 100 µl and 600 µl, re-
spectively. Cells were cultured at 37°C in 
5 % v/v CO2-95% v/v atmospheric air and 
the medium was refreshed every day. 
45Ca2+ transport measurement
For radioactive 45Ca2+ transport ex-
periments, primary cells cultured on Tran-
swell® inserts as described above were 
used. Cells were used 7 to 8 days after 
seeding; the day prior to the experiment 
transepithelial electrical resistance (TEER) 
was measured using an epithelial volt-
ohmmeter (EVOM, World Precision Instru-
ments). Cells were pretreated by adding 5 
µM indomethacin to the culture medium 
for 30 mins. Culture medium was removed 
and cells were washed once with physi-
ological salt solution (PSS: 140 mM NaCl, 
2 mM KCl, 1 mM K2HPO4, 1 mM MgCl2, 1 
mM CaCl2, 5 mM D-glucose, 5 mM D-ala-
nine, 5 µM indomethacin, 10 mM HEPES/
Tris, pH 7.4.). The apical compartment 
contained 100 µl and basolateral compart-
ment contained 600 μl. PSS was replaced 
with the same volumes of the pre-warmed 
identical solution with and without 10 μM 
dobutamine hydrochloride (sc-203031, 
Santa Cruz Biotechnology); apical medium 
contains 3 µCi/ml 45Ca2+. Ten microliters of 
basolateral medium was collected at time 
points 0, 15, 30, 60, 120 and 180 minutes 
and analyzed for radioactivity in a Perkin 
Elmer liquid scintillation counter. Unidirec-
tional flux from the apical side to the baso-
lateral side (JA→B) was calculated as previ-
ously described (23). 
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Gene             Forward primer             Reverse primer
Adrb1 GATCTGGTCATGGGATTGCT AAGTCCAGAGCTCGCAGAAG
Adrb2 CCTTAACTGGTTGGGCTACG GCTCTTGAAAGGCAATCCTG
Trpv5 CTGGAGCTTGTGGTTTCCTC TCCACTTCAGGCTCACCAG
Slc12a1 GGCTTGATCTTTGCTTTTGC CCATCATTGAATCGCTCTCC
Gapdh TAACATCAAATGGGGTGAGG GGTTCACACCCATCACAAAC
Semi-quantitative real-time PCR
To evaluate mRNA expression, RNA 
was extracted from pellets of 1,000 tubules 
isolated by COPAS using TriZol® Reagent 
(Life Technologies) according to the manu-
facturer’s protocol. The obtained RNA was 
reverse transcribed by Molony-Murine 
Leukemia Virus-Reverse Transcriptase 
(Invitrogen). cDNA was used to determine 
mRNA expression levels by Real Time PCR 
of Adrb1 (β1-AR) and Adrb2 (β2-AR). As 
controls TRPV5 and Na-K-Cl cotransporter 
2 (NKCC2) were included. The housekeep-
ing gene GAPDH was used as an endog-
enous control. Primers targeting the genes 
of interest were designed using Primer3 
and are listed in Table 1. Normal PCR us-
ing AmpliTaq Gold® (Life Technologies) 
was performed on HEK293 cDNA to check 
for β1-AR and β2-AR expression (primers: 
Adrb1 F, CCCAGAA-GCAGGTGAAGAAG 
R, CCCAGCCAGTTG-AAGAAGAC, Adrb2 
F, GGCAGCTCCAG-AAGATTGAC, R, 
TGGAAGGCAATCCTGA-AATC), products 
were visualized on a 1.5% agarose gel. 
Cell culture and transfection
HEK293 cells were grown in Dulbec-
co’s modified Eagle’s medium (DMEM, 
Bio Whittaker) containing 10% v/v fetal 
calf serum (PAA), 2 mM L-glutamine, 10 
μl/ml non-essential amino acids at 37°C 
in a humidity controlled incubator with 5% 
CO2. Cells were transiently transfected 
with the appropriate plasmids using poly-
ethyleneimine (PEI, PolySciences Inc) with 
a DNA:PEI ratio of 1:6 for biochemical or 
live-cell imaging experiments.
Cell surface biotinylation and immu-
noblotting
HEK293 cells (9 × 104 cells/cm2) were 
plated and transfected with 5 μg TRPV5-
HA pCINeo/IRES-GFP or pCINeo/IRES-
GFP in 10-cm dishes. At 24 hours after 
transfection cells were re-seeded on po-
ly-L-lysine coated (Sigma) 6-well plates. 
At 48 hours after transfection, cells were 
incubated for 1 h with 10 μM dobutamine 
or vehicle. Cells were homogenized in 1 ml 
lysis buffer as described previously (6) us-
Table 1 : Mus Musculus oligonucleotide sequences used in RT-PCR
Adrb1, β1-adrenergic receptor; Adrb2, β2-adrenergic receptor; Trpv5, transient receptor potential vanilloid type 5; 
Slc12a1 , Na+-K+-Cl- cotransporter 2 (Nkcc2); Gapdh, glyceraldehyde-3-phosphate dehydrogenase.
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ing the NHS-LC-LC-biotin (Pierce). Finally, 
biotinylated proteins were precipitated us-
ing NeutrAvidin beads (Pierce). TRPV5 ex-
pression was analyzed by immunoblotting 
for the precipitates (plasma membrane 
fraction) and for the total cell lysates using 
the anti-HA antibody (6).
Intracellular Ca2+ and cAMP measure-
ments using Fura-2 AM and EPAC-
EGFP-mCherry
For combined [Ca2+]i and cAMP mea-
surements, HEK293 cells were seeded 
onto coverslips (Ø 25 mm) and co-trans-
fected with the cAMP sensor (exchange 
protein directly activated by cAMP, 
(EPAC)-EGFP-mCherry (24), kindly pro-
vided by Dr. K. Jalink) for cAMP measure-
ments, and the appropriate TRPV5 pCI-
Neo/IRES-EGFP construct from which the 
sequence encoding EGFP was deleted. 
After 24 h, cells were loaded with 3 μM 
Fura-2 AM (Molecular Probes) and 0.01% 
v/v Pluronic F-129 (Molecular Probes) in 
DMEM medium at 37°C for 20 min. After 
loading, cells were washed with PBS and 
allowed to equilibrate at 37°C for another 
10 min in HEPES-Tris buffer (in mM: 132.0 
NaCl, 4.2 KCl, 1.4 CaCl2, 1.0 MgCl2, 5.5 
D-glucose and 10.0 HEPES/Tris, pH 7.4). 
Changes in [Ca2+]i and cAMP were simulta-
neously monitored, using a modified Fura-
2 protocol allowing simultaneous measure-
ments of Ca2+ and cAMP (8). Briefly, the 
cAMP sensor EPAC EGFP-mCherry was 
excited at 488 using a monochromator. 
Fluorescence emission light was directed 
by a 525DRLP dichroic mirror (Omega Op-
tical Inc.) through a 535af26 emission filter 
(EGFP fluorescence) and a 565ALP emis-
sion filter (mCherry fluorescence) onto a 
CoolSNAP HQ monochrome CCD-cam-
era. The integration time of the CCD-cam-
era was set at 200 msec with a sampling 
interval of 5 sec. All measurements were 
performed at room temperature. Quanti-
tative image analysis was performed with 
Metamorph 6.0 (Molecular Devices Cor-
poration). For each wavelength, the mean 
fluorescence intensity was monitored in 
an intracellular region and, for purpose of 
background correction, an extracellular 
region of identical size. After background 
correction, the fluorescence emission ra-
tio of 340 nm and 380 nm excitation was 
calculated to determine the [Ca2+]i whereas 
the fluorescence emission ratio of the red 
and green fluorescence of the cAMP sen-
sor was used to determine changes in cel-
lular cAMP content. 
Statistical analysis
If not specified otherwise, the data are 
expressed as mean±SEM. The significant 
differences between the means of two 
groups were analyzed by unpaired Stu-
dent's t-test using the measurements per 
cell/sample (n≥9) of at least three indepen-
dent experiments (N≥3). The level of statis-
tical significance is P<0.05. All data were 
analyzed using GraphPad Prism. 
Results
β1-AR and β2-AR are expressed in 
DCT2/CNT
In order to investigate the role of β1-AR 
and β2-AR on active Ca2+ reabsorption in 
DCT2/CNT, immunohistochemical staining 
was performed on frozen mouse kidney 
sections. Stainings showed colocalization 
of β1-AR with TRPV5 in DCT2/CNT seg-
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ments, but not β2-AR (Fig. 1A and C). β1-
AR and β2-AR antibody specificity was 
evaluated by negative controls of second-
ary antibody only (Fig. 1B, panel “neg ctrl”) 
and staining of liver tissue (Fig. 1B, panel 
“liver”) reported to be negative for both 
β1-AR and β2-AR (24, 25). mRNA expres-
sion of β1-AR (Adrb1) and β2-AR (Adrb2) 
in DCT2/CNT cells isolated from pTRPV5-
GFP mice using the COPAS Biosorter, was 
determined by Real Time PCR. Results 
showed that both β1-AR and β2-AR are 
enriched in DCT2/CNT when compared to 
total kidney cortex material, although the 
expression level of β1-AR is considerably 
Figure 1: β1-AR and β2-AR expression in mouse kidney. Localization of β1-AR, β2-AR, and TRPV5 is depicted by 
immunohistochemistry on mouse kidney tissue (A). Negative controls of secondary antibody only and stainings of 
liver tissue are shown (B). Higher magnification immunohistochemistry pictures of the localization of β1-AR, β2-AR, 
and TRPV5 (C).
higher (Fig. 2A), especially when com-
pared to the negative control NKCC2 (Sl-
c12a1) normally expressed in TAL. TRPV5 
expression was used as positive control. 
Altogether, these results indicated that β1-
AR is expressed at the DCT2/CNT part of 
the nephron together with TRPV5. At the 
cellular level, only part of the β1-AR sig-
nal did colocalize with TRPV5, suggesting 
expression in both apical and basolateral 
areas (Fig. 1C).
Dobutamine stimulates transcellular 
Ca2+ transport in mouse DCT2/CNT
In order to examine the role of β1-AR 
stimulation on Ca2+ reabsorption in the dis-
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Figure 2: Effect of β1-AR agonist (10 μM dobutamine) on transepithelial Ca2+ transport in mouse DCT2/CNT pri-
mary cultured monolayers. mRNA enrichment of β1-AR (Adrb1) and β2-AR (Adrb2) in isolated mouse DCT2/CNT 
cells compared to total kidney cortex; TRPV5 (Trpv5) was used as positive control, NKCC2 (Slc12a1) as negative 
control (N=6) (A). Open and closed circles, represent Ca2+ transport under control and dobutamine conditions, 
respectively. t15, t30, t60, t120 and t180
 indicate time points of sample collections after 15-, 30-, 60-, 120- and 180-min 
incubation  *P < 0.05 in comparison to control at the same time point. (N=7-8) (B). 
Figure 3: Expression of β1- and β2-AR in HEK293 
cells, (+) and (-) signify PCR products of reverse-tran-
scribed and non-reverse-transcribed mRNA, respec-
tively. Product sizes were 346 bp for β1-AR and 328 
bp for β2-AR.
tal part of the nephron, primary DCT2/CNT 
tubules were cultured on Transwell inserts 
for 7/8 days allowing the formation of tight 
monolayers (TEER of 603±80 Ω.cm2 one 
day prior to the experiment). Transepi-
thelial transport of Ca2+ from the apical to 
basolateral compartment was measured 
by apical addition of 45Ca2+ in the pres-
ence or absence of 10 μM dobutamine, a 
specific β1-AR agonist, in both the apical 
and basolateral solution. Transport of Ca2+ 
was significantly increased by 10 μM do-
butamine (19±2 and 30±4 nmol.hr-1.cm-2 
for control and dobutamine, respectively, 
P<0.05) after 60 min (Fig. 2B).
β1-AR agonist stimulates cAMP pro-
duction in HEK293 cells
To study the role of the Ca2+ channel 
TRPV5 in β1-AR-mediated activation of 
transcellular Ca2+ transport, we examined 
the effect of dobutamine in HEK293 cells, 
which were reported to express β1-AR 
(25). First, the expression of β1- and β2-
AR in HEK293 cells was confirmed (Fig. 
3). Identity of the observed bands was 
proved by sequencing of the respective 
PCR products. Since β1-AR activation 
leads to cAMP production (18) the β1-AR-
mediated TRPV5 Ca2+ influx in HEK293 
cells transfected with the cAMP sensor 
EPAC and TRPV5 was studied as de-
scribed in the materials and methods. The 
EPAC and Fura-2 ratios were measured 
before (t=0 min, t0) and after (t=3 min, t3) 
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Figure 5: Effect of β1-AR agonist on plasma membrane abundance of TRPV5. TRPV5-transfected HEK293 cells 
were treated for 60 min with or without 10 μM dobutamine. NHS-LC-LC-biotin was added to media for 30 min 
before the cells were lysed, and the biotinylated (plasma membrane) fraction was pulled down using neutravidin-
agarose beads. Representative immunoblot for TRPV5 analyzed for plasma membrane and total expression. CTRL, 
control; Dob, dobutamine-treated (A). Calculated immunoblot densities were shown (N=3, n=9) (B). 
Figure 4: Effect of β1-AR agonist dobutamine on cAMP production and Ca2+ uptake in HEK293 cells transiently 
transfected with TRPV5 and EPAC sensor. Average EPAC trace upon the addition of 10 μM dobutamine (Dob) 
(N=3, n=60 cells) (A). EPAC ratios demonstrated before (t0) and after (t3) dobutamine stimulation *P < 0.05 as com-
pared to t0 (N=3, n=60 cells) (B). Dose response curve of the effect of dobutamine treatment on cAMP production 
as measured by EPAC ratios (t3 compared to t0) (N=3, n=28-76 cells per condition) (C). Average Fura-2 trace upon 
the addition of 10 μM dobutamine (Dob) (N=3, n=59) (D). Fura-2 ratios demonstrated before (t0) and after (t3) of 
dobutamine stimulation *P < 0.05 as compared to t0 (N=3, n=59) (E). Dose response curve of the effect of dobuta-
mine treatment on Ca2+ uptake as measured by Fura-2 ratios (t3 compared to t0) (N=3, 29-70 cells per condition) (F).
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Figure 6: Effect of β1-AR agonist on TRPV5-dependent Ca2+ uptake.  Average Fura-2 traces of mock (N=3, n=10 
cells), WT-TRPV5 transfected pre-incubated with PKA inhibitor, H89, 10 μM (N=3, n=26) and without (N=3, n=12) 
upon the addition of 1 μM dobutamine (A). Fura-2 levels demonstrated before (white bar) and after (black bar) do-
butamine stimulation of mock-transfected (N=3, n=10 cells), WT-TRPV5 (N=3, n=12), and H89-treated WT-TRPV5 
(N=3, n=26) *P < 0.05 compared to untreated mock. #P < 0.05 compared to the respective dobutamine untreated 
(t0) (B). Average Fura-2 traces of T709A-TRPV5 (N=3, n=21) and T709D-TRPV5 (N=3, n=20) mutants upon the ad-
dition of dobutamine as compared to WT-TRPV5 (N=3, n=12) (C). Fura-2 levels demonstrated before (white bar) 
and after (black bar) dobutamine stimulation of WT-TRPV5 (N=3, n=12), T709A-TRPV5 (N=3, n=21), and T709D-
TRPV5 (N=3, n=20) #P < 0.05 compared to untreated WT (D). 
dobutamine treatment (10 μM) (Fig. 4A 
and D). The EPAC ratio plotted at t0 and t3 
indicated a significant increase in cAMP 
levels after 2-min incubation with dobu-
tamine as measured by a 5.1±0.1% in-
crease in eGFP/mCherry ratio due to loss 
of the FRET signal upon binding of cAMP 
(Fig. 4B). Fura-2 ratios were increased by 
19.5±0.3% upon stimulation by dobuta-
mine (Fig. 4E). The dobutamine-induced 
increase in EPAC and Fura-2 ratio was 
dose-dependent (Fig. 4C and F), imply-
ing that β1-AR signaling can functionally 
stimulate TRPV5 activity in HEK293 cells.
Dobutamine does not change TRPV5 
protein abundance at the plasma 
membrane
Ca2+ influx through TRPV5 is regulated 
by plasma membrane abundance and ac-
tivity of the channel (3). The effect of do-
butamine on TRPV5 plasma membrane 
expression was assessed in HEK293 cells 
transiently-transfected with TRPV5 using 
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cell surface biotinylation. A 60-min incuba-
tion with 10 μM dobutamine did not affect 
plasma membrane abundance of TRPV5 
(Fig. 5A and B). Total expression of TRPV5 
in the dobutamine-treated cells did not dif-
fer from control as well (Fig. 5A).
Dobutamine stimulates TRPV5-medi-
ated Ca2+ uptake in HEK293 cells via 
PKA phosphorylation of T709 residue
TRPV5 channel activity is known to be 
stimulated by cAMP/PKA-mediated path-
ways (6). HEK293 cells were transfected 
with TRPV5 and loaded with the Fura-2 
Ca2+ sensor in order to measure Ca2+ up-
take. After 1-min incubation with dobuta-
mine, Ca2+ uptake reached maximal activa-
tion, approximately 2 times elevated when 
compared to basal uptake levels (Fig. 6A). 
Interestingly, these stimulatory effects 
were prevented when the cells were pre-
incubated (30 min) with the PKA inhibitor, 
H89 (Fig. 6A and B), indicating that β1-AR 
activation is mediated by PKA phosphory-
lation of the TRPV5 channel. Previously, a 
threonine residue 709 on the C-terminus 
of TRPV5 has been identified as the sole 
TRPV5 PKA phosphorylation site (8). In 
order to study the effects of dobutamine 
on phosphorylation of TRPV5 at this resi-
due, WT-TRPV5, non-phosphorylated mu-
tant T709A-TRPV5 and the T709D-TRPV5 
mutant mimicking phosphorylation at this 
residue were used. The stimulatory effect 
of dobutamine was absent in the non-
phosphorylable T709A-TRPV5 mutant and 
the phosphorylation-mimicking T709D-
TRPV5 mutant, the latter already showing 
activation, indicating that the T709 residue 
is crucial for β1-AR-mediated PKA phos-
phorylation (Fig. 6C and D).
Discussion
The present study indicates that activa-
tion of β1-AR stimulates TRPV5-mediat-
ed Ca2+ transepithelial transport via PKA 
phosphorylation of the Ca2+ channel. Our 
conclusion relies on the following findings: 
i) β1-AR colocalizes with TRPV5 in mouse 
DCT2/CNT; ii) the β1-AR agonist dobu-
tamine stimulates cAMP production and 
TRPV5-mediated Ca2+ uptake in HEK293 
cells; iii) dobutamine increases the TRPV5 
channel activity which can be prevented 
by the PKA inhibitor H89 and mutation of 
the channel at the T709 residue; iv) dobu-
tamine stimulates the apical-to-basolateral 
transepithelial Ca2+ flux in the mouse pri-
mary DCT2/CNT culture.
To our knowledge, the expression pro-
file and the consequences of activation of 
β-ARs in mouse DCT2/CNT have not been 
characterized. Boivin and colleagues elab-
orately investigated β1- and β2-ARs in 
rat kidney by immunohistochemistry (15). 
In their study, β2-AR is faintly present in 
DCT and undetectable in CNT (15), while 
in our study β2-AR did not colocalize with 
TRPV5 in the mice DCT2/CNT. For β1-AR, 
Boivin et al. showed colocalization with 
CaBP-D28K on the apical membrane (15) in 
line with our finding that β1-AR colocalizes 
with TRPV5, although we did not observe 
a clear apical localization. 
Gesek and White demonstrated that 
the immortalized mouse DCT (MDCT) cell 
line expresses both β1- and β2-ARs (26). 
In the present study, both receptors were 
detected by PCR in material from DCT2/
CNT as isolated by the COPAS biosorter. 
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Considering the lower amounts of β2-
AR detected in highly enriched DCT2/
CNT material, combined with absence 
of β2-AR in immunohistological stain-
ings in DCT2/CNT, we conclude that β2-
AR seems not present in the DCT2/CNT. 
Gesek et al. showed that isoproterenol 
stimulated both cAMP production and Na+ 
uptake, but not Ca2+ influx into the cells. 
However, they selected thiazide-sensitive 
DCT1 cells, which contain no TRPV5, re-
sulting in very low Ca2+ transport rates (18, 
22, 27). In contrast, in the present study, 
DCT2/CNT tubules were selectively sorted 
from TRPV5-expressing cells. In the polar-
ized mouse primary DCT2/CNT culture we 
demonstrated that dobutamine stimulates 
apical-to-basolateral transepithelial Ca2+ 
transport. Due to generally lower expres-
sion levels of β1-AR, in primary cultures 
compared to the in vivo situation, relatively 
high concentrations of dobutamine were 
applied (10 μM) to maximally stimulate 
transepithelial Ca2+ transport.
HEK293 cells are generally used as a 
model for studying molecular mechanism 
of TRPV5-mediated Ca2+ uptake, since 
they lack endogenous expression of this 
Ca2+ channel (28), allowing transfection 
of exogenous wild-type (WT) or residue-
specific TRPV5 mutants. In addition, due 
to over-expression of TRPV5 faster and 
stronger effects are to be expected when 
compared to primary cultures. Moreover, 
the cells were reported to express β1-AR, 
which could be stimulated by a non-spe-
cific β-AR agonist isoproterenol, showing 
enhanced cAMP synthesis (25). Here, we 
show that the intracellular level of cAMP 
is increased within minutes after addition 
of dobutamine, indicating that β1-AR was 
functionally expressed in HEK293 cells 
and that the cells are suitable for study-
ing β1-AR-initiated intracellular signaling. 
Accordingly, dobutamine was demon-
strated to stimulate Ca2+ uptake in TRPV5-
expressing HEK293 cells with maximal 
activation at 2 min. This rapid action of 
the agonist is likely non-genomic as ex-
emplified by the hormonal action of PTH 
on TRPV5 activity that exerted similar 
maximal stimulation within 2 min. It is re-
ported that TRPV5 activation is stimulated 
by the cAMP-dependent PTH1R signaling 
pathway leading to PKA-mediated phos-
phorylation of TRPV5 on the C-terminus 
of the channel (6). Moreover, Topala and 
colleagues showed that the activation of 
the Ca2+-sensing receptor (CaSR) induces 
TRPV5-mediated Ca2+ peak current in less 
than 1 sec (4). They elaborated that the 
CaSR-agonist neomycin mediated PKC 
phosphorylation of the residues S299 and 
S654. Interestingly, Gkika and co-workers 
demonstrated that long-term (1 h) stimu-
lation of bradykinin receptor type 2 (B2R) 
with tissue kallikrein resulted in increased 
plasma membrane accumulation of TRPV5 
(10). In the present study, however, 1 h do-
butamine incubation did not affect plasma 
membrane abundance as well as total ex-
pression of TRPV5. Altogether, activation 
of β1-AR enhanced TRPV5 activity via 
cAMP-dependent PKA phosphorylation of 
the TRPV5 channel at residue T709 in the 
intracellular C-terminus. 
Apart from the classic cAMP-dependent 
signaling mechanism of β-ARs, β1-AR has 
been reported to be PLC-dependent (18). 
In the study of Kang and colleagues, a non-
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specific β-AR agonist isoproterenol stimu-
lated Mg2+ uptake in isolated mouse DCT1 
cell culture (18). Isoproterenol is known 
to preferentially bind to β1-AR and to a 
lesser extent to β2-AR. In the latter study, 
both PKA and PLC inhibitors inhibited the 
stimulatory effects of isoproterenol. Phor-
bol-12-myristate-13-acetate (PMA), a DAG 
analog, had no effect on Mg2+ reabsorp-
tion, but potentiated effects of isoproter-
enol (18). There is no report of dobutamine 
action on signaling mechanisms other than 
the cAMP-dependent pathway and the 
PKA inhibitor H89 completely blocked the 
dobutamine action. Thus, the β1-AR sig-
naling pathway in the present study seems 
to be solely mediated by the cAMP/PKA. 
The present study indicates a novel 
calciotropic role of dobutamine in renal 
DCT2/CNT in addition to the positive ino-
tropic effect in cardiac myocytes. In addi-
tion, β-blockers widely used in treatment 
of CHF, might have adverse effects on 
maintaining body Ca2+ homeostasis. CHF 
initiates when the heart fails to sufficiently 
supply blood to match the body demand 
due to reduced cardiac contractility (19, 
29). Heart rate is accelerated (30) leading 
to a decreased effective circulating vol-
ume (ECV), which in turn triggers the renin-
angiotensin-aldosterone system (RAAS) in 
the kidney (31). As a result of CHF, patients 
develop secondary aldosteronism leading 
to increased fecal and urinary Ca2+ excre-
tion (32). In addition, patients are generally 
treated with loop diuretics and often suffer 
from vitamin D deficiency (32, 33). More-
over, hypercalciuria and osteopenia have 
been implicated in patients with advanced 
CHF awaiting cardiac transplantation (32, 
34). Hence, potential calciotropic effects of 
β-blockers might further increase chances 
of developing hypocalcemia in these pa-
tients. In addition, β-blockers are used 
to resolve hypercalcemia among other 
symptoms in hyperthyroidism (35, 36). 
The mechanism of action of β-blockers in 
hyperthyroidism is unclear, but principally 
appears to antagonize overstimulated 
β-AR-mediated signaling. Interestingly, 
the Ca2+-lowering effect of propranolol 
(non-selective β-blocker) was proposed to 
be caused by a direct effect on bone or 
renal Ca2+ handling (36).
In conclusion, the present study dem-
onstrates that dobutamine, a β1-AR 
agonist, stimulates TRPV5 activity via a 
PKA-dependent pathway. PKA activation 
results in phosphorylation of the T709 resi-
due and consequently enhances TRPV5 
activity. Epi and NE, by activating TRPV5 
activity, could potentially be involved in 
normal physiological renal Ca2+ handling 
in the DCT2/CNT. Therefore, β-adrenergic 
receptor agonists and blockers, increas-
ingly administered to patients, potentially 
exert adverse calciotropic effects.
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Introduction
Ca2+ is an important cation inside and 
outside the cell (1). In cytoplasm and in-
tracellular organelles, Ca2+ governs cellular 
functions by acting as co-factor for protein 
kinases and ATP-synthesizing enzymes 
(2). Meanwhile, extracellular Ca2+ is es-
sential for maintaining the potential across 
the plasma membrane of excitable cells 
and serves as major component of bone 
skeleton (3). Therefore, Ca2+ homeostasis 
needs to be delicately controlled and con-
sequently various Ca2+-regulating organs 
are involved including the intestine, kid-
ney, and bone (4). Intestinal and renal Ca2+ 
(re)absorption consists of transcellular (ac-
tive) and paracellular (passive) pathways 
(5). The transcellular Ca2+ (re)absorption is 
composed of three steps: TRPV5/6-me-
diated Ca2+ influx, intracellular Ca2+ (Ca2+i) 
buffering and movement by calbindins 
(CaBP-D28K/D9K) and Ca
2+ extrusion by 
the Na+/Ca2+ exchanger (NCX1) and/or the 
plasma membrane Ca2+ ATPase-type 1b 
(PMCA1b) (6). Subsequently, the majority 
of total Ca2+ is precipitated in bone while 
only 1% is freely circulating or conjugated 
with other ions and proteins in blood (7). 
The kidney filters blood in glomeruli and 
reabsorbs Ca2+ mainly in proximal seg-
ments via the paracellular process (6). The 
process of Ca2+ reabsorption in the lumen 
of distal convolution (late distal tubule and 
connecting tubule) is tightly controlled, es-
pecially by the entry step through TRPV5, 
buffering with CaBP-D28K, and the extru-
sion through NCX1 and PMCA1b (6). The 
factors controlling Ca2+ reabsorption are 
called “calciotropic factors” which are 
exemplified by 1,25-dihydroxyvitamin D3 
(1,25-(OH)2D3) and parathyroid hormone 
(PTH) (8). 
Bone stores Ca2+ in the form of hy-
droxyapatite [Ca5(PO4)3(OH)] with an ex-
tracellular matrix (ECM) that strengthens 
and stabilizes the skeleton (9). Two major 
cell types – osteoclasts (OCs) and osteo-
blasts (OBs) – coordinately remodel bone 
by communicating to each other through 
a receptor activator of nuclear factor-KB 
(RANK)/RANK ligand/osteoprotegerin 
(RANK/RANKL/OPG) system (10). Matura-
tion of OCs is stimulated by surface RANK 
signaling upon its binding with RANKL 
secreted from OBs (11). In order to bal-
ance OC maturation, OBs secrete OPG 
that binds and neutralizes RANKL (9,11). 
Under normal remodeling cycle, OCs ini-
tiate resorption of inorganic Ca2+ and or-
ganic bone matrix by secreting acids and 
proteases, then OBs produce collagenous 
matrix and ground substances for bone 
formation (10) As explained in Chapter 1, 
a reduction in RANKL/OPG ratio indicates 
predominant bone resorption over bone 
formation and vice versa. Imbalance in 
RANKL/OPG ratio leads to skeletal ab-
normalities characterized by osteoporosis 
and osteopetrosis (12).
Proteases hydrolyze peptide bonds to 
activate or inactivate the target proteins 
inside or outside the cell (13). Extracel-
lular proteases can trigger cellular re-
sponses by two means: directly cleaving 
substrate proteins or cleaving/binding to 
plasma membrane receptors that convey 
signals to downstream targets (13). Ser-
ine proteases and their receptors have 
been recognized as important players in 
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fibrinolytic processes, cell adhesion and 
development, and recently bone Ca2+ me-
tabolism (14-18). In the intestine, serine 
protease matriptase localized with E-cad-
herin at the apical junctional complex is 
important for tight junction barrier integrity 
(19). Matriptase maintains normal paracel-
lular permeability by blocking expression 
of claudin-2, a major charge-selective tight 
junction protein (19,20). 
In kidney, serine proteases have been 
shown to regulate transport of ions; for 
in stance, dipeptidyl-peptidase IV (DP-
PIV) stimulates Na+-H+ exchanger type 
3 (NHE3) activity in proximal tubule (21). 
Moreover, serine protease prostasin acti-
vates epithelial Na+ channel (ENaC) activ-
ity by cleaving the regulatory γ-subunit of 
the channel in the cortical collecting duct 
(CCD) (22). In distal convolution, where the 
active Ca2+ reabsorption takes place, tis-
sue kallikrein (TK) has been shown to stim-
ulate TRPV5-mediated Ca2+ reabsorption 
(19). Our studies suggest a possible role of 
urinary factors and associated receptors in 
the regulation of the Ca2+ balance. In this 
chapter the newly discovered role of serine 
proteases and associated molecules on 
systemic Ca2+ metabolism are discussed 
and summarized. 
Roles of urinary factors on 
TRPV5 activity
Various exogenous and endogenous 
urinary enzymes have been identified con-
trolling renal Ca2+ reabsorption under nor-
mal conditions and pathophysiology (23). 
Patients with nephrotic-range proteinuria, 
especially when treated with the loop di-
uretic furosemide, exhibit microscopic 
nephrocalcinosis (24). It has long been 
unidentified which factors take part in for-
mation of these Ca2+ stones. Catalytically 
active plasmin is present in the pro-urine 
of nephrotic patients (25) and can acti-
vate Na+ channel activity by cleavage of 
the regulatory γ-subunit (25,26). Thus, it 
was hypothesized that plasmin could be a 
potential candidate. TRPV5 malfunction in 
TRPV5 and klotho-deficient mice causes 
osteopenia and Ca2+-phosphate precipita-
tion in cortical tubules (27,28). This finding 
suggests an important role of the channel 
in regulating Ca2+ reabsorption in the dis-
tal convolution. In Chapter 2, plasmin was 
found to inhibit TRPV5 activity. However, 
plasmin did not directly cleave TRPV5; 
instead, it bound to protease-activated 
receptor type 1 (PAR-1) and conveyed its 
inhibitory signal through phospholipase C 
(PLC-β)/protein kinase C (PKC)-depen-
dent phosphorylation of the N-terminus 
of the channel of which details will be dis-
cussed later in this chapter. This discov-
ery might be useful for further allosteric 
ligand (see below) development in order 
to prevent nephrocalcinosis in nephrotic 
syndrome.
Chapter 3 describes that tTG directly 
enhances crosslink formation between 
TRPV5 molecules. tTG belongs to a family of 
protein-glutamine γ-glutamyltransferases 
(29). It creates crosslinks between a lysine 
residue and glutamine residue of another 
molecule, forming an intermolecular bond 
that is resistant to proteolysis (30). Similar-
ly to the urinary enzyme klotho, tTG action 
on TRPV5 required the presence of the 
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N-glycan even though the exact mecha-
nism is not known (31). Functional TRPV5 
is composed of four subunits (homotetra-
mers), which connect to each other with 
their N- and C-termini (32,33). However, 
formation of TRPV5 crosslinked by tTG re-
lies on the N-glycan, which is located on 
the first extracellular loop (28). Therefore, 
these crosslinks misfolded TRPV5, reduc-
ing the pore size diameter and eventually 
Ca2+ reabsorption.
Implications of G protein-
coupled receptors (GPCRs) 
in the regulation of Ca2+  
homeostasis
Ligand-receptor binding is an important 
step for cell-surface receptor activation by 
hormones, neurotransmitters, and other 
extracellular factors (34). In general, an or-
thosteric (endogenous) ligand binds to its 
receptor on an orthosteric site and trans-
mits an agonistic signal to trigger cellular 
responses (Fig. 1) (34). These responses 
can be modulated by an allosteric ligand, 
which is able to bind another site on the 
receptor (allosteric site) to modify ortho-
steric binding affinity as well as signaling 
efficacy. In pharmaceutical industry, allo-
steric sites are considered as targets for 
therapeutic agents (34). GPCRs are ubiq-
uitously expressed in various tissues and 
are the largest group of cell-surface recep-
tors (35). Moreover, many diseases are as-
sociated with these receptors (34). For this 
reason, the GPCR family is a major target 
of drug discovery industry (36). Currently, 
more than 40 allosteric ligands for GPCRs 
have been developed and administered in 
order to agonize or antagonize orthosteric 
effects (34). 
As described in Chapter 2, GPCR PAR-
1 (thrombin receptor, TR) transduced plas-
min action. In Chapter 4, the role of TR 
was further investigated by in vivo studies. 
Previously, the thrombin/TR system has 
Figure 1 : Cellular model of ligand-receptor binding and modulation by allosteric ligand. An orthosteric ligand 
(orange) binds to G protein-coupled receptor (GPCR) on an orthosteric site to convey an agonistic signal to initiate 
cellular responses. The cellular responses can be modulated by an allosteric ligand (green) that binds to a distinct 
site (allosteric site) on the cell.  An allosteric binding can change binding affinity or efficacy of orthosteric ligand. 
Eventually, summation of the signals dictates physiological responses of the cell (adapted from (34)).
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been found to facilitate the bone healing 
after fracture (37). Our study showed that 
TR-deficient mice have primary osteope-
trosis, indicating a novel role of TR in bone 
metabolism. The role of an orthosteric li-
gand for β1-adrenergic receptor (β1-AR) 
has also been investigated in Chapter 5. 
Characterization of the role of β-ARs in 
the kidney is attractive since epinephrine 
and norepinephrine can be produced by 
the kidney and their urinary levels rise con-
comitantly with plasma Ca2+ during regular 
exercises (38,39). The finding that β1-AR 
activation enhanced TRPV5 activity indi-
cates an extra role of the catecholamine 
besides its inotropic action.
Roles of protein kinase C 
(PKC) and protein kinase A 
(PKA) phosphorylation sites 
on TRPV5 function
When orthosteric ligands bind to GP-
CRs, the receptors undergo conforma-
tional changes that capacitate them to 
further activate GTP-binding proteins (G 
proteins) (40). G proteins are constituted of 
heterotrimeric subunits–α, β, and γ (41). In 
the basal state, the α subunit is bound to 
GDP, keeping the G protein inactive (42). 
When stimulated by an agonist, GTP sub-
stitutes GDP and the G protein becomes 
active. This phenomenon dissociates the 
three subunits into two activated compo-
Figure 2 : Identification of functional protein kinase C (PKC) and protein kinase A (PKA) phosphorylation sites on 
the intracellular N- and C-termini of transient receptor potential vanilloid type 5 (TRPV5) through activation of G pro-
tein-coupled receptors (GPCRs). Tissue kallikrein (TK) binds to bradykinin receptor type 2 (B2R) and induces PKC 
phosphorylation of TRPV5 on S229 (1) and S654 (2) residues, resulting in an up-regulation of TRPV5 abundance 
on plasma membrane, thereby increasing Ca2+ influx. Parathyroid hormone (PTH)-activated parathyroid hormone 
receptor type 1 (PTH1R) and norepinephrine (NE)-activated β1-adrenergic receptor (β1-AR) convey a common 
signal to PKA, which further phosphorylates T709 on the N-terminus of TRPV5 (3 and 5). T709 phosphorylation 
impedes calmodulin (CaM) binding to the N-terminus and leads to an increase in NPo of the channel. On the other 
hand, plasmin-activated protease-activated receptor type 1 (PAR-1) induces PKC phosphorylation of TRPV5 on 
S144 residue, resulting in a diminished open probability (NPo) and pore size of TRPV5 and modification of CaM 
binding to the CaM-binding sequence (4).
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nents, the α-subunit and the βγ complex 
(42). Twenty different Gα subunits alone 
can directly activate downstream targets 
and are categorized into 4 families: Gs, 
Gi, Gq, and G12/13 families (43). These 
families of Gα differentially influence their 
downstreams. While Gs activates adenylyl 
cyclase (AC)/PKA, Gi inhibits this pathway 
(43). Gq activates PLC-β/PKC signaling 
pathway whereas G12/13 activates Rho 
GTPases (43).
Several TRP channels including TRPV5 
are downstream of PLC-β, which hydro-
lyzes phosphatidylinositol 4,5-bisphos-
phate (PIP2) to produce diacylglycerol 
(DAG) and further activates PKC. Gkika et 
al. have demonstrated the importance of 
S299/S654 PKC phosphorylation sites on 
the N- and C-termini of TRPV5 (Fig. 2) (44). 
They found that activation of bradykinin re-
ceptor type 2 (B2R) by serine protease TK 
intensified plasma membrane abundance 
of TRPV5 (44). Parathyroid hormone recep-
tor type 1 (PTH1R) employed either PKC or 
PKA signaling pathway to stimulate TRPV5 
membrane insertion and to increase open 
probability, respectively (45,46).
In Chapter 2, plasmin was shown to 
activate PKC-dependent phosphoryla-
tion of the N-terminus of TRPV5 (Fig. 2). 
Plasmin cleaved PAR-1, which in turn 
activated PLC-β assumingly through Gq. 
This process increased the binding affin-
ity of calmodulin (CaM) to the N-terminus 
of TRPV5, resulting in pore size reduction 
and a lower open probability. On the other 
hand, in Chapter 5, activation of β1-AR led 
to PKA phosphorylation of the C-terminus 
of TRPV5 (Fig. 2). Previously, de Groot et 
al. demonstrated that this phosphorylation 
reduces CaM-C-terminus binding affin-
ity and eventually enhances TRPV5 open 
probability (47). T709 phosphorylation 
plays a central role in regulating TRPV5 
opening by impeding CaM binding to the 
N-terminus (see Fig. 2 and texts for de-
tails). Therefore, β1-AR activation is pre-
sumed to convey its signal through a Gs 
subunit since it is PKA-mediated (43). 
Taken together, PKC and PKA have 
been identified as important regulators of 
TRPV5. Thus, drug targeting of PKC/PKA-
associated GPCRs are of interest for miti-
gating renal Ca2+ disturbances.
Differential roles of GPCRs in 
kidney and bone.
Renal tubular diseases might coexist 
with bone disorders such as osteopenia 
and osteoporosis, and can be the conse-
quence of systemic electrolyte derange-
ments (48). Defective bone phenotypes 
like osteodystrophy occur when the kidney 
fails to synthesize 1,25-(OH)2D3 (49). Vari-
ous hormones have been identified as reg-
ulators of kidney and bone functions. For 
instance, mice lacking the anti-aging hor-
mone klotho have primary renal Ca2+ loss, 
nephrocalcinosis, and secondary osteo-
penia (27).  Meanwhile, fibroblast growth 
factor 23 (FGF23), a phosphaturic hor-
mone produced by osteocytes (OCYs) can 
modulate renal synthesis 1,25-(OH)2D3, 
indicating that bone can also influence re-
nal functions (48). Discoveries of novel hu-
man diseases associated with FGF23 and 
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Figure 3 : Two major structural bone diseases–osteoporosis and osteopetrosis. Osteoporosis is characterized by 
an uncoupled bone-remodeling process mainly from a reduction in osteoblast (OB) activity, leading to bone loss 
(middle panel) (10). Trabeculae are more separated and thinner compared to normal (left panel). Osteopetrosis is 
caused by a defect in osteoclast (OC) resorptive functions manifested by a slow degradation rate of the mineralized 
extracellular matrix (ECM) and subsequently increased trabecular thickness (right panel) (61).
klotho exemplifies the importance of this 
bone-kidney relationship.
A variety of external factors, such as 
hormones and growth factors can acti-
vate GPCRs. Kato et al. demonstrated that 
GPCR48 (Leucine-rich repeat-containing 
GPCR-4) deficiency causes renal hypo-
plasia and impaired kidney function (50). 
Recently, Luo et al. reported that GPCR48-
/- mice had low bone mineral density (BMD) 
and bone formation indices (51). They also 
showed that GPCR48 regulates bone min-
eralization and ECM synthesis through 
3’-5’-cyclic adenosine monophosphate 
(cAMP)/PKA signaling pathway (51). The 
ligand responsible for GPCR48 action 
has not been identified; however, a bone 
morphogenetic protein (BMP)-regulating 
protein norrin and R-spondins have been 
proposed to be ligands for the receptor 
(52,53).
Another example of bone-kidney axis-
associated GPCRs is the angiotensin II 
(Ang II) receptor type 1 (AT1R). Ang II is a 
very potent vasoconstrictor for kidney and 
intestinal vessels. Moreover, its receptor 
AT1R is also expressed in OBs and OCs 
(54). Losartan, an AT1R antagonist, nor-
malized BMD as well as bone strength in 
ovariectomized rats presumably by acti-
vation of OB activity through Gq/ERK1/2 
pathway (54,55). In kidney, AT1R activa-
tion induced phosphorylation of WNK4, a 
serine-threonine protein kinase that has 
been found to antagonize the stimulatory 
effect of PKC on TRPV5 membrane ex-
pression (56,57). As discussed in previous 
paragraphs, PAR-1 can be activated by 
both plasmin in the kidney and thrombin in 
bone (Chapter 2 and Chapter 4). In PAR-
1-deficient mice, the serum RANKL/OPG 
ratio is reduced, resulting in high bone 
mass phenotype (Fig. 3). Thrombin/PAR-
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1 had no effect on TRPV5-mediated Ca2+ 
reabsorption. This observation implies that 
thrombin and plasmin stimulate PAR-1 via 
different ways. 
Concluding remarks and  
future perspectives 
In the past decade, several studies dis-
covered novel roles of serine proteases 
and GPCRs on Ca2+ metabolism. In 1999, 
two independent groups have character-
ized the gatekeepers of intestinal and re-
nal active Ca2+ (re)absorption, TRPV6 and 
TRPV5, respectively (58,59). The first Ca2+-
regulating serine protease, TK, has been 
identified in 2005 (44,60). A year later, the 
effect of TK on TRPV5 trafficking was re-
ported. In the same year, Ca2+ phenotypes 
of PTH-deficient rats were delineated. This 
thesis implements novel knowledge on the 
regulation of Ca2+ metabolism through of 
PAR-1 that controls renal Ca2+ reabsorp-
tion and bone remodeling upon activation 
by plasmin and thrombin, respectively (Fig. 
4). Moreover, we disclosed a calciotropic 
role of β1-AR. In addition to GPCRs, tTG 
was also found to regulate TRPV5 activ-
ity. However, there is still a window of op-
portunity to elucidate detailed molecular 
mechanisms of these extracellular factors. 
First, how do different PKC isoforms dif-
ferentially regulate TRPV5 activity and traf-
ficking? Secondly, how does phosphory-
Figure 4 : Summarization of newly identified extracellular factors that regulate the Ca2+ homeostasis in the intes-
tine, kidney and bone in this thesis. In kidney, tissue transglutaminase (tTG) and plasmin inhibit transient receptor 
potential vanilloid type 5 (TRPV5) activity while catecholamines (β1-adrenergic receptor agonists) activates TRPV5. 
In bone, thrombin inhibits bone formation, but its role in the intestine is not clear.
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Introductie
Ca2+ is een belangrijk kation zowel bin-
nen als buiten de cel. Door op te treden 
als co-factor voor eiwitkinases en ATP-
synthetiserende enzymen, regelt Ca2+ cel-
lulaire functies in intracellulaire organellen 
en in het cytoplasma. Extracellulair Ca2+ 
is essentieel voor het handhaven van de 
plasmamembraanpotentiaal van exciteer-
bare cellen en is een belangrijke com-
ponent van het skelet. Daarom wordt de 
Ca2+ homeostase strak gereguleerd via 
verschillende organen, zoals de darm, de 
nier en het bot. Intestinaal en renaal Ca2+ 
transport bestaan uit twee verschillende 
mechanisme, namelijk transcellulair (actief) 
en paracellulair (passief) transport. 
Transcellulair Ca2+ transport bestaat 
uit drie opeenvolgende stappen: te be-
ginnen met TRPV5/6-gemedieerde Ca2+ 
influx, gevolgd door intracellulaire Ca2+ 
(Ca2+i) buffering door calbindine (CaBP-
D9K/D28K) en tot slot de afgifte van Ca
2+ 
via de Na+-Ca2+ uitwisselaar (NCX1) of 
het plasmamembraan eiwit Ca2+-ATPase-
type 1 (PMCA1b). De nier resorbeert Ca2+ 
voornamelijk in de proximale segmenten 
via paracellulair transport. Ca2+ resorptie 
in het distale deel van het nefron wordt 
nauwkeurig gereguleerd, voornamelijk via 
TRPV5. De factoren die Ca2+ transport 
reguleren, zoals  1,25-(OH)2D3 en PTH, 
worden "calciotrope factoren" genoemd. 
Anderzijds, paracellulair Ca2+ transport 
wordt gedreven door de elektrochemische 
gradiënt tussen de luminale en basolater-
ale compartimenten en is onafhankelijk van 
1,25-(OH)2D3. Het meeste Ca
2+ is in gebon-
den vorm aanwezig in het bot, slechts 1% 
is ongebonden of geconjugeerd met ande-
re ionen en eiwitten aanwezig in het bloed.
Bot slaat Ca2+ op als hydroxyapatite 
zout [Ca5(PO4)3(OH)] in de extracellulaire 
matrix (ECM), een proces dat het skelet 
versterkt en stabiliseert. Twee belangrijke 
cellulaire componenten van het bot zijn 
osteoclasten (OC) en osteoblasten (OB). 
Deze cellen communiceren met elkaar via 
het RANK/RANKL/OPG systeem. Matu-
ratie van OC’s wordt gestimuleerd door 
receptor activator van de nucleaire fac-
tor-KB (RANK) gesignaleerde binding met 
de RANK ligande (RANKL) afkomstig van 
OB’s. Het rijpen van latente OCs wordt 
geïnitieerd door RANK/RANKL binding. 
Om OC rijping tegen te gaan, scheiden OBs 
osteoprotegerine (OPG) uit, welke RANKL 
bindt en neutraliseert. Tijdens de normale 
bot cyclus, initiëren de OCs de resorptie 
van anorganische Ca2+ en organische bot 
matrix door het afscheiden van zuren en 
proteases, terwijl OBs collageenmatrix en 
grondstoffen voor de botvorming produ-
ceren. Een vermindering van de RANKL/
OPG-ratio resulteert in botresorptie boven 
botvorming en vice versa. Disbalans van 
de RANKL/OPG-ratio leidt tot skeletafwi-
jkingen, welke gekenmerkt zijn door osteo-
porose en osteopetrose.
Proteases hydrolyseren peptide-
verbindingen waardoor de activiteit van 
eiwitten wordt gereguleerd. Extracellulaire 
proteases kunnen cellulaire reacties acti-
veren op twee manieren: door het direct 
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splitsen van substraateiwitten of door het 
splitsen/binden aan plasmamembraanre-
ceptoren, wat vervolgens leidt tot de ac-
tivering van signaaltransductieroutes. Ser-
ine proteases en hun receptoren spelen 
een belangrijke rol in het fibrinolytische 
proces, celadhesie, groei en het Ca2+ me-
tabolisme van het bot. In de darm is de 
serine protease matriptase van belang 
voor het in stand houden van de zonula 
occludens. Matriptase handhaaft een 
normale paracellulaire permeabiliteit door 
claudin-2 expressie te blokkeren.
In de nieren reguleren serine proteases 
het ionentransport bijvoorbeeld via dipep-
tidyl-peptidase IV (DPPIV), welke Na+-H+ 
uitwisselaar 3 (NHE3) activiteit stimuleert in 
de proximale tubulus. Daarnaast activeert 
de serine protease prostasin, die epiteliële 
Na+ kanaal (ENaC) door de regulerende 
γ-subeenheid van het kanaal in de cotrica-
le verzamelbuis (CCD) vrij te geven. In het 
distale convoluut 2 (DCT2) en de verbind-
ingsbuis (CNT) van het nefron, waar actief 
Ca2+ transport plaatsvindt, is aangetoond 
dat weefsel-kallikreïne TRPV5-geme-
dieerde Ca2+ resorptie stimuleert. Deze 
studies suggereren een mogelijke rol van 
het plasminogeen-systeem in de regulatie 
van het renale en intestinale Ca2+-trans-
port. Deze sectie geeft een overzicht van 
de recentelijk gepubliceerde functies van 
serine proteases en bijbehorende molecu-
len op het systemische Ca2+ metabolisme.
Het effect van eiwitten in de urine op 
de activiteit van TRPV5
Verschillende exogene en endogene 
enzymen in de urine reguleren renaal 
Ca2+ transport onder (patho)fysiologische 
omstandigheden. Patiënten met een ne-
frotische proteïnurie vertonen microsco-
pische nefrocalcinose, vooral na behan-
deling met het lisdiureticum, furosemide. 
Tot nu toe zijn slechts enkele factoren geï-
dentificeerd die betrokken zijn bij de vorm-
ing van Ca2+-bevattende nierstenen. 
Katalytisch actief plasmine is aanwezig 
in de pro-urine van nefrotische patiënten 
en kan het Na+ kanaal activeren door de 
regulerende γ-subunit te splitsen. Daarom 
wordt verondersteld dat plasmine een po-
tentiële kandidaat voor de vorming van 
nierstenen is. Het slecht functioneren 
van TRPV5 in klotho-deficiënte muizen 
veroorzaakt calciumfosfaat neerslagen in 
de corticale tubuli. Deze bevinding sug-
gereert dat het kanaal een belangrijke rol 
in de Ca2+ resorptie in het distale deel van 
het nefron speelt. In hoofdstuk 2 wordt 
beschreven hoe plasmine de TRPV5 ac-
tiviteit kan remmen, echter niet via splits-
ing van TRPV5, maar door binding aan de 
G-proteïnegekoppelde receptor PAR-1. 
Dit resulteert in PLC-β/PKC-afhankelijke 
fosforylering, waarbij de N-terminus van 
het kanaal wordt gefosforyleerd, de details 
hiervan zullen later in dit hoofdstuk worden 
besproken. Deze ontdekking kan van be-
lang zijn voor de ontwikkeling van een allo-
sterische ligand waarmee de vorming van 
nefrocalcinose bij het nefrotisch syndroom 
voorkomen zou kunnen worden.
Naast de exogene factor plasmine, 
werd een endogeen enzym transglutamin-
ase (tTG), in de urine gevonden welke de 
TRPV5 activiteit remt zoals beschreven 
in hoofdstuk 3. tTG stimuleert de bind-
ing van TRPV5. Net als het urine enzym 
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klotho, vereist tTG-gemedieerde remming 
de aanwezigheid van het N-glycaan op 
TRPV5, hoewel het exacte mechanisme 
niet bekend is. tTG behoort tot de familie 
van glutamine γ-glutamyltransferases en 
zorgt voor intermoleculaire verbindingen 
die bestand zijn tegen proteolyse, door 
glutamine en lysine-residuen van eiwitten 
met elkaar te verbinden. TRPV5 bestaat uit 
vier identieke subunits (homotetrameren), 
die verbonden zijn via hun N- en C-termini. 
Het verbinden van TRPV5 moleculen door 
tTG resulteert in het foutief vouwen van het 
kanaal, wat leidt tot een kleinere diameter 
van de porie en uiteindelijk een afname in 
Ca2+ transport. Deze laatste verbinding is 
afhankelijk van het N-glycaan, welke gelo-
kaliseerd is op de eerste extracellulaire lus 
en een rol speelt bij de eiwitvouwing. Sa-
mengevat, tTG verstoort de TRPV5 stabil-
iteit en de poriegrootte via een nog onbek-
end mechanisme.
Implicaties van GPCR's in de regulatie 
van Ca2+ homeostase
G-proteïnegekoppelde receptoren 
(GPCR) komen tot expressie in verschil-
lende weefsels en vormen de grootste 
groep van receptoren op het celoppervlak. 
Bovendien worden veel ziekten geasso-
cieerd met deze receptoren. Dit maakt de 
GPCR familie een belangrijk doelwit voor 
de farmaceutische industrie. 
Ligand-receptor binding is belangrijk 
voor de activering van receptoren op het 
celoppervlak door hormonen, neurotrans-
mitters en andere extracellulaire factoren. 
Het is gebruikelijk dat een orthosterische 
(endogeen) ligand bindt aan zijn receptor 
op een orthosterische locatie en vervol-
gens een agonistisch signaal uitzendt, die 
cellulaire reacties activeert. Deze reacties 
kunnen gemoduleerd worden door een al-
losterische ligand, die een andere site van 
de receptor bindt (allosterische plaats), 
waardoor zowel de orthosterische bind-
ingsaffiniteit als de signalering verandert. 
De allosterische bindingsplaatsen kunnen 
door de farmaceutische industrie worden 
gebruikt voor de ontwikkeling van nieuwe 
therapeutische middelen. Om orthoster-
ische effecten tegen te werken, zijn er mo-
menteel meer dan 40 allosterische ligan-
den voor GPCR's ontwikkeld en getest.
Zoals vermeld is in hoofdstuk 2, stimu-
leert GPCR PAR-1 (trombinereceptor, TR) 
plasmine activiteit. In hoofdstuk 4, is meer 
onderzoek uitgevoerd om de rol van GPCR 
TR in vivo te bepalen. TR-deficiënte mui-
zen hebben primaire osteopetrosis met 
secundaire hypercalciurie. Deze fenotypes 
wijzen op een nieuwe rol van TR in het 
botmetabolisme. Bovendien suggereren 
deze data dat de activatie van TR in het 
bot wordt gemedieerd door de serine pro-
tease trombine. Eerder onderzoek heeft 
aangetoond dat het trombine/TR systeem 
de genezing van een botbreuk vergemak-
kelijkt. Onze studie impliceert een nieuwe 
rol van GPCR TR in het botmetabolisme.
In hoofdstuk 5 wordt de rol van een 
andere GPCR, de β-adrenerge receptor 
(β-AR), onderzocht naast zijn functie als 
orthosterische ligand. In principe worden 
β-AR agonisten gebruikt om de hartfunc-
tie te verbeteren. Het was interessant om 
de rol van β-AR's in de nier te karakter-
iseren omdat epinefrine en norepinefrine 
ook daar worden geproduceerd en de ex-
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pressie in de urine gelijktijdig met plasma 
Ca2+ stijgt tijdens sportbeoefening. β1-AR, 
maar niet β2-AR, komt tot expressie in de 
DCT2/CNT segmenten in het nefron. Onze 
bevinding dat dobutamine-gemedieerde 
β1-AR activatie de TRPV5 activiteit ver-
hoogt, suggereert een extra rol van cat-
echolamines, naast hun inotropische rol 
in het hart. Aangezien een niet-specifieke 
β-AR agonist Ca2+, Mg2+ en Na+ resorp-
tie in het dikke opstijgende been van lis 
(TAL) kan stimuleren, moet er rekening ge-
houden worden met mogelijke bijwerkin-
gen van β-AR agonisten op het renaal io-
nentransport.
De rol van de proteine kinase C (PKC) 
en proteine kinase A (PKA)-geme-
dieerde fosforylering op de TRPV5 
activiteit.
Wanneer orthosterische liganden bin-
den aan GPCR's, veranderen de recep-
toren van vorm en dit stelt hen in staat 
om GTP-bindende eiwitten (G-eiwitten) 
te activeren. G-eiwitten zijn heterotrimere 
eiwitten die bestaan uit de subeenheid-α, 
β, en γ. In rust is de α-subeenheid GDP-
gebonden, en daarmee is het G-eiwit 
geïnactiveerd. Na stimulatie door een ge-
activeerde receptor wordt het GDP ver-
vangen voor GTP. Dit fenomeen disso-
cieert de drie subeenheden in twee actieve 
bestanddelen, de α-subeenheid en het 
βγ-complex. Twintig verschillende Gα-
subeenheden kunnen een direct stroomaf-
waarts signaalmechanisme activeren. 
Deze Gα-subeenheden zijn onderverdeeld 
in 4 families : Gs, Gi, Gq en G12/13. Deze 
families hebben verschillende invloeden op 
hun onderliggende mechanisme. Terwijl 
Gs AC/PKA activeert, remt Gi deze route. 
Gq activeert de PLC-β/PKC signaalroute, 
terwijl G12/13 Rho GTPasen activeert.
Meerdere TRP kanalen, waaronder 
TRPV5, zijn afhankelijk van PLC-β die 
verantwoordelijk is voor de hydrolyse 
van phosphatidylinositol (PIP2) en daarbij 
diacylglycerol (DAG) produceert en ver-
volgens PKC activeert. Gkika et al. toonde 
het belang aan van S299/S654 PKC fos-
forylatie op de N- en C-termini van TRPV5. 
Zij demonstreerde dat activering van de 
bradykininereceptor type 2 (B2R) door 
serine protease TK, de aanwezigheid van 
TRPV5 op het plasmamembraan verhoogt. 
De bijschildklierhormoon receptor type 1 
(PTH1R) zet de PKC of de PKA signaal-
route aan, om respectievelijk TRPV5 mem-
braaninsertie en de waarschijnlijkheid dat 
het kanaal open staat te stimuleren. 
In hoofdstuk 2 is aangetoond dat 
plasmine PKC-gemedieerde fosforyler-
ing van het S144 residu op de N-terminus 
van TRPV5 stimuleert. Plasmine bindt 
aan PAR-1, welke op zijn beurt PLC-β 
activeert, waarschijnlijk via Gq. Dit pro-
ces verhoogt de bindingsaffiniteit van 
calmoduline (CaM) voor de N-terminus 
van TRPV5, waardoor de poriegrootte en 
de kans dat het kanaal open gaat kleiner 
worden. Anderzijds, in hoofdstuk 5 leidt 
activatie van β1-AR tot PKA-gemedieerde 
fosforylering van residu T709, die op de C-
terminus van TRPV5 gelokaliseerd is. Ee-
rder toonde de Groot et al. aan dat deze 
fosforylering de bindingsaffiniteit van de 
CaM aan de C-terminus vermindert en 
uiteindelijk de kans dat het TRPV5 kanaal 
geopend is verhoogt. Omdat het signaal 
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PKA-gemedieerd is, wordt aangenomen 
dat geactiveerde β1-AR het signaal over-
brengt door middel van een Gs subunit.
Kortom, PKC en PKA zijn geïdenti-
ficeerd als belangrijke regulatoren van 
TRPV5. Het ontwikkelen van medicatie die 
PKC/PKA-geassocieerde GPCR’s beïn-
vloeden is van belang voor het verhelpen 
van renale Ca2+ disbalans.
Verschillende rollen van GPCR's in de 
nier en het bot.
Renale tubulaire ziekten kunnen sa-
mengaan met botaandoeningen zoals 
osteopenie en osteoporose, en worden 
veroorzaakt door elektrolytstoornissen in 
het lichaam. Defecte botontwikkelingen 
zoals osteodystrofie, treden op wanneer 
de nier niet in staat is om 1,25-(OH)2D3 
te synthetiseren. Verschillende hormonen 
zijn geïdentificeerd als regulatoren van de 
nieren en het bot. Bijvoorbeeld, muizen die 
het anti-verouderings hormoon klotho niet 
produceren hebben primair renaal Ca2+ 
verlies, nefrocalcinose en secundaire os-
teopenie. Daarnaast kan fibroblast growth 
factor 23 (FGF23), een fosfaat-afdrijvend 
hormoon geproduceerd door osteocyten 
(OCYs), de synthese van 1,25-(OH)2D3 in 
de nier moduleren, wat impliceert dat bot 
ook invloed kan hebben op de nierfunctie. 
Ontdekkingen van nieuwe ziekten geasso-
cieerd met FGF23 en klotho laten het be-
lang van de bot-nier relatie zien.
Een aantal externe factoren, zoals hor-
monen en groeifactoren, kunnen GPCR’s 
activeren. Kato et al. toonden aan dat 
GPCR48 deficiënties renale hypoplasie 
en verminderde nierfunctie veroorzaken. 
Onlangs heeft Luo et al. laten zien dat 
GPCR48-/- muizen een lage BMD en bot-
vorming indices hadden. Zij toonden ook 
aan dat GPCR48 botmineralisatie en de 
ECM-synthese reguleert via de cAMP/PKA 
signaalroute. De ligand verantwoordelijk 
voor de GPCR48 activatie is nog niet geï-
dentificeerd, maar de bot morfogenetische 
(BMP)-regulerende eiwitten Norrin en R-
spondins worden als ligand kandidaten 
beschouwd.
Een ander voorbeeld waarbij de bot-
nier-as gekoppeld is aan een GPCR, is 
de angiotensine II (Ang II) receptor type 1 
(AT1R). Ang II is een potente vasoconstric-
tor voor bloedvaten in de nieren en dar-
men. Bovendien komt de receptor AT1R 
ook tot expressie in OB's en OC's. Losar-
tan, een AT1R antagonist, normaliseerde 
BMD evenals botsterkte bij ratten waarvan 
de eierstokken waren verwijderd, vermo-
edelijk door de activering van OB door 
middel van de Gq/ERK1/2 route. In de 
nier resulteerde AT1R activatie in de fos-
forylering van WNK4, een serine-threonine 
eiwitkinase die het stimulerende effect 
van PKC op TRPV5 membraanexpressie 
tegenwerkte. Samen suggereren deze be-
vindingen dat GPCR signaaltransductier-
outes weefselspecifiek zijn. Zoals bespro-
ken in de bovenstaande alinea, is PAR-1 
geactiveerd door zowel exogeen plasmine 
in de nier als trombine in het bot (hoofd-
stuk 2 en hoofdstuk 4) In PAR-1 defi-
ciënte muizen is de serum RANKL/OPG 
ratio lager, wat resulteert in verhoogde bot 
massa. Trombine/PAR-1 heeft geen effect 
op TRPV5-gemedieerd Ca2+ transport. Dit 
impliceert dat trombine en plasmine PAR-
1 op verschillende manieren stimuleren.
127
Conclusie
In de afgelopen tien jaar is de rol van 
serine proteasen en GPCR's op het Ca2+ 
metabolisme onderzocht. In 1999 heb-
ben twee onderzoeksgroepen de poort-
wachters van renaal en intestinaal Ca2+ 
transport, respectievelijk TRPV5 en 
TRPV6, gekarakteriseerd. De eerste Ca2+-
regulerende serineprotease geïdenti-
ficeerd in 2005, was TK. Een jaar later is 
het moleculaire mechanisme waarmee TK 
TRPV5 activeert ontrafeld. In datzelfde jaar 
werden de fenotypes van PTH-deficiënte 
ratten beschreven en bleek dat PTH func-
tioneert via de PTH1R. Dit proefschrift im-
plementeert nieuwe kennis over de regul-
ering van renaal Ca2+ resorptie door middel 
van PAR-1, welke de renale Ca2+ resorptie 
en botvorming na activering door plasmine 
(hoofdstuk 2) en trombine (hoofdstuk 4) 
regelt. Bovendien beschrijft dit proefschrift 
ook een calciotropische rol voor β1-AR 
(hoofdstuk 5). Naast de GPCR, vermin-
deren de serine protease receptor uPAR 
en de transglutaminase tTG (hoofdstuk 3) 
TRPV5 expressie en functie respectieveli-
jk. Uiteindelijk kunnen deze bevindingen 
de weg vrijmaken voor de ontwikkeling van 
nieuwe medicijnen.
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 ATP adenosine triphosphate
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 BW body weight
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 CT computed tomography
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D
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 dP diameter of pore
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E
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 EGF epidermal growth factor
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 ELISA enzyme-linked immunosorbent assay
 ENaC epithelial Na+ channel 
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 Epi epinephrine
 ER endoplasmic reticulum
 ERK extracellular signal-regulated kinase
F
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 FGF fibroblast growth factor
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 F2R  coagulation factor II receptor gene
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G
 g  gram
 GAPDH glyceraldehyde-3-phosphate dehydrogenase
 GBM glomerular basement membrane
 GFP green fluorescent protein
 GFR glomerular filtration rate
 GPCR G protein-coupled receptor
 GPI glycosylphosphatidylinositol
 GSDB goat serum dilution buffer 
 GTP guanosine triphosphate
H
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 H+ hydrogen
 H2N amino terminus 
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 HEK-293 human embryonic kidney-293 cells
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 HCl hydrochloric acid
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I
 I electrical current
 IB immunoblot
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 Ig immunoglobulin
 IL-11 interleukin-11
 ip intraperitoneal injection 
 IP immunoprecipitate, immunoprecipitated, immunoprecipitation
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 IRES internal ribosome entry site
 IU international unit
 iv intravenous injection 
 I/V current-voltage relationship
J
 JNK c-Jun N-terminal kinases
K
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 KCC2 K+-Cl- cotransporter type 2 
 KCl potassium chloride
 kb kilobase
 kDa kilodalton
 KO knockout
 kV kilovolt
L
 l litre
 LaCl3 lanthanum chloride
 log logarithm
 LRP2 low density lipoprotein receptor-related protein 2 gene
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 M molar
 mA microampere
 mAb monoclonal Ab
 MAPK mitogen-activated protein kinase
 Mb megabase
 ME mercaptoethanol
 MEK MAPK/ERK kinase kinase
 MEM minimal essential medium
 mEq milliequivalent
 mg milligram
 MgCl2 magnesium chloride
 Mg2+ magnesium
 min minute
 ml millilitre 
 mM millimolar
 mmHg millimetre of mercury
 mmol millimole
 MMP matrix metalloproteinases 
 MOI moment of inertia
 mol mole
 MΩ megaohm
 mRNA messenger RNA
 mV millivolt
 MW molecular weight
N
 n number in group
 N total sample size
 nA nanoampere
 NA not applicable
 Na2ATP sodium ATP
 NaCl sodium chloride
 NaOH sodium hydroxide
 Na+ sodium
 NCC Na+-Cl- cotransporter
 NCX1 Na+-Ca2+ exchanger type 1
 NE norepinephrine
 NH2 amino terminus 
 NHE3 epithelial Na+-H+ exchanger type 3 
 NKCC2 Na+-K+-2Cl- cotransporter type 2 
 nm nanomolar
 NMDG N-methyl-D-glucamine
 no. number
 NP-40 Nonidet P-40
 NS nephrotic syndrome
 nt nucleotide
 N-terminus amino terminus
O
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 Ob.N osteoblast number
 Ob.S osteoblast surface
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 Oc.N osteoclast number
 Oc.S osteoclast surface
 OCYs osteocytes
 OD optical density
 OPG osteoprotegerin
 Osm osmole
P
 P permeability
 P probability
 pAb polyclonal antibody
 PAGE polyacrylamide gel electrophoresis
 PAR-1 protease-activated receptor-1
 PBS phosphate-buffered saline 
 PCR polymerase chain reaction
 PDZ post synaptic density protein (PSD95), Drosophila disc large tumor  
  suppressor (Dlg1), and zonula occludens-1 protein (zo-1)
 PEI polyethylenimine
 pF picofarad
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 PGE2 prostaglandin E2
 pH hydrogen ion concentration
 PI3K phosphatidylinositol-3’-kinase
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 PKA protein kinase A 
 PKB protein kinase B 
 PKC protein kinase C 
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 PLC phospholipase C
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 PLP periodate-lysine-paraformaldehyde
 PMCA1b plasma membrane Ca2+ ATPase type 1b
 PO peroxidase
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 PRSS8 protease, serine, 8 gene 
 PSS physiological salt solution 
 PT proximal tubule
 PTH parathyroid hormone
 PTH1R parathyroid hormone receptor type 1
 PV parvalbumin
 PVDF polyvinylidene difluoride
Q
 qPCR quantitative real time polymerase chain reaction
R
 r correlation coefficient
 RAAS renin-angiotensin-aldosterone system 
 Rac1 Ras-related C3 botulinum toxin substrate 1
 RANK receptor activator of nuclear factor-κB
 RANKL receptor activator of nuclear factor-κB ligand 
 Ras rat sarcoma 
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 RFU relative fluorescence unit
 Rho GTPase Ras homologous guanine triphosphatase
 RNA ribonucleic acid
 ROMK renal outer medulla K+ channel 
 RR ruthenium red
 RT reverse transcriptase
 RT-PCR real time polymerase chain reaction
 
S
 s second
 SD standard deviation
 SDS sodium dodecyl sulphate
 SEM standard error of the mean
 siRNA small, interfering RNA
 SNP single nucleotide polymorphism
 Src sarcoma
T
 t time
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 Tb.N trabecular number
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 TGF-β transforming growth factor-β
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 TM transmembrane
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 TRPV5 transient receptor potential vanilloid type-5
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 tTG tissue transglutaminase
 TV tissue volume
U
 U unit
 uPA urokinase-type plasminogen activator
 uPAR urokinase-type plasminogen activator receptor
 UV ultraviolet
V
 V volt(s)
 Vmax maximum velocity
 vol volume
 v/v volume per volume
W
 wk week(s)
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 wt weight
 WT wild type
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